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Abstract 
 
 
Despite over 20 years of pharmaceutical targeted research, no antagonist of inflammatory 
chemokine receptors (iCCR) has been licensed for use in treating inflammatory diseases. 
Marked promiscuity of ligand binding, simultaneous expression of multiple chemokine 
receptors in individual leukocytes and the inability to generate compound receptor knock 
out mice make it almost impossible to discern the function of a specific iCCR (especially for 
inflammatory CC chemokine receptors CCR1, CCR2, CCR3 and CCR5). 
 
To address this complexity, two novel mouse models have been recently developed at the 
Chemokine Research Group: a full iCCR-/- strain in which the whole chromosomal CC-iCCR 
cluster has been deleted, (resulting in a compound CCR1, CCR2, CCR3 and CCR5-/- mouse) 
and a novel iCCR fluorescent reporter strain, which expresses specific fluorescent proteins 
under the endogenous iCCR promoters. 
 
Experiments on the iCCR-/- have provided a ‘clean slate’ to assess the development of the 
immune response in the absence of CCR1, CCR2, CCR3 and CCR5, while studies on the iREP 
strain allowed for direct visualisation of changes in iCCR expression on the surface of 
several leukocyte subsets. 
 
The findings presented in this thesis not only validate our current understanding of the 
crucial roles of CCR2 and CCR3 in the mobilisation of monocytes and eosinophils from the 
bone marrow to the site of inflammation, but also provide clues on the role of CCR1 in 
monocyte trans-endothelial migration and describe a novel role for iCCRs in the 
proliferation and differentiation of dendritic cells and macrophages in vitro. 
 
More studies on these new iCCR mouse models will provide clarity on our current 
understanding of the orchestration of the CC-chemokine driven inflammatory responses, 
and the results will not only increase our understanding of basic chemokine biology, but 
could also inform future pharmacological intervention on the chemokine system. 
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1    Introduction 
 
 
1.1 Overview 
 
 
 
The development of an effective immune response in a tissue requires coordinated and 
sequential interactions between leukocytes at the site of inflammation and other immune 
cells in specialised anatomical compartments. This complex web of interactions between 
different cell types throughout the body is largely controlled by chemokines, small (8-
12kDa) highly conserved cytokines capable of inducing migration of leukocytes to and from 
tissues[1].  
 
While leukocyte recruitment to the site of infection is a requirement for effective pathogen 
clearance, aberrant immune recruitment can be the trigger for inflammatory conditions 
such as allergies, or for chronic inflammatory systemic diseases like rheumatoid arthritis or 
multiple sclerosis which can ultimately result in life-long debilitating illness, increased 
mortality and high costs for therapy[2]. 
 
Current treatments for inflammatory conditions heavily rely on either glucocorticoids or 
non-steroidal anti-inflammatory agents (NSAIDs) which have broad inhibitory effects on a 
wide range of immune responses. While effective,  this non-specific approach weakens the 
whole immune system, leaving patients vulnerable to infections[3].  
 
The discovery of chemokines and their receptors in the 1980s raised the hopes for a more 
specific approach to treat inflammatory conditions. In theory, it should be possible to 
interfere with the chemokine system and prevent the recruitment of the leukocytes 
responsible for a particular pathology to the site of inflammation without affecting other 
leukocyte subsets. However, despite over 25 years of pharmaceutical targeted research, 
no antagonist of inflammatory chemokine receptors has been licensed for use in treating 
inflammatory diseases. This failure as been attributed to an incomplete understanding of 
the inflammatory chemokine receptor system and confounding effects attributable to the 
promiscuity of each receptor[4].  
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1.1.1 Classification of the Chemokine Family 
 
Chemokines (chemotactic cytokines) are defined by structure, and can be divided in two 
large and two small subgroups depending on the number and arrangement of conserved 
cysteine motifs in their mature sequence[5].  Even though sequence identity between 
chemokines varies from about 20% to 90%, their structure overall is highly conserved and 
most chemokines essentially adopt the same fold[5]. The general chemokine structure 
consists of a flexible N-terminus and N-terminal loop, followed by a three-stranded 
antiparallel β-sheet on to which is folded a C-terminal α-helix. Intramolecular disulphide 
bonds typically join the highly conserved cysteine residues, maintaining the structural 
integrity necessary for binding to their respective receptor (Figure 1-1)[6]. 
 
Figure 1-1 General Chemokine Structure- Graphical representation showing how 𝜶-helix, 𝜷-sheets and 
disulphide bonds between cysteine residues interact to give a chemokine its tertiary structure. The figure 
also shows the position of the cysteine residues in the 4 chemokine subfamilies: C-, CC-, CXC- and CX3C 
chemokines. Figure adapted from ‘Chemokines’ by Dr. Habil Kohidai. 
 
Initially, chemokines were grouped in two major subgroups: the CXC and CC-chemokine 
families, according to the presence or absence of an amino acid (X) between a pair of 
cysteine residues near the amino terminus of the protein. As a general rule, members of 
the CXC chemokines were thought to be chemotactic for neutrophils while the CC-
chemokines were found to be chemotactic for monocytes and small subsets of 
lymphocytes[7]. For example, Interleukin-8 (CXCL8) was regarded as the typical CXC 
chemokine whereas CCL2, which attracts monocytes and T-cells, was regarded as the 
typical CC chemokine[8]. 
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Rapid advancement in automated sequencing of human and mouse genomes has 
uncovered numerous other chemokines [9], expanding the chemokine family and adding 
two novel subgroups: C-type chemokines that lack the first and third cysteine residue, and 
CX3C chemokines that have three amino acids between the first two cysteine residues. The 
only CX3C chemokine discovered to date, CX3CL1, has an extended mucin-like stalk and a 
transmembrane domain which can be cleaved[10]. This feature allows the chemokine to 
bind to the surface of certain cells, thereby serving both as a chemoattractant and as 
an adhesion molecule[11].  
 
Based on expression pattern and function, chemokines can also be grouped as 
‘inflammatory’ or ‘homeostatic’ according to the biological contexts in which they function. 
Inflammatory chemokines are typically dramatically induced during an immune response 
to recruit inflammatory leukocytes to sites of infection or tissue damage. Examples include 
CCL2, CCL3, CCL5, CXCL1, CXCL2 and CXCL8. In contrast, homeostatic chemokines are 
continuously secreted at low levels and are involved in controlling migration of cells during 
normal processes of tissue maintenance or development. Examples of homeostatic 
chemokines include CCL19, CCL21, CCL27, CXCL12 and CXCL13 [12]–[14]. 
 
Nevertheless, classification via structure is generally preferred, as some chemokines can 
be both pro-inflammatory and homeostatic under different physiological conditions. For 
example, CCL21, is constitutively expressed on the luminal side of high endothelial venules 
(HEVs), allowing direct access to lymphoid organs by naïve T and B-cells under homeostatic 
conditions[15].  However, CCL21 can also be superinduced on afferent lymphatics by 
inflammatory stimuli[16], thereby promoting recruitment of mature dendritic cells to the 
draining lymph node and the initiation of the adaptive immune response. 
 
1.2 Chemokine Receptor Structure and Regulation 
 
1.2.1 Chemokine Receptor Structure 
 
Chemokines themselves are recognised by chemokine receptors, G-protein coupled 
receptors (GPCRs) with 7 transmembrane domains predominantly found on the surface of 
leukocytes. The human chemokine superfamily currently includes at least 46 ligands, which 
bind to 18 functionally signalling chemokine receptors and four decoy or scavenger 
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receptors[17]. Chemokine receptors are denoted by the motif of their ligands: CC 
chemokine receptors only bind to CC chemokines, CXC chemokine receptors bind to CXC 
chemokines. Chemokine receptors also share particular features: they measure 
approximately 350 amino acids in length, have a short acidic extracellular N-terminus which 
has been shown to be crucial for the initial recognition and selective chemokine binding[18] 
and an intracellular C-terminus containing serine and threonine residues that act as 
phosphorylation sites for receptor regulation[19]. The receptor’s structure is stabilised by 
the formation of disulphide bonds between highly conserved cysteines in the first and 
second extracellular loops, while the G-proteins required for signal transduction are 
coupled through the C-terminus segment and the intracellular loops[20] (as seen in Figure 
1-2). Disulphide bonds also link the N-terminus to the third extracellular loop, forcing the 
membrane spanning helices into a stable circular conformation (extracellular view, figure 
1-2)[18]. 
 
 
Figure 1-2 General Structure of a CC-chemokine receptor. The extracellular domain of the receptor is 
responsible for chemokine engagement. As the N-terminus of the ligand binds to the receptor pocket, a 
conformational change is induced in the transmembrane region, exposing the DRYLAIV motif. The newly 
exposed DRYLAIV domain allows GPCR coupling to G-proteins, and the intracellular domain amplifies the 
signals, initiating a signalling ‘domino effect’ of secondary messengers that eventually reaches the 
nucleus and changes gene expression. Disulphide bridges between cysteines stabilise the three-
dimensional structure of the receptor. Adapted from Atlas Genetics Ontology and Textbook of Receptor 
Pharmacology (3rd Edition). 
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1.2.2 Chemokine Receptor Activation 
 
Numerous studies have investigated the molecular mechanisms of chemokine receptor 
binding and activation, leading to the discovery of two distinct regions of chemokines that 
interact with disparate regions of their receptors. Ultimately, this discovery lead to the two-
site, two-step model as a general paradigm for chemokine-receptor interactions [21] 
[22][23]. This model has been refined recently, with groups proposing a ’three step’ model 
of engagement for specific receptors, such as CCR1 [24] or CXCR4 [25]. 
 
In the first step, the core globular domain of a chemokine binds to the N-terminal extension 
and the second extracellular loop of its receptor. These regions, which are called the 
chemokine recognition sites, define receptor specificity and affinity[26]. In the second step, 
the flexible N-terminus of the chemokine interacts with the ‘major ligand binding pocket’ 
buried in the cavity formed by the circular arrangement of the receptor’s transmembrane 
domains[24]. This induces an overall change in the receptor conformation that initiates 
signal transduction. 
 
1.2.3 Chemokine Receptor Signalling 
 
Upon binding of the chemokine to a cognate chemokine receptor, the receptor undergoes 
a conformational change exposing the highly conserved DRYLAIV domain in the second 
intracellular loop. The exposed motif allows the receptor to bind to heterotrimeric G-
proteins required for signal transduction (G𝛼, G𝛽 and G𝑦 subunits)[28]. The interaction 
with the receptor’s intracellular domains activates the G-proteins by stripping the low 
energy guanidine diphosphate (GDP) from the G𝛼 subunit and allowing guanidine 
triphosphate (GTP) to bind to it instead[29].  
 
This change forces the separation of the G𝛼 subunit from the G𝛽 and G𝑦 complex, which 
can now interact with other signalling effectors such as GPCR kinases (GRKs), ion channels, 
and phospholipase C-𝛽 (PLC-𝛽). The interaction between active G-protein subunits and 
signalling effectors leads to the production of second messengers.  
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For example, phospholipase C (PLC) cleaves PIP2 (phosphatidylinositol-bisphosphate) into 
two second messenger molecules, inositol triphosphate (IP3) and diacylglycerol (DAG), 
which further propagate the signal transduction pathway [30]. Second messenger IP3 
diffuses into the endoplasmic reticulum and binds to the IP3 receptor. The IP3 receptor 
functions as a calcium channel, and IP3 binding results in the release of calcium ions from 
the endoplasmic reticulum, which in turn bind to Protein Kinase C (PKC) and activate it[31] 
 
Similarly, increased concentrations of second messenger DAG can also activate PKC 
directly. DAG/Ca2+-activated PKC in turn activates PI3K, a family of enzymes involved in a 
variety of cellular functions, including cell growth, motility and survival. PI3K activation 
phosphorylates AKT (also known as Protein Kinase B) which has a variety of downstream 
effects, such as increasing the activity of cellular transcription factor CREB[32], inhibiting 
cell cycle inhibitor protein p27 and recruiting FOXO proteins (a family of transcription 
factors important in the regulation of cell growth, differentiation and proliferation)[33]. 
 
Furthermore, PKC can also activate the NK-kB pathway directly through an IκB-
independent cytosolic interaction, which subsequently leads to enhanced p65 
phosphorylation and DNA binding affinity [34]. 
 
PI3K can also synthesise PIP3 by phosphorylating PIP2 [35]. An increase in PIP3 results in 
the localised recruitment of signalling proteins containing PIP3-pleckstrin homology (PH) 
domains[36], proteins that drive actin polymerisation and morphological changes at the 
leading edge of the cell, causing polarisation and mediating migration towards the highest 
concentration of chemokine[37]. 
 
Although these signalling events are common to all chemokine receptors, it is well known 
that the activation of further downstream pathways is quite different. Ligand affinity, 
engagement of multiple receptors simultaneously or even the differentiation state of a 
leukocyte itself can affect internal chemokine receptor signalling[38]. As such, different 
leukocytes will respond the same chemokine in different ways, adding an additional level 
of complexity to understanding the unique role of each receptor. 
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1.2.4 Chemokine Receptor Regulation 
 
 
Chemokine receptor signalling can be regulated by the process of receptor internalisation 
and desensitisation: a feedback mechanism which protects cells from ligand 
overstimulation[39]. Following chemokine-chemokine receptor binding and release and 
activation of the G protein subunits, G-protein coupled receptor kinases phosphorylate the 
receptor’s intracellular domains, enhancing their ability to bind to β-arrestins. This reaction 
induces a conformational change that releases β-arrestin’s C-terminal tail which contains 
binding sites for a variety of endocytic proteins, including trafficking regulators such as 
clathrin and the clathrin adaptor AP2 [40].  
 
Thus, β-arrestins act as scaffolding intermediates with components of the endocytic 
machinery, stabilising the receptor’s association with clathrin-coated pits (CCPs) and 
targeting it for internalisation via endosomes for lysosomal degradation[41]. In some cases, 
endocytosed receptors are dephosphorylated by endosomal-associated phosphorylases 
and recycled back to the cell surface in a process called resensitisation[42]. 
 
Different chemokines active at a given receptor may have different effects on its 
internalization: CCR1, CCR3 and CCR5 are efficiently internalized by CCL5, but the trafficking 
of the receptors follows different pathways. CCR5 is entirely recycled back to the cell 
surface[43], CCR3 is partially degraded and recycled[44], while CCR1, once internalised, 
cannot be recycled and has to be synthesised de novo[45]. The strength and stability of the 
interaction between the chemokine receptor and β-arrestins appears to be critical in 
determining if a chemokine receptor is internalised: receptors that preferentially bind to β 
-arrestin 2 with low affinity and dissociate from it upon internalization are rapidly recycled 
back to the cell surface, while receptors that bind both β-arrestins 1 and 2 with high affinity 
and remain β-arrestin-bound inside the cell and are eventually degraded[46]. 
 
1.2.5 Atypical Chemokine Receptors 
 
Conventional chemokine receptors are not the only receptors capable of binding 
chemokines. At least four other receptors exist: ACKR1, ACKR2, ACKR3 and ACKR4[47]. 
These molecules structurally resemble conventional chemokine receptors but cannot 
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initiate classical chemokine receptor signalling responses upon ligand binding as they 
lack the canonical DRYLAIV motif necessary for G-protein coupling and induction of classical 
signalling pathways[48][49]. This led to their exclusion from the systematic chemokine 
receptor nomenclature and they are thus referred to as atypical chemokine receptors 
(ACKRs). 
 
An important GPCR feature retained by atypical chemokine receptors is their ability to 
efficiently internalize their chemokine ligands, affecting chemokine availability and shaping 
chemokine gradients during an immune response. For example, ACKR2 displays 
promiscuous binding of inflammatory CC chemokines and acts as a scavenger receptor for 
its ligands, internalising them and targeting them for intracellular destruction. As 
exaggerated inflammation is seen at all sites of normal ACKR2 expression in Ackr2−/− mice 
[50], this suggests ACKR2 has an important role in the resolution of chemokine-driven 
inflammatory responses in the tissues in which it is expressed[48].  
 
The fate of internalised ligands is not the same for every atypical receptor. Upon 
internalisation, ACKR1 does not target its ligands for lysosomal degradation, but instead 
transports the chemokines across biological barriers in a process called transcytosis[51]. 
ACKR1 is thus part of an active chemokine transendothelial transport mechanism by which 
soluble chemokines are intercepted and carried to other microanatomical domains, 
altering chemokine gradients and at the same time preventing the spreading of chemokine-
mediated inflammatory stimulation into distal organs[52]. 
 
Due to their role in regulation of chemokine availability in inflamed tissues, atypical 
chemokine receptors tend to be expressed on the surface of non-leukocyte cell types, such 
as erythrocytes, lymphatic or vascular endothelial cells, ensuring tight control of chemokine 
availability necessary to attain gradients for efficient leukocyte recruitment and for 
resolution of inflammation[53]. 
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1.3 General Role of Chemokine Receptors 
 
Leukocyte migration requires multiple chemokine-mediated signals for both migration to, 
and permanence within, the site of inflammation. In broad terms, an infectious or 
inflammatory stimulus rapidly triggers the release of alarmins and other cytokines which 
cause localised activation of epithelial and other tissue resident cells, including vascular 
endothelial cells. In response to inflammation, these endothelial cells upregulate 
expression of several leukocyte binding proteins, including intercellular adhesion 
molecules ICAM-1, ICAM2, vascular cellular adhesion molecules (VCAM), as well as 
members of the selectin family of adhesion molecules, E and P-selectins[54]. P-selectins 
are found in endothelial cells and platelets and are stored intracellularly. Exposure to 
inflammatory mediators such as histamines, TNFs or LPS induces their rapid translocation 
to the plasma membrane in as little as two minutes[55].  On the other hand E-selectins are 
produced ‘on demand’, with peak expression happening just four hours after the initial 
inflammatory insult[56]. 
 
1.3.1  Arrest in Shear Flow 
 
E-selectins mediate initial low affinity interaction between leukocytes and the walls of 
blood vessel, a process described as leukocyte rolling. This slows down the leukocyte, 
increasing its mechanical resistance to shear stress and reducing its velocity in the blood 
stream from 1,000-4,000 μm/s to 5-40 μm/s [57]. This 100-fold decrease in speed allows 
the leukocytes to further sample the vascular walls for other signals.  
 
Epithelial cells and tissue resident leukocytes exposed to an inflammatory stimulus also 
rapidly release pro-inflammatory cytokines and various chemokines, which diffuse from 
the tissue and enter circulation. While the blood carries a fraction of these chemokines 
away from the site of inflammation, ultimately inducing migration and activation of distal 
leukocytes residing in the periphery, chemokines are also retained at the site of 
inflammation by binding to glycosaminoglycans (GAGs) on the surface of endothelial 
cells[58].  
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1.3.2 Interaction with Glycosaminoglycans (GAGs) 
 
GAGs are long, linear polysaccharides which display varying patterns of sulphation, which 
in addition to carboxyl groups, give these proteins one of the highest negative charge 
densities of any known biological macromolecules[59]. This negative charge is a critical 
determinant of chemokine binding, as chemokines are generally positively charged[60] and 
will bind to GAGs via electrostatic interactions[59]. 
 
As a result, leukocytes rolling along the vasculature encounter clusters of GAG-immobilised 
chemokines, recognised by specific sets of chemokine receptors on the leukocyte’s surface. 
Engagement of the chemokine receptors initiates a signalling cascade which, in a few 
milliseconds[61], causes surface integrin molecules to switch from a default ‘low affinity’ 
state to a ‘high affinity’ state, immobilising the leukocyte. Additional chemokine signals are 
implicated in crawling of leukocytes across the endothelium in search of a suitable site for 
extravasation[62], which usually happens at endothelial cell borders where expression of 
adhesion molecule PECAM is highest[63]. 
 
 
1.3.3 Transendothelial Migration (TEM) 
 
Leukocyte rolling, activation and adhesion are generally reversible, with most leukocytes 
that attach to the venules at the site of inflammation ultimately separating and re-entering 
the circulation. Indeed, this series of adhesion events almost resembles a ‘combination 
lock’[63]: the correct molecule must interact in the correct order within a short temporal 
window for transmigration to occur. This tightly controlled system restricts recruitment, 
allowing trans-endothelial migration (TEM) only in leukocytes that are expressing the right 
combination of receptors. The combination of chemokine receptor engagement, integrin 
binding and homophilic interaction between leukocyte PECAM and endothelial border 
PECAM[64] induce a signalling cascade which ultimately results in the cytoskeletal 
rearrangement required to squeeze through endothelial cell junctions. Like PECAM, JAMs 
(Junctional Adhesion Molecules) are also enriched at the endothelial cell junctions, and 
their inhibition via neutralising antibodies was shown to reduced trans-endothelial 
migration both in vivo[65] an in vitro[66]. 
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This method of trans-endothelial migration is also known as ‘paracellular’ or ‘junctional 
migration’, as the leukocyte migrates through endothelial cell junctions to reach the site 
on inflammation. There is however increasing evidence that under certain conditions, 
leukocytes can also pass through the endothelial cells directly, in a process termed 
transcellular route[67]. This method of trans-endothelial migration relies on adhesion 
molecules ICAM-1, VCAM-1 and PECAM, but also requires the leukocyte to extend 
pseudopodia into the endothelial cells[68] and the involvement of metalloproteinases 
which help remodel the leukocyte-endothelial cell interaction to facilitate the formation of 
trans-cellular channels required for migration[69]. 
 
 
Figure 1-3 Leukocyte Trans-endothelial Migration- This figure shows a simplification of the different 
stages and steps required for effective exit of leukocytes from the bloodstream into the site of 
inflammation. 1- Circulating leukocytes express chemokine receptors, low affinity integrins and selectins. 
2-Tethering and rolling:  L-selectins and P/E selectins on the epithelial cells bind to each other, slowing 
down the leukocyte by a factor of 100 and allowing the leukocyte to come into interaction with 
chemokine-bound GAGs. 3- Tight Adhesion: engagement of the chemokine receptor activates integrins, 
strengthening adhesion. 4- Trans-endothelial migration: Signalling cascades induce actin cytoskeleton 
reorganisation which allows the cell to squeeze through epithelial cells at PECAM rich sites. 5- 
Differentiated leukocytes reach the site of inflammation following other chemotactic cues. Adapted from 
‘Leukocyte Recruitment from Vasculature’ [70] 
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1.3.4  Localisation within Inflamed Tissues 
 
Once diapedesis has occurred, local chemokine and inflammatory cytokine gradients are 
responsible for directional migration and positioning of the leukocytes within the inflamed 
tissue. In these conditions, migrating leukocytes will probably encounter multiple 
overlapping chemoattractant signals. While it is still unclear how a leukocyte ‘decides’ 
which chemotactic signal to follow, studies on neutrophils have shown evidence of 
‘multistep navigation’[71], a mechanism by which cells can use chemokine receptors 
sequentially to move along different chemotactic gradients.  
 
The switch from one receptor to the next appears to be determined by receptor 
desensitisation, a process by which repeated stimulation of the same chemokine receptor 
decreases its responsiveness[36]. This would allow for different chemokine receptors to 
take over and contribute to overall migration[39] and would also explain why leukocytes 
generally express several types of chemokine receptors, as each one is required to perform 
distinct steps in the process of extravasation and localisation within tissues. 
 
 
1.4 Biological Role of the Main Inflammatory 
Chemokine Receptors (iCCRs) 
 
1.4.1 Role of CCR2 
 
CCL2 was first characterized as a monocyte-chemoattracting protein [72]. Its receptor, 
CCR2, is highly expressed on monocytes and is critical for bone marrow egress of classic 
monocytes and trafficking to sites of inflammation [73][74].  Subsequent studies showed 
that CCR2 is also expressed on activated and memory T cells[75], including both TH1 and 
TH2 cells[76][77][78], and mediates, to different extents, chemotaxis in a variety of other 
cell types[79] including mast cells[80], neutrophils (only in mice)[81] NK cells[82] and 
Immature B-cells [83]. In basophils, CCR2 engagement is strongly linked to histamine 
release and leukotriene secretion [84] while in endothelial cells it promotes proliferation 
and may play a central role in angiogenesis and wound healing[85]. Overexpression of CCR2 
mRNA was also found in prostate cancer metastatic cells[86], and more aggressive cancer 
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cells were found to express greater levels of CCR2 compared to less aggressive cancer or 
non-neoplastic cells[87], suggesting that CCR2 is a key regulator of chemotaxis. 
 
1.4.1.1 Phenotype of Ccr2-/- mice 
 
Although Ccr2-/- mice are developmentally normal[88], it was initially observed that 
deletion of Ccr2 reduces the number of macrophages recruited into the peritoneum after 
thioglycolate administration[88]. Further studies have uncovered a much wider range of 
effects ranging from susceptibility to infections[89], to pain[90], metastases of certain 
tumours[87] and neurodegenerative disorders[91]. Generally, deletion of Ccr2 results in 
protection in non-infectious models of inflammation, where aberrant and sustained 
leukocyte accumulation is responsible for the pathology. Indeed, Ccr2-/- mice are protected 
from the development of EAE (experimental autoimmune encephalomyelitis) pathology, 
with reduced infiltration of both monocytes and T-cells into the central nervous 
system[92]. Selective absence of CCR2 decreases atherosclerotic lesion formation in ApoE-
/- mice without any effects on plasma lipid or lipoprotein concentrations [93],   while Ccr2-
/- mice are protected from DSS (Dextran Sulfate Sodium)-induced intestinal adhesions and 
mucosal ulcerations[94]. In addition, Ccr2-/- mice showed 70% reduction in pain behaviour 
after intraplantar formalin injection[95], mediated by a reduced infiltration of 
monocytes/macrophages into the sciatic nerve and dorsal root ganglion and less activation 
of microglia in the spinal cord. 
1.4.1.2  Resistance to Inflammation vs Susceptibility to Infection 
 
Lack of CCR2 has also been shown to protect mice from acute transplant rejection, as both 
Ccr2-/- mice, and WT mice treated with neutralizing antibodies to CCL2, showed significantly 
reduced recruitment of mononuclear phagocytes following tracheal transplantation and an 
attenuation of bronchiolitis obliterans syndrome (BOS), a major limitation to survival after 
lung transplantation[96]. Furthermore, CCR2 inhibition reduces the transmigration of 
patient-derived  sarcoma cells in vitro and reduces the metastatic burden in the lungs of 
treated mice[97].  
However, lack of CCR2 is deleterious when the pathology is mediated by an infectious 
agent. Decreased recruitment and retention of immunocompetent cells in the bone 
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marrow[74] promotes survival and spread of pathogens worsening symptoms and 
increasing lethality. For example, the accumulation of blood-derived macrophages at the 
site of infection is critical for controlling bacterial growth of L. monocytogenes in infected 
organs. Ccr2-/- mice are unable to clear L. monocytogenes infection, and eventually 
succumb by day 5, while WT mice show no obvious symptom [98]. 
Genetic deficiency in Ccr2 also markedly increases mortality in West Nile virus encephalitis, 
with Ccr2-/- mice showing sustained monocytopenia, reduced accumulation of monocytes 
in the brain and an increase in cerebral viral load [99]. Granuloma formation is also 
diminished in Ccr2-/- mice in both PPD (purified protein from M.bovis) and SEA (S. mansoni 
egg antigens) experimental models, suggesting defects in clearance of intracellular 
pathogens [100]. Indeed, further studies showed that Ccr2-/- mice are highly susceptible to 
i.v. M. tuberculosis infection, with significantly higher bacterial loads by 14 days post-
infection, severe pathology, and increased mortality [89]. A dramatic reduction in IFNy 
levels and TH1 cytokine response in the draining lymph nodes of Ccr2-/- mice was also 
observed, suggesting that CCR2 might have a direct role in T-cell function[88]. 
Further studies have however shown that this effect is primarily due to a defect in the 
trafficking of monocytes to the site of immunisation. Reduced numbers of monocytes 
differentiating in situ results in fewer antigen-loaded antigen presenting cells (APC) 
reaching the draining lymph nodes, ultimately affecting the maturation and polarisation of 
the T-helper cell response[101].  These findings were also supported by the discovery that 
Ccr2-/- CD11c+ DCs display a persistent activation/maturation defect, with decreased MHCII 
and CD40 expression and abrogated cytokine production[102].  Indeed, while monocytes 
seem to be directly affected by CCR2 inhibition, other cell types show defects in 
recruitment and function only because of the lack of monocyte-derived signals at the site 
of infection. For example, even if neutrophils express low levels of CCR2, their recruitment 
kinetics seem to be unaltered[103][104]. Although some other studies have reported a 
slight delay in neutrophil recruitment and a modest decrease in neutrophil numbers at the 
site of infection in Ccr2-/- mice[105], this is probably caused by a decrease in monocyte-
derived chemoattractants and not a direct effect of CCR2 on neutrophil chemotaxis[106].  
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1.4.2 Role of CCR1 
 
CCR1 was originally cloned in 1993 and was shown to be expressed by neutrophils, T cells, 
B lymphocytes, natural killer (NK) cells, monocytes, and CD34+ bone marrow cells [107].  
 
Ccr1-/- mice develop normally, show no histologic differences in lymphoid organs, 
peripheral blood counts or any altered susceptibility to spontaneous infections, but the 
receptor has been implicated in the development of the immune response after 
experimentally induced renal injury. Indeed, Ccr1-/- mice showed 35% fewer neutrophils 
and 45% fewer macrophages in injured kidneys compared to wild type controls[108].  This 
reduction in inflammatory leukocyte infiltration reduced oedema and improved renal 
function, suggesting that treatment with CCR1 antagonists could protect against 
experimentally induced renal injury. Indeed, administration of CCR1 agonist reduced 
macrophage and T cell infiltrates, reducing tubular injury and interstitial fibrosis as a result. 
CCR1 blockade with the small molecule antagonist BX471 also reduced inflammation in 
mice with glomerulosclerosis and nephrotic syndrome [109].  
 
Inhibition of CCR1 also resulted in protection against Arthus reaction (an immune complex 
mediated type III hypersensitivity induced by the accumulation of antigen/antibody 
complexes in the vascular wall and glomeruli) by preventing recruitment of leukocytes to 
the kidney and reducing inflammatory damage to surrounding tissues[110]. The Arthus 
reaction is a mouse model for several other IC (immune complex) mediated diseases such 
as vasculitis syndrome, systemic lupus erythematosus, RA and cryoglobulinemia, 
suggesting that CCR1 could be involved in several immune complex mediated autoimmune 
conditions. 
 
CCR1 expression can also be increased on the surface of certain leukocytes during 
particular inflammatory conditions. Mononuclear phagocytes have been shown to 
upregulate CCR1 in multiple sclerosis plaques [111] and in endometriosis[112], while the 
upregulation of CCR1 during inflammation has also been reported in T-cells of mice 
exposed to respiratory syncytial virus (RSV). Its inhibition prevented T-cell recruitment to 
the infected lung, but the lack of recruitment to the lung was actually protective, as it 
decreased the number of infection-permissive leukocytes at the site, ultimately limiting 
viral spread[113]. 
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1.4.3 Role of CCR3 
 
CCR3 is mainly expressed by eosinophils and basophils[114], with some expression also 
reported in mast cells[115] and Th2 cells[116]. Ccr3−/− mice show normal development, but 
impaired eosinophil trafficking to the lung, skin and intestinal mucosa. Ccr3−/− mice also 
failed to recruit eosinophils to the skeletal muscle in response to Trichenella spiralis 
inoculation, resulting in inability to clear the pathogen and a 2-fold increase in muscle larval 
cysts when compared to WT controls[117]. Recruitment of eosinophils to lung parenchyma 
and bronchoalveolar lavage (BAL) fluid is also severely impaired in Ccr3–/– mice, which also 
fail to develop AHR (airway hyperresponsiveness) in response to antigen inhalation, 
suggesting that targeting CCR3 may offer a possible therapy for allergic airway diseases and 
asthma [118] 
 
Normal numbers of eosinophils in Ccr3-/- blood and bone marrow suggest that there are 
multiple chemokine/chemoattractant factors involved in sequestration of eosinophils out 
of the bone marrow and into the bloodstream[119]. However, histological studies on Ccr3-
/- lungs using OVA as model antigen showed the presence of large numbers of ‘trapped’ 
eosinophils within the blood vessels themselves  (under the endothelial cells and on top of 
elastic lamina), suggesting that CCR3 is largely required for the ‘final steps’ of the migratory 
process[119]. 
 
1.4.4 Role of CCR5 
 
CCR5 belongs to a diverse group of chemokine receptors which have sparked interest not 
just for their chemotactic functions, but as highly versatile players that fine tune immune 
responses by functioning as co-receptors[120]. CCR5 (and CXCR4) are required for correct 
T-cell activation by stabilising the immunological synapse (IS) between an antigen 
presenting cell and the T-cell itself.  The adhesins interact with the chemokine receptor at 
the IS, keeping the cells in close proximity, facilitating and ensuring that additional 
activating signals in the form of cytokines are delivered to the target cells and not lost in 
the surrounding area, preventing aberrant activation of bystander cells[120]. 
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Ccr5 polymorphism also influences the severity of progression of various inflammatory 
conditions, suggesting that blocking this receptor might ameliorate symptoms. Indeed, 
studies on a specific CCR5 variant with a 32 base pair deletion of the Ccr5 gene (Ccr5Δ32) 
have uncovered several unexpected of phenotypes, both protective and deleterious. This 
deletion involves a frameshift mutation with the inclusion of seven novel amino acids 
following amino acid 174 and a stop codon at amino acid 182 and results in the 
transcription a non-functional version of CCR5[121]. 
 
Homozygotes for Ccr5Δ32 show reduced incidence of renal transplant rejection[122], 
reduced incidence of childhood asthma[123], increased survival in IgA nephropathy[124], 
reduced incidences of Sjogren syndrome[125] and rheumatoid arthritis[126] and a delay in 
onset of myocardial infarction [127]. As CCR5 also acts as a viral co-receptor that facilitates 
entry of HIV (Human Immunodeficiency Virus) into the cell, individuals homozygous for 
Ccr5Δ32 are protected against HIV infection whereas those heterozygous for Ccr5Δ32 have 
lower pre-AIDS viral loads and delayed progression to AIDS[128]. 
 
In contrast, Ccr5 polymorphism is responsible for increased susceptibility to sarcoidosis and 
more severe progression of the disease[129], doubles mortality rates in patients with MS 
[130], increases susceptibility to Mycobacterium tuberculosis[131], worsens prognosis in 
patients with Bechet’s disease (a form of systemic vasculitis)[132] and increases the risk of 
symptomatic West Nile virus infection[133].  
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1.5 Chemokine-Independent Migration 
 
Chemokine receptors are not the only regulators of chemotaxis, and many other GPCRs 
receptors and soluble mediators assist leukocyte migration during the immune response.  
 
1.5.1 Formyl Peptide Receptors 
 
These receptors were originally identified by their ability to bind to N-formyl peptides that 
are secreted by invading pathogens or passively released from dead and dying host cells 
after tissue injury [134]. Engagement of these GPCRs elicits a wide variety of cellular 
responses, ranging from chemotaxis to an increased ability to phagocytose and degrade 
pathogens. 
 
FPR1 and FPR2 are critical for neutrophil chemotaxis in the early stages of Listeria 
monocytogenes infection, and their engagement also increases the generation of reactive 
oxygens species and the secretion of proteolytic enzymes necessary for effective pathogen 
clearance[135]. In human primary macrophages, FPR1 engagement result in polarisation 
towards a pro-inflammatory M1 state, characterised by an increase inflammatory cytokine 
secretion and increased chemotactic activity in vitro towards FPR1 ligands[136]  
 
1.5.2 Leukotriene Receptors  
 
Leukocytes exposed to formyl peptides (or other inflammatory stimuli) also increase the 
production of leukotrienes, inflammatory mediators synthesised in leukocytes by the 
oxidation of arachidonic acid (AA) via the 5-lipoxygenase pathway[137]. This pathway is 
predominant in leukocytes such as mast cells, eosinophils, neutrophils, monocytes, and 
results in the production of leukotriene A4 (LTA4), an unstable epoxide[138] which serves 
as a ‘parent molecule’ for the production of other types of leukotrienes. Cells expressing 
LTA hydrolase (such as neutrophils and monocytes) can covert LTA4 into LTB4, a potent 
chemoattractant that dramatically amplifies formyl peptide-mediated neutrophil 
polarization[139]. 
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On the other hand, cells expressing LTC4 synthase (such as mast cells and eosinophils) 
convert LTA4 in LTC4 and LTD4, leukotrienes responsible for the increase in vascular 
permeability and contraction of bronchial smooth muscle associated with acute allergic 
reactions or asthma attacks[137]. The production of leukotrienes is usually also 
accompanied by the production oh histamine and prostaglandins, which also act as 
inflammatory mediators. 
 
1.5.3 Prostaglandins 
 
Prostaglandins  are also produced from arachidonic acid, but, unlike leukotrienes, are 
produced by most nucleated cells and  their production requires the action of 
cyclooxygenase (COX) enzymes and terminal prostaglandin synthases to produce four 
principal bioactive prostaglandins, namely PGE2, PGI2, PGD2 and PGF2a [140].  
Prostaglandin production is generally very low in uninflamed tissues and regulated by the 
enzyme COX-1, while inducible cyclooxygenase COX-2 produces prostaglandins through 
stimulation, especially during an immune response[141]. Prostaglandins also exert their 
effects by binding to G protein-coupled receptors (GPCRs), and are powerful locally acting 
vasodilators and inhibitors of platelet aggregation. This increase in microvascular 
permeability and arterial dilation result in the characteristic ‘redness’ and swelling during 
inflammation. Prostaglandins E2 and I2 can also function as neurotransmitters on 
peripheral sensory neurons, delivering the ‘pain’ signal also associated with 
inflammation[142].  Prostaglandins E2 has also been shown to increase integrin expression 
on endothelial cells, allowing recruited leukocytes to stick to the vessel walls and initiate 
trans-endothelial migration[143] 
 
1.5.4 Histamines 
 
Another class of potent vasodilators are the histamines, nitrogenous compounds produced 
by basophils and mast cells residing in connective tissue. The effects of histamines are 
mediated by four different histamine receptors, H1R, H2R, H3R and H4R, and together 
coordinate a wide variety of functions including cell differentiation, haematopoiesis and 
cell regeneration[144]. 
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Upon engagement of their IgE receptor by an antigen, basophils and mast cells rapidly 
release histamines stored in granules, activating nearby cells. Histamine disrupts the 
endothelial barrier by acting on H1R on vascular cells, increasing vascular 
permeability[145]. Engagement of H1R on endothelial cells also increases arachidonic acid 
metabolism, resulting in increased prostaglandin production, synthesis of nitric oxide and 
contraction of smooth muscle cells[146]. Binding of histamine to the H4 receptor on 
eosinophils directly increases the expression of integrins Mac-1 and adhesion molecule 
ICAM-1, promoting eosinophil chemotaxis and trans-endothelial migration[147].   
 
Furthermore, histamines can also modulate leukocyte maturation and differentiation 
directly at the site of inflammation. Indeed, in vitro studies have shown that histamine 
binding to H1R can directly increase IL-6 secretion by human primary macrophages and co-
stimulatory molecule expression in dendritic cells[148]. Histamine release from mast cells 
can also be directly induced by C5a, a product of the complement protein C5[149].  
 
1.5.5 Anaphylatoxins (Complement Peptides) 
 
The complement system consists of numerous proteins that are present in either soluble 
form or in bound form at local inflammatory sites and in cell membranes. These soluble 
proteins normally exist in an inactive form that can be rapidly activated and amplified by a 
series of sequentially acting proteases that are tightly regulated[150]. Complement 
activation ultimately leads to the formation of the membrane attack complex (MAC), a 
structure that embeds itself in lipid bilayers on the surface of a pathogen forming a pore 
that can cause cell death by osmotic flux[151].  Some by-products of the complement 
cascade, such as C5a and C3a, can act as potent chemoattractants: administration of C5a 
in vivo induced a rapid activation-dependent adhesion of both rolling neutrophils and 
eosinophils[152], while C3a was shown to be a potent attractant for mast cells[153]. 
 
The receptor for C5a, C5aR, has been found on a wide range of leukocytes, such as 
neutrophils. eosinophils, monocytes, and T-lymphocytes, and has been shown to mediate 
phagocytosis and the release of cytotoxic granules and generation of oxidants. 
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1.6 The Evolution of the Chemokine Receptors 
 
Chemokine receptors can share very high levels of homology across different species, 
suggesting an ancient origin. While fruit flies, sea urchins and sea squirts have no 
identifiable chemokines or chemokine receptors[154][155],more complex organisms, such 
as chickens (G.gallus), frogs (X. tropicalis), zebrafish (D.rerio) and pufferfish (F.rubripes) all 
share chemokine receptors which have very high similarities to their human counterparts. 
For example, human CCR7, the chemokine receptor present on dendritic cells which allows 
them to migrate to the lymph node, shares 82% of its sequence with chicken CCR7, 80% 
with frog and 64% with Zebrafish[156].   
 
1.6.1 The Original Chemokine Receptor 
 
Amphioxus, the closest living invertebrate relative to the vertebrates, has no chemokine 
receptors while lampreys, one of the earliest vertebrates, have a single chemokine-
chemokine receptor pair: CXCL12 and CXCR4. Thus, the CXCR4-CXCL12 was identified as 
the ‘primordial chemokine-chemokine receptor pair’ [157][158] and the sequence of 
CXCR4 was analysed and compared across different species to understand how and why 
chemokine receptors evolved[159]. By tracking the mutations of this conserved chemokine 
receptor back through time, some groups have placed the origins of ancestral chemokine 
receptors between 650 and 564 million years ago, at the emergence of the vertebrate 
lineage[156][160]. Indeed, this period is marked by the evolution of neural crest tissue, a 
closed circulatory system, blood-based oxygen transport, and a hematopoietic system- all 
of which require some sort of controlled primitive cell migration. 
 
1.6.2 Diversification of the Chemokine Receptors 
 
The CXCL12-CXCR4 axis is still essential today for the proper migration of haemopoietic 
stem cells to the bone marrow, both late in development and in the adult[161] and for the 
migration of primordial germ cells to the genital ridge during development[162][163]. From 
this single gene and its defined biological role, the family has expanded through gene 
duplication throughout our evolutionary history, giving rise to all the other chemokine 
receptors.   Specifically, the main inflammatory CC-chemokine receptors CCR1, CCR2, CCR3 
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and CCR5 evolved very recently in evolutionary terms, diversifying from a primordial CC- 
chemokine receptor and coinciding with the emergence of mammals [156]. The emergence 
of the mammalian lineage also corresponds with the establishment of homeothermy, 
lymph nodes and a more sophisticated adaptive immune response.  
 
While a higher body temperature provided a fitness advantage against fungal infections 
during the massive ‘fungal bloom’ that followed the mass-extinction event that wiped out 
up to 90% of cold-blooded reptiles and all non-avian dinosaurs at the end of the Cretaceous 
[164][165], it is also believed that the increase in body temperature and metabolism may 
have made certain infections by thermotolerant bacteria more rapid and severe, adding a 
selective pressure on the primordial CC chemokine receptor to diversify into the 
inflammatory CC chemokine receptors (iCCRs) we see today. 
 
1.6.3 Pathogen Perturbation of the Chemokine System 
 
Several pathogens have evolved the ability to either degrade host, or secrete their own 
‘decoy’ chemokines to avoid being detected by the immune system[166]. Natural selection 
in viruses, helminths, and ticks has resulted in the convergent evolution of a wide range of 
proteins and soluble factors that are capable of interfering with the chemokine system by 
disrupting glycosaminoglycan binding or preventing chemokine binding to its receptor. 
 
1.6.3.1 Viruses 
 
Many viral chemokines and chemokine receptors generally share a high degree of similarity 
with host proteins, suggesting that the virus has acquired them from the host and modified 
them in a process termed viral piracy[167][168]. These proteins, termed viral chemokine 
binding proteins (vCKBP), are secreted by infected cells and inhibit chemokine activity by 
preventing formation of the chemokine gradient or by blocking chemokine-chemokine 
receptor interaction[169]. 
 
The genome of M. contagiosum, a member of the poxvirus family responsible for the 
formation of small skin tumours in children and young adults, encodes for MC148, a protein 
capable of binding to CCR1, CCR5, CCR2, CCR8, CXCR2 and CXCR4 [170]. Studies suggest 
MC148 functions by masking the chemokine’s own receptor interaction site, resulting in 
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decreased binding and biological activity impairment[171]. Similarly, both vaccinia virus 
and cowpox virus express a secreted chemokine binding protein that binds to CC 
chemokines (but not CXC or C) with high affinity, blocking their interaction with chemokine 
receptors and inhibiting cell migration in vitro[172]. 
 
Other viruses employ a completely different tactic: promote leukocyte recruitment to 
ensure dissemination throughout the host. Viral chemokine U83A, secreted by cells 
infected with human herpesvirus 6 (HHV-6), shows highly potent chemokine activity for 
CCR1, CCR4, CCR5, CCR6 and CCR8. These receptors are present on a wide array of cell 
types, including monocytes, DCs and skin-homing T-cells, suggesting that the virus is 
capable of actively recruiting leukocytes to promote its dissemination[173]. Similarly,  
Kaposi’s sarcoma herpesvirus (KSHV) encodes three secreted chemokines; vCCL1, vCCL2 
and vCCL3, which activate CCR8, CCR3 and CCR4, respectively[174]. This set of chemokines 
antagonizes the recruitment of antiviral Th1 and NK cells, skewing the immune response 
towards an antibacterial/antiparasitic Th2 profile which allows the virus to survive and 
disseminate[175]. 
 
1.6.3.2 Bacteria and other Parasites 
 
 
While viruses generally produce receptor and chemoattractant mimics, parasites and 
bacteria such as S. aureus[176] and S. pyogenes[177] can secrete proteins that affect 
inflammatory chemokine receptor (iCCR) signalling by directly antagonising the receptors 
and cleaving signalling messengers, thus preventing stimulus generation[178].  
 
Pertussis toxin (PT), secreted by B. pertussis (a small gram-negative bacterium that infects the 
human respiratory tract and causes whooping cough), is not only capable of inhibiting GPCR 
signaling[179], but can also inhibit early chemokine gene expression in alveolar macrophages 
and lung epithelial cells. This in turn causes a delay in neutrophil recruitment, allowing B. 
pertussis to establish itself early during colonisation[180]. Soluble chemokine binding proteins 
have also been identified in the human parasite S. mansoni [181], while hookworms have 
been shown to be capable of directly cleaving chemokines, such as CCL11, via 
metalloproteinase expression[182]. 
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Ticks, uniquely, have two classes of chemokine binding proteins called evasins that have 
evolved to bind to either CC or CXC chemokines. ‘8-Cys’ tick chemokine binding protein 
(CBK) contains 8 cystein residues and targets CC chemokines specifically, while the 6-Cys 
evasin targets CXC chemokines. Binding of evasins to their cognate chemokine prevents 
chemokine-glycosaminoglycan (GAG) interactions, reducing leukocyte recruitment and 
inflammation at the site of the bite and allowing for continued feeding[183]. 
 
The result of this evolutionary arms race between pathogens and hosts has resulted in the 
diversification and expansion of the chemokine-chemokine receptor system: by expressing 
many different chemokines and chemokine receptors, the immune system can rely on 
other signals to correctly move to the site of infection, even if the pathogen has managed 
to disable a few.  
 
In addition, different copies of the same chemokine receptor gene can evolve 
independently and develop specialised functions, allowing for discrete recruitment of 
specialised leukocytes to the site of infection. For example, while CCR2 and CCR3 derive 
from the same CC primordial receptor and share 78% of amino acid structure homology, 
CCR3 controls eosinophil recruitment, while CCR2 controls monocyte and dendritic cell 
migration. 
 
Figure 1-4- Apparent Redundancy in the Inflammatory Chemokine System. Chemokines are redundant 
in their action on target cells and promiscuous in receptor usage. Moreover, certain cells simultaneously 
produce several chemokines with an overlapping spectrum of action. 
 39 
1.7 Problems with iCCR Studies 
 
As gene duplication is the major driver of chemokine and chemokine receptor 
evolution[156], related chemokines share high sequence homology with each other and 
high degrees of similarity in structure[23].  Thus, many chemokine receptors can bind to 
multiple chemokines, creating an apparent redundancy in the inflammatory chemokine 
system where several ligands bind and activate multiple receptors and each receptor 
displays marked promiscuity of ligand binding (Figure 1-4). 
 
Although redundancy, promiscuity and overlapping gene expression patterns in the 
chemokine system may protect from possible pathogen induced perturbation of 
chemotactic signals, this complexity has hindered research on the individual role of each 
inflammatory chemokine[184]. More specifically, the amino acid sequence of CCR2 shares 
51% of identity with CCR1, 78% with CCR3 and 71% with CCR5[185], which makes it hard 
to develop specific antibodies for flow cytometry or immunohistochemistry which do not 
cross-react with other chemokine receptors. In addition, gene duplication has resulted in 
related chemokines being found in ‘clusters’ throughout the genome. 
 
1.7.1 Gene Clustering 
 
There are two major clusters of CC chemokine genes and two of CXC genes, plus numerous 
non-clustered or mini-cluster genes of both types, in both the mouse and human genomes 
[17].  Similarly, inflammatory CC-chemokine receptors Ccr1, Ccr2, Ccr3 and Ccr5 are all 
found on the same 170kb tight cluster on murine chromosome 9 (Figure 1-5). This 
‘clustering’ of similarly sequenced chemokines and chemokine receptors makes it 
extremely difficult to create compound knock-out mice, as their proximity does not allow 
for easy genetic recombination during crossing over events.  
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Figure 1-5- Genes for chemokines and chemokine receptors are found in clusters across the genome. 
There are two major clusters of CC chemokine genes and two of CXC genes, plus numerous non-clustered 
or mini-cluster genes of both types, in both the mouse and human genomes. This schematic 
representation is adapted from Ensembl genome database project data 
 
1.7.2 Fluctuating Chemokine Receptor Expression 
 
A further factor complicating studies on inflammatory chemokine receptors is that 
expression of chemokine receptors in leukocytes is not static, but fluctuates depending on 
activation, differentiation state and localisation.  For example, differentiation of monocytes 
into macrophages is achieved by exposure to CSF-1, which is secreted by epithelial cells 
exposed to cytokines such as IL-1 or TNF-α [186]. Not only does this terminal differentiation 
alter the behaviour of the monocyte by inducing an inflammatory state characterised by 
elevated phagocytic rates, proteolytic activity and up-regulation of pro-inflammatory 
surface markers[187], but chemokine receptors expressed on the surface also change as 
differentiation progresses (Ccr2 expression is shut down, while Ccr1 and Ccr5 are 
upregulated [188][189]).  
 
This coordinated regulation of chemokine receptor expression and altered functional 
responsiveness during differentiation adds even more complexity to the chemokine 
system, as a pharmacological antagonist might only be effective at blocking migration at a 
specific temporal window in the life of a leukocyte. As a result, research so far has failed to 
pin-point the relative contribution of each single iCCR, resulting in sometimes very costly 
failed attempts to pharmacologically alter the chemokine system in clinical trials (see 
below). 
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1.8 Role of CC-Chemokines in Inflammatory 
Conditions 
 
While studies on single iCCR knock out murine strains have identified multiple roles for 
CCR1, CCR2, CCR3 and CCR5 in the development of the immune response, they fail to 
address how different chemokines and chemokine receptors interact with each other to 
drive a particular pathology. Indeed, both acute and chronic inflammatory conditions are 
generally characterised by simultaneous expression of a wide variety of chemokines and 
chemokine receptors. Thus, targeting multiple chemokines at once might be the only way 
to fully explore the combinatorial mechanisms of the chemokine network. 
 
Acute inflammation is a short-term process occurring in response to tissue injury, usually 
appearing within minutes or hours. Characterised by the five cardinal signs of inflammation 
(pain, redness, loss of function, swelling and heat), the acute phase response is generally 
initiated by resident immune cells already present in the involved tissues and relies on 
vasoactive substances released by activated endothelial cells[190]. CXCL8, one of the most 
potent neutrophil chemoattractants in inflammation[191], is consistently among the first 
chemokines expressed and released by various cell types involved in inflammation and, via 
CXCR1 and CXCR2, induces specific intracellular signalling cascades that result in rapid 
neutrophil recruitment[192]. 
 
On the other hand, CC-chemokine receptors are generally expressed predominantly by 
monocytes/macrophages and T-cells, leukocyte subsets largely associated with chronic 
inflammation occurring over weeks or years[193]. Chronic inflammatory diseases like 
rheumatoid arthritis and atherosclerosis are characterised by continued leukocyte 
infiltration into the inflammatory site, driven in large part by excessive chemokine 
production[194].  
 
1.8.1 CC-chemokines in Atherosclerosis 
 
Atherosclerosis is a chronic inflammatory disease of medium and large size arteries, 
characterised by accumulation of oxidised low-density lipoprotein (oxLDL) within the 
arterial wall and a progressive accumulation of inflammatory cells[195]. One of the key 
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initiating events in atherogenesis is believed to be endothelial dysfunction[196], which can 
occur as a result of hypertension, diabetes, smoking, or elevated plasma low-density 
lipoprotein (LDL) levels[197].  
 
Endothelial dysfunction leads to decreased nitric oxide (NO) production, a potent 
vasodilator and inhibitor of platelet aggregation and leukocyte adherence[198]. Reduced 
bioavailability of NO results in increased vasoconstriction, coagulation, production of 
inflammatory cytokines and expression of adhesion molecules on the arterial walls[197]. 
The enhanced permeability of the endothelium and high levels of chemokines, such as CCL2 
and CCL5, presented on the arterial wall promote the recruitment of monocytes from the 
blood into the innermost layer of the arteries, where they differentiate into 
macrophages[199]. Differentiated macrophages then phagocytose the oxLDL in the vessel 
wall via scavenger receptors, leading to accumulation of cholesterol droplets in the 
cytoplasm and the generation of the canonical ‘foam cells’ that are typical of early 
atherosclerotic lesions[200].  
 
In turn, activated foam cells release TNF and other pro-inflammatory cytokines and 
chemokines[201] which fuel the inflammatory cycle by recruiting T cells, B cells and more 
monocytes into the lesion site[202]. Continued recruitment of inflammatory cells and 
accumulation of modified lipids on the arterial walls leads to the generation of an 
atherosclerotic plaque composed largely of recruited macrophages, T-cells, modified lipids 
and smooth muscle cells[203]. As the plaque increases in size over the years, it develops a 
necrotic core composed of dead and dying cells, as well as extracellular cholesterol. The 
atherosclerotic plaque then either continues growing, eventually occluding the lumen of 
the artery and leading to angina or ischemic attacks, or ruptures, releasing the contents of 
the necrotic core into circulation and forming a sudden blood clot that can lodge into the 
coronary arteries resulting in a heart attack, or in the brain causing a stroke[204]. 
 
Flow cytometric analysis of plaques in the aorta of ApoE-/- (Atherosclerosis-prone 
apolipoprotein E-deficient) mice revealed several monocyte/macrophage subsets 
differentially employing CCR2, CCR5 and CXCR1 to accumulate within atherosclerotic 
plaques[205].  Histologic analysis of lesions in Ccr2/Apo E double deficient mice revealed 
that the absence of CCR2 inhibited plaque formation and reduced macrophage infiltration 
into the vessel wall[206], while bone marrow transfer of Ccr5-/- bone marrow in lethally 
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irradiated low-density lipoprotein-receptor (LDLr)-deficient mice resulted in decreased 
plaque macrophage content and reduced collagen degradation[207]. In addition, 
overexpression of CCL2 in ApoE-/- mice was shown to increase the progression of 
atherosclerosis by increasing both macrophage numbers and oxidized lipid 
accumulation[208]. Overall, these studies hint at a central role for CC-chemokines in the 
development of atherosclerosis. 
 
1.8.2 CC-chemokines in Rheumatoid Arthritis 
 
Rheumatoid Arthritis is also a chronic inflammatory disease, characterised by massive 
infiltration of synovial tissue and synovial fluid with immune cells and mediated by 
chemokines and adhesion molecules[209]. Although the exact cause of RA remains 
unknown[210], recent findings hint at a genetic basis for disease development as more 
than 80% of patients express disease-associated alleles in the HLA-class II region, namely 
DRB1*0101, DRB1*0401, DRB1*0404 and DRB1*0405 [211]. The HLA gene complex 
encodes for the antigen presenting protein MHC-II, suggesting that these disease 
associated alleles may allow antigen presenting cells (such as macrophages, dendritic cells 
and B-cells) to present arthritis-related peptides to the immune system, leading to the 
stimulation and expansion of autoantigen-specific T cells in the joints and lymph 
nodes[212]. 
 
Activation of T-cells via arthritis-associated antigens stimulates CD4 T-cell proliferation and 
differentiation, characterised by increased secretion of IL-2 and IFNy in the synovial 
fluid[210]. Activated T-cells in turn support B-cell differentiation and autoantibody 
production[213].  Secreted autoantibodies can form larger immune complexes that can 
further stimulate the production of pro-inflammatory cytokines, including TNF-α, through 
complement and Fc-receptor activation on macrophages and dendritic cells[214]. This 
increased production of cytokines and chemokines activates more leukocytes, leading to a 
feedback loop for additional T-cell, macrophage and B-cell recruitment. 
 
Exposure of synoviocytes (synovial fibroblasts) to pro-inflammatory cytokines such as IL-1, 
IL-6 and TNF-α also results in the secretion of matrix metalloproteinases (MMPs) which are 
involved in tissue degradation and irreversible destruction of the cartilage, tendon, and 
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bone[215]. Similarly, ex vivo studies stimulating synovial fibroblasts with IL-1, TNF-α or IFNy 
revealed that these cells are the major source of monocyte chemoattractant CCL2[216]. 
These findings indicate that synoviocytes are central players in the creation of the 
inflammatory feedback loop that sustains the progression of the pathology. Other 
chemokines expressed at high levels in inflamed rheumatoid synovium include monocyte 
chemoattractants CCL3, CCL4 and CCL5 and neutrophil chemoattractants CXCL8 and 
CXCL10[217][218]. 
 
Interestingly, a meta-analysis on Ccr5 polymorphism and rheumatoid arthritis revealed a 
negative association between the non-functional CCR5-Δ32 receptor and RA progression 
and severity[219], suggesting pharmacological inhibition of CCR5 might be a strategy for 
treatment of this degenerative autoimmune conditions. 
 
1.9 Failure of Therapeutic iCCR Blockade in Clinical 
Trials 
Despite over 25 years of pharmaceutical targeted research, no antagonist of inflammatory 
chemokine receptors has been licensed for use in treating inflammatory diseases such as 
rheumatoid arthritis or other conditions in which excessive inflammation is the main driver 
of the pathology (Figure 1-6). 
 
Figure 1-6- Pharmacological Intervention with antagonists against the main inflammatory chemokine 
receptors has resulted in several failed clinical trials. Despite over 20 years of pharmaceutical targeted 
research, no antagonist of inflammatory chemokine receptors (iCCR) has been licensed for use in treating 
inflammatory diseases. Adapted from ‘International Union of Basic and Clinical Pharmacology. Update 
on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical 
Chemokine Receptors by Bachelerie et al.[47]  
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1.9.1 Pharmacological Inhibition of CCR2 
 
The CCL2-CCR2 axis is  attractive for pharmacological intervention as it is involved in a wide 
range of human pathologies  such as Alzheimer’s disease[220], ischemic brain injury [221], 
asthma[222], myocardial infarction[223] and multiple sclerosis[224] and its inhibition 
drastically affects monocytes/macrophages while leaving other cell types relatively 
unaffected. Therefore, inhibition of CCR2 in pathologies where monocytes are the key 
players and regulators of the disease (such as RA) should be effective and have few side-
effects. 
While attempts to inhibit CCR2 pharmacologically to treat inflammatory conditions in mice 
with CCR2 antagonists [225]–[228] and neutralising antibodies[229] have been successful 
to varying degrees, they have ultimately resulted in disappointing clinical trials which were 
mostly discontinued due to lack of efficacy [230][231]. For instance, Merck’s CCR2 inhibitor 
MK-0812 inhibited chemokine binding in vitro [232] but failed to demonstrate any 
improvement in the treatment of either RA or MS in Phase II clinical trials. Likewise, 
treatment with Millennium’s CCR2 neutralising antibody MLN1202 did not result in 
amelioration of synovial inflammation in active RA [231]. 
 
Like RA, Multiple Sclerosis (MS) is an example of an extremely heterogeneous disease 
which consists of at least four distinct patterns of demyelination: macrophage mediated, 
antibody mediated, distal oligodendroglopathy and primary oligodendrocyte damage with 
secondary demyelination[4]. These different stages are characterised by different 
leukocytes and driven by different chemokine receptors. CCR1, CCR2, CCR5 and CXCR3 
have all been implicated in the development and progress of MS[233]. Thus, similarly to 
RA, depending on the expression and activation of these receptors in patients with the 
disease, targeting more than one receptor might be necessary to show any efficacy in a 
clinical trial. 
 
1.9.2  Pharmacological Inhibition of multiple iCCRs 
 
As inhibition of CCR2 alone did not decrease disease progression in patients with MS and 
RA, clinical studies began to focus on simultaneous inhibition of several iCCRs. Monocytes 
are thought of as the effector cells in the pathogenesis of RA, and as their numbers in 
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affected joints usually correlate with clinical signs and symptoms[234], several clinical trials 
were set in place to inhibit recruitment of monocytes to inflamed joints by inhibiting the 
chemokine receptors responsible for monocyte chemotaxis: CCR2, CCR5 and CCR1. 
Although CCR2 and CCR5 receptor blockade had shown positive results in RA animal 
models, using chemokine antagonists to block these receptors was not effective in patients 
affected by RA [231]. In vivo and in vitro studies had also shown a positive correlation 
between blocking CCR1 ligands and inhibition of chemotaxis and reduction of synovial 
inflammation [235], but clinical trials using a CCR1 antagonist gave conflicting results, with 
some groups reporting a modest trend towards clinical improvement [236] and others 
reporting no efficacy at the Phase II stage [237]. Initially, it had been suggested that the 
redundancy in the chemokine system could have explained the failed trials using CCR2 and 
CCR5 antagonists, as both CCR2 and CCR5 share common ligands[238].  
 
However, another trial in which both chemokine receptors were blocked simultaneously 
using antibodies showed no inhibition of monocyte recruitment to the inflamed joint, 
possibly indicating that other chemokine receptors are at play[209].  In addition, lack of 
efficacy of treatment by CCR5 antagonists could be explained by inhibition of regulatory T-
cell (T-reg) recruitment to the site of inflammation. T-regs also use CCR5 in chemotaxis and 
are responsible for suppressing the immune response by scavenging IL-2 (necessary for 
proliferation of activated leukocytes) and releasing anti-inflammatory IL-10 and TGF-𝛽. By 
preventing recruitment of T-regs to the inflamed joint, the resulting excessive inflammation 
might counter-balance the positive effect of reduced monocyte recruitment [239]. Several 
reasons have been suggested as to why clinical trials blockading chemokine receptors have 
not worked, ranging from off-target effects to redundancy of the target. 
 
1.9.3 iCCR Antagonist Cross-Reactivity 
 
Antagonist dosage might have also been to blame for the failed CCR1 blockade trials, as a 
group using a daily 10mg dose of CCR1 antagonist MLN389 showed no clinical 
efficacy[238][240], while another group reported clinical improvements after 
administration of 300mg of another CCR1 antagonist CP-481715 every eight hours[237]. 
These results suggest that CCR1 blockade may be sufficient to inhibit monocyte 
recruitment to the synovial compartment only in the presence of high levels of receptor 
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occupancy[241]. However, off-target effects have been considered as the potential reason 
behind the modest protection observed at very high antagonist concentrations. At such 
high levels (almost 1g of antagonist/day), there was sufficient drug present to cross-react 
effectively with other GPCRs, even those for which the compound had low affinity. It is 
therefore possible that the protective effects reported by the group could have been 
mediated through these other GPCRs. This was the case with Compound 1, a highly potent 
human CCR1 inhibitor which could cross react with other GPCRs including adenosine A and 
dopamine D2[242]. The compound was not developed further as it was discovered that the 
protective effects were not mediated by CCR1 inhibition but by affecting dopamine, which 
is known to attenuate T-cell functions and secretion of Th1 cytokines that are involved in 
the pathophysiology of multiple sclerosis[243].  
Although studies have suggested that it is possible to alter monocyte recruitment 
pharmacologically, the examples elucidated so far underline the complexity of the 
chemokine system and the unanticipated and sometimes ineffectual consequences of 
downregulating the expression of a single receptor. Before any attempt can be made to 
treat inflammatory conditions by targeting critical chemokine-ligand combinations, it is 
necessary to fully understand and determine how the various chemokine receptors and 
their ligands interact with each other and which one (or combinations of) is necessary for 
the correct functioning of a specific leukocyte subset. 
 
1.10 Aims of the Project 
 
Studying the contribution of CCR1, CCR2, CCR3 and CCR5 to the development of the 
immune response presents various hurdles. Simple crossing of single knock out mice to 
obtain double chemokine knock outs for analysis is not possible, as inflammatory 
chemokine receptors CCR1, CCR2, CCR3 and CCR5 are all found on the same cluster on 
chromosome 9. Their proximity prevents chromosomal recombination and this has 
hindered research, especially as the use of antibodies to target specific chemokine 
receptors can induce potent changes to the cell by cross linking the monocyte’s Fc 
receptors and altering their phenotype[244]. To investigate the contribution each iCCR has 
on the development of the inflammatory immune response, this project has focused on 
characterising two novel mouse models recently developed by the Chemokine Research 
Group, an iCCR-/- and an iCCR reporter strain.  
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iCCR-/-: a novel knock-out model in which the whole iCCR cluster on murine chromosome 9 
has been deleted via CRE-LoxP recombination, resulting in an iCCR-/- (CCR1, CCR2, CCR3, 
CCR5 knock-out) mouse. Removing all iCCRs gives us the opportunity to investigate the 
inflammatory response when the main inflammatory chemokine receptors are completely 
absent and therefore unable to compensate for each other. Not only does this model allow 
for assessment of the importance of CCR1, CCR2, CCR3 and CCR5 in leukocyte chemotaxis, 
it also allows us to determine to what extent leukocytes require inflammatory chemokine 
receptors to modulate their activity and differentiation, highlighting the importance of 
these iCCRs in the correct functioning of the inflammatory system and the effect of their 
absence on both inflammation and cancer progression.  
iCCR Reporter: this novel murine iCCR reporter strain possesses a BAC (bacterial artificial 
chromosome) inserted in its genome, which encodes for the iCCR locus, but the coding 
sequences for the iCCRs themselves have been replaced with genes encoding for 
fluorescent proteins. Thus, these reporter mice express both the inflammatory chemokines 
receptors and specific fluorescent proteins under the same conditions, which allows for 
direct tracking of leukocytes with intra-vital microscopy and a direct visualisation of 
chemokine expression in leukocytes. This model also allows us to assess whether 
leukocytes express all iCCRs at the same time, if some chemokine receptors are 
preferentially expressed at different stages or if their expression is stochastic and follows 
random probability distribution. 
 
Inflammatory chemokine receptors are regarded as major contributors to in vivo 
inflammatory cell recruitment. However, the totality of their combined contribution to the 
overall orchestration of the inflammatory responses, and residual inflammatory cell 
recruitment in their absence, has not yet been defined. We hypothesise that the severe 
immune dysregulation caused by the lack of iCCRs will be protective in acute inflammatory 
models in which the pathology is driven by excessive leukocyte recruitment, but will be 
deleterious and increase the severity of chronic conditions due to the inability to resolve 
inflammation and to clear pathogens. 
This study will provide some clarity on our current understanding of the orchestration of 
the chemokine-driven inflammatory response. The results will not only increase our 
understanding of basic chemokine biology, but could also inform future pharmacological 
intervention on the chemokine system.  
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2 Materials and Methods 
 
2.1 Mice  
 
Animal experiments conformed to the animal care and welfare protocols approved by the 
University of Glasgow, carried out under UK Home Office Project Licence (70/8377). 
The mice used in these experiments (regardless of strain) were all females of 7-8 weeks of 
age. The mice were bred in-house at the specific pathogen-free facilities at the Beatson 
Institute for Cancer Research, Glasgow. 
 
 iCCR-/- : C57BL/6NTac (iCCR KO) (Taconics, UK) The ‘Wild-Type’ mice used in the 
experiments were of the same age, sex and background as those lacking the iCCR deletion. 
 
CCR1/CCR2/CCR5: C57BL/6J. The ‘Wild-Type’ mice used in the experiments of the same 
age, sex and background as those lacking the specific CCR deletion. 
 
CCR3: BALB/CJ.  The ‘Wild-Type’ mice used in the experiments were of the same age, sex 
and background as those lacking the specific CCR deletion. 
 
GGiREP: C57BL/6NTac. The ‘Wild-Type’ mice used in the experiments were of the same 
age, sex and background as those lacking expression of fluorescent proteins. 
 
2.2 Data Normalisation across murine strains 
 
Most of the experiment in this project involved comparing the iCCR knock-out strain to the 
single Ccr1, Ccr2, Ccr3 and Ccr5-/-. However, the different knock-out strains are on different 
backgrounds, making it difficult to draw meaningful conclusions when comparing data 
across strains as different backgrounds have slightly different immune system 
compositions. For example, B-cells in the C57BL/6J strain account for 45% of blood 
leukocytes, while only comprising 20% in the BALB/CJ strain.  To compare different strains, 
each knock-out was first normalised to its own WT (knock-out sample/ average WT) (Figure 
2-1). Only after transforming all values into ‘fold of WT’, can the data then be pooled and 
compared across strains. 
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Figure 2-1 Example of Data Normalisation when comparing changes in leukocyte populations across 
different murine strains. For each experiment, all samples were divided by the average WT value to 
transform all samples in ‘fold of WT’. Normalised data can then be pooled across experiments and 
strains to uncover the contribution each iCCR has on leukocyte recruitment. 
 
2.3 In Vivo Models of Inflammation 
 
2.3.1 Imiquimod Application to Skin 
To simulate local skin inflammation and induce a dermatitis-like pathology, Aldara cream 
was used as a model of inflammation[245]. The active ingredient, Imiquimod, is a TLR-7 
agonist which induces the localised production of IL-1𝛽, TNF𝛼 and other pro-inflammatory 
cytokines. ¼ of the content of an Aldara cream sachet (5% Cream, approximately 3.12mg 
of Imiquimod) was applied to the shaved back of a mouse every day for four days. On the 
fifth day, mice were culled, and the shaved skin was removed. The tissue was then cut 
coarsely and digested enzymatically to achieve a single cell suspension which could be 
stained and analysed via flow cytometry. 
 
2.3.2 Air Pouch Model 
To study acute inflammation in the synovial cavity, the air pouch model was selected[246]. 
Briefly, mice were anaesthetised in an isoflurane chamber and once unresponsive, an air 
pouch was produced by subcutaneous injection of 3ml of sterile air into the back of the 
mouse (Figure 2-2). The process was repeated every two days for a total of 3 times (day 0, 
day 2, day 4). The day after the last air injection (day 5), the inflammatory irritant 
carrageenan (Sigma, C1867-5G) was resuspended in PBS (1% w/v), autoclaved and 1ml 
injected (always under isoflurane anaesthesia) into the air pouch to induce local 
inflammation. 48 hours after the addition of carrageenan to the air pouch, the mice were 
culled with rising CO2 concentration. 3ml of PBS were then injected in the air pouch, 
removed using the same syringe and spun down at 300g for 5 minutes to extract cells that 
had migrated inside the cavity. The membrane surrounding the pouch was also collected, 
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weighed and digested enzymatically to produce a single cell suspension which was then 
stained and analysed via flow cytometry.  
 
Figure 2-2-  Air Pouch Generation. Diagram describing the outline of the air pouch model. 3ml of sterile 
air are injected subcutaneously 3 times over a 6-day course. The resulting air pouch stabilises and forms 
a membrane which can then be filled with any mediator that induces inflammation. The air pouch 
generated provides a localized environment in which to study cell trafficking and the inflammatory 
response. 
 
 
2.3.3 LPS Lung Challenge and Broncho-alveolar Lavage 
 
The LPS lung challenge was chosen as a model for lung inflammation. Briefly, mice were 
anaesthetised in a chamber with isoflurane gas. Once unresponsive, the mice were quickly 
removed from the chamber and 30μl of 250ng/ml of LPS was dropped onto the nostrils 
using a pipette. Once the LPS was breathed in, the mice were placed into a separate cage 
to recover from the anaesthesia, before placing them back to their respective housing 
cages. Mice were culled 48 hours later using rising CO2 concentrations. Once culled, a 
catheter was surgically placed into the trachea through the neck, and 1ml of PBS with 2mM 
EDTA was injected into the lungs. The fluid was then taken out using the same syringe. 
Overall, the lungs were washed three times (1ml each time), with a final BAL (broncho-
alveolar lavage) volume of around 3ml. Cells were counted, spun down, resuspended, and 
stained for flow cytometry. 
 
2.4 Tissue Processing for Flow Cytometry 
 
2.4.1 Skin Preparation 
Digestion Mix= in Hanks BSS (Gibco, 14175.053), 1mg/ml of collagenase D (10mg/ml, 
Roche), 500μg/ml of dispase II (10mg/ml, Roche or Invitrogen) and 100μg /ml of DNase I 
(10mg/ml, Roche) 
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The dorsal skin of the mice was shaved and 8 dorsal skin disks (5mm) were cut into smaller 
pieces and submerged in 1ml of digestion mix in 2ml Eppendorf tubes and placed on a 
shaker for 30 minutes at 37°C at 1000rpm. After 30 minutes, 1 extra ml of digestion mix 
was added to the Eppendorf tubes and incubated under the same conditions for an 
additional hour. The digested tissue was then passed through a 70μm nylon mesh strainer, 
washed in RPMI (Gibco) + 10%FBS (Gibco) to inactivate digesting enzymes and resuspended 
in FACS buffer (PBS (Invitrogen) +2mM EDTA (Ambicon) + 0.5% FBS (Gibco)). 
 
2.4.2 Lung Tissue Preparation 
Digestion mix= in RPMI (Gibco), dispase II (1600μg /ml, Roche), collagenase P (200μg /ml, 
Roche), DNase I (100μg /ml, Roche) 
Murine lung tissue was extracted and coarsely minced with scissors. Lung pieces were 
resuspended in 5ml of enzymatic digestion mix and incubated in a water bath at 37°C for 
40 minutes. The digested tissue was then passed through a 40μm nylon mesh strainer, 
washed in RPMI before resuspending in 1ml of red blood cell lysis buffer (Ebiosciences) for 
1 minute. Cells were then washed twice in FACS buffer (PBS (Invitrogen) +2mM EDTA 
(Ambicon) + 0.5% FBS (Gibco). 
 
2.4.3 Spleen Preparation 
The spleens from the mice were collected, carefully removing any visible fat or connective 
tissue. The spleens were inserted in 2mL Eppendorf tubes containing 1ml of RMPI and 
coarsely cut in smaller pieces mixing roughly. The pieces were then forced through a 70μm 
nylon mesh strainer using the internal plunger of a 5ml syringe. The nylon filter was then 
washed with 5ml of PBS. The cell suspension was then spun down at 300g for 5 min and 
the red blood cells in the pellet lysed with 1ml of ACK (Ammonium-Chloride-Potassium) 
lysis buffer (Gibco) for 1 minute. 9ml of RPMI were added to stop the reaction, and the cell 
suspension was again passed through a 70μm filter to obtain a single cell suspension. 
 
2.4.4 Blood Preparation 
Before blood extraction, 1ml syringes with a 26G ½” needle were soaked in 0.5M EDTA 
(Invitrogen) to prevent blood coagulation during extraction. Blood was then collected by 
inserting a 1ml syringe into the inferior vena cava and placed in a 1.5ml Eppendorf tube 
containing 100μl of 0.5M EDTA. The blood samples were then spun down at 300g for 5 
minutes. The plasma component was carefully removed for multiplex analysis of circulating 
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cytokines and stored at -80°C. The pellet containing the leukocytes and red blood cells was 
resuspended in 1ml of ACK lysis buffer and incubated for 5 minutes. The lysis reaction was 
stopped by adding 0.5ml of RPMI and the samples were spun down again. Blood samples 
underwent a second round of RBC lysis with 1ml of ACK lysis buffer for 2 minutes to ensure 
that all RBCs had been removed. The remaining leukocytes were then resuspended in FACS 
Buffer (PBS (Invitrogen) +2mM EDTA (Ambicon) + 0.5% FBS (Gibco)). 
 
2.4.5 Bone Marrow Preparation 
Tibia and Femurs were collected from culled mice and excess tissue was removed. Both 
ends of each bone were cut, and the bone marrow was flushed out using 5ml of RPMI-1640 
(Sigma) (10% FBS) in a 5ml syringe with a 23G needle. The cell suspension was collected 
and forced through the same syringe to reduce clumps, filtered through a 70μm cell 
strainer and spun down for 5 minutes at 300g. The resulting pellet was incubated for 1 
minute with 1ml of ACK lysis buffer (Gibco) to remove red blood cells. Cells were spun down 
again and the pellet resuspended in FACS Buffer. 
 
2.4.6 Air Pouch Membrane Preparation 
The membrane surrounding the airpouch was dissected and digested for 1 hour at 37˚C 
with shaking in 1ml of HBSS containing 0.44 Wünsch units of Liberase (Roche). Liberase was 
then deactivated by adding 20µl of FBS and membrane cell suspensions were passed 
through 70µm nylon mesh filters and washed in PBS.  
 
2.5 Flow Cytometry  
2.5.1 Surface Antigen Staining 
Starting from single cell suspensions from various tissues (spleen, skin, lung and lymph 
node), 300.000 cells per condition were added to polystyrene tubes (BD Falcon) and 
washed with FACS buffer (PBS (Invitrogen) +2mM EDTA (Ambicon) + 0.5% FBS (Gibco)). 
Cells were then spun down at 300g and resuspended in 100μl of Zombie Aqua Viability Dye 
at a 1:1000 dilution in PBS and incubated for 15 minutes on ice. Cells were then spun down, 
washed in FACS buffer, and incubated for 15 minutes at room temperature with 100μl of 
Fc Block (Macs Miltenyi Biotech) at a 1:100 concentration in FACS buffer. Cells were washed 
again and stained with the appropriate antibodies (Figure 2-3) on ice for 30 minutes. Cells 
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were washed one last time with FACS Buffer and resuspended in Fixation Buffer (Biolegend, 
420801), incubated at room temperature for 20 minutes, and once fixed, cells were washed 
and resuspended in 200μl of FACS buffer and filtered through a nylon mesh to remove any 
clumps before being analysed.  Data were acquired using either the MACSQuant (Miltenyi) 
or LSRII (BD Biosciences) flow cytometer and analysed using MACSQuantify version 2.5 
software (Miltenyi Biotec). Voltages and compensation were determined using UltraComp 
eBeads (Bioscience, 01-2222-42) as single controls. Positive staining was determined using 
Fluorescence Minus One controls. 
 
Figure 2-3 List of Antibodies for flow cytometry- Supplier, clone number and fluorophore of all the 
different antibodies used to stain different organs and cell types. 
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2.5.2 Intracellular Staining 
 
2.5.2.1 Proliferation Marker Ki67 
 
The day before intracellular staining, a Falcon tube of 70% Ethanol was chilled at -20°C 
overnight. The next day, after normal surface antigen staining, cells were spun down and 
vortexed for a few seconds in 500μl of cold ethanol. After resuspension, each sample 
received an additional 1ml of cold ethanol and 1 hour incubation at -20°C. Cells were then 
spun down at 300g for 5 minutes and washed in FACS buffer. The pellet was then 
resuspended in 150μl of FACS Buffer+ Ki67 antibody (Biolegend, 652403, clone 16A8, 1/220 
dilution) and incubated in the dark at room temperature for 30 minutes. Cells were then 
washed x2 with FACS Buffer and analysed on the MacsQuant on the PE channel. Positive 
staining was determined using an isotype control (IgG2ak, PE Rat 400507, Biolegend). 
 
2.5.2.2 Forkhead Box transcription Factor FoxP1 
 
After normal surface antigen staining, cells were spun down and resuspended in 500μl of 
Fixation/Permeabilisation Buffer provided in the Intracellular Staining Buffer Set (Miltenyi, 
130-093-142). Samples were incubated for 30 minutes at 4°C in the dark. After incubation, 
each sample received additional 500μl of FACS buffer and was spun down at 300g for 5 
min. Samples were then resuspended in 110μl of FoxP1 antibody (Miltenyi, 130-110-417, 
clone REA682) in Permeabilisation Buffer solution (100μl Buffer+10μl antibody) and 
incubated for 30 minutes at 4°C. After incubation, samples were washed twice in FACS 
Buffer and analysed on the MacsQuant on the PE channel. Positive staining was determined 
using an isotype control 
 
2.6 Tissue Culture 
2.6.1 Collecting Bone Marrow Stem Cells 
Tibia and Femurs were collected from culled mice and excess tissue was removed. The 
bones were taken to a sterile hood and briefly dipped for 1 minute in 70% ethanol to kill 
any bacteria. Bone marrow was extracted and the red blood cells were lysed using the same 
method for preparing bone marrow samples for flow cytometry. The cells in the single cell 
suspension were counted and resuspended in an appropriate volume of media depending 
on the cell type required for analysis. 
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2.6.2 L929 Conditioned Media- Source of CSF-1 
L929 CM (conditioned media) was produced by growing L929 cells (kindly provided by Dr. 
Helen Taylor, University of Edinburgh) to confluency in T225 flasks (CytoOne, Starlabs) in 
DMEM/F12 with Glutamax (1:1) (Gibco, 31331) supplemented with Heat Inactivated FBS 
(Gibco, 0270, 56°C for 30min) and Primocin (Invivogen). A vial was first thawed and cells 
allowed to recover in a vented T75 flask. Once confluent, cells were detached using 
Trypsin/EDTA 0.005%, spun down and counted.  9 million cells were used to seed each T225 
flask in 90ml of media (100,000 cells/ml). Cells were then allowed to grow undisturbed for 
4 days. Medium was changed (90ml) and cells were left for an additional 7 days. After 1 
week, the medium (now containing CSF-1) was collected, filter sterilised with a 0.22μm 
Millipore sterile vacuum (EMD, Millipore) and frozen at -80°C to be added as a source of 
CSF-1 in GMEMdiff and GMEMcult. 
 
2.6.3 Embryonic Stem Cell Derived Macrophages 
The murine embryonic stem cells (ES) used in the in vitro experiment are from cell line E14 
derived from inbred mouse strain 129/OLA. ES cells were kindly provided by Dr. Derek 
Gilchrist from the University of Glasgow. 
 
Murine Embryonic Stem cells (ES) were cultured in GMEMsr with LIF (Leukaemia Inhibitory 
factor) in a T25 flask to maintain their undifferentiated state. Before confluency was 
reached, ES cells were washed and detached with trypsin/EDTA 0.05%. Cells were counted 
and resuspended in GMEMdiff at a concentration of 37.500 cells/ml. A square petri dish 
was then filled with 15ml of PBS and 27μl drops of cell suspension (containing 
approximately 1000 ES cells/drop) were pipetted on the lid. Each lid can hold a total of 120-
150 individual drops. The lid was turned slowly but decidedly over the square petri dish, 
and the ES cells were left to grow undisturbed for 4 days (Figure 2-4). 
 
Upon withdrawal of LIF and addition of IL-3 (Peprotech, 2131310UG) and CSF-1 (L929 
conditioned medium), ES cells start differentiating in embryoid bodies which increase in 
size over the next few days. By day 4, embryoid bodies were collected from the lids and 
allowed to settle by gravity in a 50ml falcon. The media was carefully removed and replaced 
with 20ml of fresh GMEMdiff and the cell suspension placed in a petri dish. Media was 
changed again at Day 6. 
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Figure 2-4 Generating ES-derived Macrophages- A visual summary of the stages of macrophage 
differentiation protocol from murine embryonic stem cells  used in this study from day 0 to day 14, 
acquired via phase contrast microscopy. Briefly, ES cells are maintained in GMEMsr (Day 0), while 
differentiation into embryoid bodies requires GMEMdiff containing IL-3 and CSF-1  from day 1 to day 10. 
Macrophage precursors can be collected every 2 days from day 12 to day 20. The collected precursors 
are then grown in GMEMcult, and differentiated macrophages can be collected from day 3 to day 5 post-
precursors collection. 
 
By day 8, Embryoid bodies were collected and re-plated in a gelatin-coated (EmbryoMax, 
Millipore) petri dish, where they adhered and released macrophage precursors in the 
medium. Every two days (day 10, 12, 14, 16, 18), macrophage precursors were collected, 
pelleted and resuspended in 20ml GMEMcult. Differentiated macrophages were collected 
from day 3 to day 5 after replating using TrypLe Select (Gibco, A12177.01) as detachment 
buffer. 
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Figure 2-5  List of Reagents for ES-derived Macrophage Generation– A description of the contents of 
the three different media required at different stages of macrophage differentiation. ** L929 
conditioned media generation described previously. 
 
2.6.4  Bone Marrow Derived CSF-1 Macrophages 
Bone marrow cells were isolated using the method described above, counted and 5x106 
cells were resuspended in 10ml of GMEM cult in a 90mm petri-dish. At day 4, cells were 
washed with 1X PBS to remove cell debris and undifferentiated cells and 10ml of fresh 
GMEMcult was added to cultures. Differentiated macrophages can be collected from day 
5-7 after replating using TrypLe Select (Gibco, A12177.01) as detachment buffer. 
Macrophages were generally collected at Day 5, stimulated for 24 hours with 
cytokines/growth factors and collected at days 6-7 for analysis. 
 
2.6.5 Bone Marrow Derived DCs and GM-CSF Macrophages 
Bone Marrow was collected as above and 107 cells were resuspended in 10ml of RPMI-1640 
(Sigma) (+10% FBS, L-glutamine, 50μM b-mercaptoethanol, primocin and 20ng/mL of 
murine recombinant GM-CSF (Peprotech).  Cells were placed in tissue culture treated petri 
dishes. At Day 3, supernatant containing cells in suspension was collected, spun down at 
300g for 5 minutes and the pellet re-plated in a new petri dish with 10ml fresh medium. 
Macrophages left stuck to the petri dish were discarded. This was repeated again at Day 5 
and Day 7. After collection at Day 7, dendritic cells were counted and replated as required 
for phagocytosis and cross presentation assays.  
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2.6.6 Growing FLT3 Dendritic Cells 
Bone Marrow was collected as described above and 1.5x107 cells were resuspended in 
10ml of RPMI-1640 (Sigma) (+10% FBS, L-glutamine, 50μM b -mercaptoethanol, primocin 
and 100ng/ml of murine recombinant FLT3L (Peprotech)).  Cells were placed in tissue 
culture-treated petri dishes. At Day 5, 2/3 of the supernatant was collected and replaced 
with fresh FLT3L containing media. At Day 8 non-adherent and loosely adherent cells were 
collected, replated and stimulated for 24/48 hours and analysed via flow cytometry and 
ELISA. 
 
 
2.6.7 In vitro Macrophage and Dendritic Cell Stimulation 
The following cytokines/inflammatory signals (Figure 2-6) were used to stimulate 
macrophages and dendritic cells in numerous assays. Generally, cells were always 
resuspended at 106/ml before exposure to various cytokines at the concentrations shown 
below. 
 
Figure 2-6 Macrophage and DC Stimulation- List of reagents and the concentrations used for in vitro 
macrophage and dendritic cell stimulation 
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2.7 Analysing GM-CSF Derived Proliferation Clusters 
Bone Marrow was collected as above and 107 cells were resuspended in 10ml of RPMI-1640 
(Sigma) (+10% FBS, L-glutamine, 50μM b-mercaptoethanol, primocin and 20ng/ml of 
murine recombinant GM-CSF (Peprotech).  Cells were placed in tissue culture treated petri 
dishes. At day 3, medium was removed and replaced gently with fresh media, taking care 
not to disrupt growing proliferation clusters. Clusters were then either examined under 
light contrast microscopy and imaged by selecting consistent fields of view (Figure 2-7A) 
and analysing cluster number using Fiji Software’s Particle analyser (detection of particles 
>6000μm2) (Figure 2-7 B,D) or collected by vigorous pipetting at day 4-5 and analysed via 
Flow Cytometry.  
 
Figure 2-7 Cluster Identification- A- Diagram showing fixed fields of view to acquire unbiased images for 
cluster quantification of cultures. Petri cultures have 25 fields of view. If cultures were grown in 12 well 
plates, each well had 5 fixed fields of view. B- Pictures were taken at x4 magnification on a light 
microscope for each field of view. C- Bright field images were analysed with the ‘Particle Count’ program 
on Fiji Image Software to determine the number of clusters larger than 6000μm2. D- At the end of the 
analysis, Fiji provides an outline and a size for each identified cluster. 
 
2.8 In Vitro Assays 
 
2.8.1 Adhesion Assay 
The outlines of three circular coverslips were drawn onto a glass slide with an ImmEdge 
Pen as shown in Figure 2-8A. Recombinant mouse ICAM-1-Fc Chimera (553004, Biolegend) 
was resuspended in PBS to a final concentration of 10μg/ml. 50μl of ICAM-1 were then 
pipetted on top of the coverslips and incubated overnight at 4°C. The following day, the 
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ICAM solution was gently removed and the coverslips were washed x3 with 200μl of PBS. 
To block any residual binding sites, 50μl of 1% BSA in PBS were pipetted onto the coverslips 
and incubated at room temperature for 30 minutes. Coverslips were then washed again x3, 
and 50μl of GM-CSF cell suspension (200,000/ml) from WT or iCCR-/- cultures were added 
to the coverslips. The slides were then incubated at 37°C for 20 minutes to promote 
attachment of cells to ICAM-1. Before counting, the coverslips were again gently washed 
x3 with 200μl of PBS. 5 fields of view were recorded for each coverslip with a light 
microscope at a x10 magnification, and cell quantification was performed via Fiji Software 
Particle Analyser Program (Figure 2-8 B,D). Setting for detection: particles >50μm. 
 
Figure 2-8 Static Adhesion Assay- A- Diagram showing the arrangement of coverslips on the slide. 5 
fields of view were taken for each coverslip. B- Pictures were taken at x10 magnification on a light 
microscope for each field of view. C- Bright field images were analysed with the ‘Particle Count’ program 
on Fiji Image Software to determine the number of cells larger than 50μm2 D- At the end of the analysis, 
Fiji provides an outline and a size for each identified cell. 
 
2.8.2 Phagocytosis Assay 
 
2.8.2.1 Ovalbumin AF488 – 
 
Day 8 Dendritic cells were incubated at 37°C with Ovalbumin Alexa Fluor 488 Conjugate 
(Invitrogen) at various concentrations (60μg/ml – 15μg/ml) for 30-45 minutes. Controls 
were performed at 4°C. Fluorescence on the FITC channel was detected on the MACS Quant 
and analysed via FlowJo. 
 
2.8.2.2 pHrodo Red E. coli BioParticles Conjugate- 
 
Day 8 Dendritic cells were incubated with 250μg/ml of pHrodo E.coli BioParticles for 30 
minutes at 37°C. pHRodo Bioparticles do not fluoresce but emit bright green light 
detectable on the FITC channel when exposed to pH change in lysosomes. Cells were 
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washed x3 with ice-cold PBS before analysis, and fluorescence on the FITC channel was 
detected on the MACS Quant and analysed via FlowJo. 
 
2.8.3 Antigen Presentation and Cross Presentation Assay 
 
BM derived Dendritic cells were grown in RPMI supplemented with 10% FBS, primocin and 
20ng/ml of recombinant GM-CSF for 7 days. The protocol was adapted from an established 
procedure described by Alloatti et al [247]. Briefly, DCs were then incubated with 
ovalbumin coated beads (simulating particulate antigen), stimulated with LPS, fixed, and 
then co-incubated for 24 hours with cognate T-cells. Supernatants were then collected and 
analysed via ELISA for IL-2 to assess the extent of T-cell activation. 
 
2.8.3.1 Coating Beads 
 
 The day before the assay, 250μl of 3μm latex beads (Polysciences) were spun down 
(19.000g) and resuspended in 3ml of Ovalbumin solution in PBS (10mg/ml). The beads were 
then incubated overnight on an agitator at 4°C to promote attachment of ovalbumin to 
their surface. The next day, the beads were spun down again at 19,000g, washed in PBS x3 
to remove any unbound ovalbumin protein, and resuspended in 400μl of RPMI. 10μl of 
bead suspension was then added to the DCs to simulate particulate antigen (200:1 bead/DC 
ratio) 
 
2.8.3.2 OVA Peptide Controls  
 
Specific ovalbumin peptides were chosen as controls to determine if the detected changes 
in antigen presentation are due to defects in the cell’s antigen processing capabilities or 
just decreased expression of MHCI/II or other costimulatory molecules. The peptides are 
fragments of ovalbumin protein that bind directly to either MHCI (OVA 323-339) or MHCII 
(OVA 257-264), without requiring any processing by cell’s antigen degradation machinery. 
 
2.8.3.3 OVA-Specific T-cells 
 
The T-cells used in this assay come from the lymph nodes of OT-1 and OT-2 mice. The OT-
1 mouse strain contains transgenic inserts for Tcra-V2 and Tcrb-V5 genes[248]. Thus, most 
CD8 T-cells in this murine line recognise ovalbumin residues 257-264 in the context of MHCI 
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(mimicking antigen cross presentation). On the other hand, the OT-2 strain expresses the 
mouse alpha-chain and beta-chain T cell receptor that pairs with the CD4 coreceptor and 
is specific for ovalbumin 323-339 [249]. Thus, most CD4 T-cells in this murine line recognise 
ovalbumin residues 323-339 in the context of MHCII (mimicking antigen presentation). To 
extract the T-cells for co-incubation with OVA-loaded DCs, cervical and inguinal lymph 
nodes were extracted from OT-1 and OT-2 mice, mechanically disaggregated through a 
70μm nylon mesh and resuspended in complete RPMI at a concentration of 2x106/ml. 
 
 
2.8.3.4 Antigen Presentation Assay 
 
After 7 days of culture, 100μl of GM-CSF cells were incubated for 5 hours with OVA-coated 
3μm latex beads (Polysciences) (particulate antigen, 200:1 bead/DC ratio), and OVA control 
peptide binding to either MHCI or MHC II (OVA 257-264, OVA 323-339) in tissue-culture 
treated 96 well plates (Costar, 3799) at a density of 106/ml. After incubation, cells were 
washed extensively (x3 in PBS) to remove unbound beads and stimulated with LPS 
overnight to allow the cells to process ovalbumin and present it on MHC together with co-
stimulatory molecules. The next day, cells were washed and fixed with 50μl of 0.008% 
glutaraldehyde (G7526-10ml, Sigma-Aldrich) in PBS for 3 minutes on ice. Immediately 
afterwards, cells were quenched to remove any unreacted aldehyde with 50μl of 0.4M PBS-
glycine. Cells were then spun down at 300g for 5 minutes, washed one more time with 
100μl of PBS-glycine 0.2M and resuspended in 100μl of RPMI. 100μl of OT-1 or OT-2 T-cell 
suspension in RMPI was then added to each well (cell suspension= 2x106/ml à 200.000 T-
cells/well à 2:1 T-cell/DC ratio), bringing the final volume of each well to 200ul. After 24 
hours of co-incubation of fixed DCs with cognate T-cells at 37°C, the supernatant was 
collected and IL-2 levels were measure via ELISA. 
 
 
2.9 ELISA 
 
To determine the activation status of ES-derived macrophages, bone marrow GM and M-
CSF macrophages, GM-CSF and FLT3 derived DCs, cells were collected and replated in 
tissue-culture treated 96 well plates (Costar, 3799) at a density of 106/ml. Their supernatant 
was collected after overnight stimulation with LPS or other inflammatory mediators. The 
following cytokines were measured via Affymetrix’s ELISA Ready-SET-GO! Kits according to 
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manufacturer’s instruction: IL-6, IL-10, IL-1𝛽, IL-12p70, TNF𝛼, GM-CSF, IL-2, CCL2. CCL5 
levels were instead measured using R&D DuoSet ELISA Kit. Samples were measured in 
triplicate. Briefly, wells of a 96 well plate were coated at 4°C overnight with a specific 
capture antibody. The next day, wells were washed with PBS Tween 0.05%, blocked for 1.5 
hours with assay diluent, and the supernatant was added and incubated at room 
temperature for 2 hours. Wells were then washed, and a monoclonal detection antibody 
specific to the cytokine in question was added to the samples and incubated for 1 hour. 
This second antibody is linked to HRP-peroxidase, an enzyme which induces a colour 
change when a substrate (TMB) is added. Colour develops in proportion to the amount of 
cytokine bound in the initial step, and the reaction is stopped with 50μl of H2SO4. The final 
optical density of the solution in each well was measured using a microplate reader set to 
450nm (Sunrise, Tecan). A best-fit curve was constructed by plotting mean absorbance of 
the standards on the Y-axis against their known concentrations on the X-axis. The 
concentration of the samples was extrapolated using the equation of the line and 
substituting for X. 
 
 
2.10 RNA extraction and cDNA generation 
 
ES-derived macrophages, DCs or GM-CSF clusters were detached, pelleted, resuspended in 
RLT Buffer and spun through a QIAshredder (QIAGEN, #79654). The resulting elute was 
placed in a spin column from an RNeasy Mini Kit (QIAGEN, #74104) and the manufacturer’s 
instructions were followed to obtain RNA in a final 40μl volume. RNA concentration was 
measured via Nanodrop 1000 (Thermo Scientific). cDNA was then obtained using 
ThermoFisher’s High Capacity RNA to cDNA Kit according to manufacturer’s instructions 
and using the following PCR programme (37°C 60 min, 95°C 5min, hold at 4°C) run on the 
Veriti 96 well Thermal Cycler (Applied Biosystems, #4947). cDNA samples were stored at -
20°C. 
 
2.11 qPCR 
 
qPCR reactions were performed in 384 well –plates, providing quadruplicate values for 
each cDNA sample. Each well contained 10μl of reaction volume (1μl cDNA, 5μl SYBR 
Green Mix (Quanta Biosciences, #013590), 0.15μl primer mix (1:1) and 4μl nuclease free 
H2O). Expression levels of inflammatory chemokine genes CCR1, CCR2, CCR3 and CCR5 
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were assessed via Real Time PCR analyser (Applied Biosystems, #7900HT). GAPDH was 
used as a housekeeping gene to normalise samples. The primer sequences are shown 
below in Figure 2-9. 
 FORWARD PRIMER REVERSE PRIMER 
CCR1 GCCCTCATTTCCCCTACAA CGGCTTTGACCTTCTTCTCA 
CCR2 TGTGGGACAGAGGAAGTGG GGAGGCAGAAAATAGCAGCA 
CCR3 TTTCCTGCAGTCCTCGCTAT GGAAAGAGGCAGTTGCAAAG 
CCR5 TTTGTTCCTGCCTTCAGACC TTGGTGCTCTTTCCTCATCTC 
GAPDH TGTCTCCTGCGACTTCAA TGCAGCGAACTTTATTGAT 
Figure 2-9 Primer Sequences- Primer sequences of the inflammatory chemokine receptors CCR1, CCR2, 
CCR3, CCR5 and housekeeping gene GAPDH. 
 
2.12 PCR Array 
 
To further characterise the gene expression of GM-CSF monocyte derived DCs and 
macrophages, a PCR array (RT2 Profiler PCR Array, PAMM-406ZE-4, Qiagen) was used to 
simultaneously determine the expression of 84 genes involved in dendritic cell maturation 
and activation, including cytokines, chemokines, cell surface receptors and signal 
transduction molecules. Genes involved in antigen uptake, processing and presentation 
were also represented in the array. Briefly, cells were collected, washed in PBS, spun down 
and lysed with a QiaShredder column at 23,000g for 1 minute. The lysate was then added 
to an RNeasy column for RNA extraction  
2.12.1 RNA extraction and cDNA synthesis 
 
RNA was isolated using an RNeasy spin column and the RNA was cleaned of genomic DNA 
contamination with a brief incubation with DNAse. cDNA was prepared using 400ng of 
purified RNA from both WT and iCCR-/- samples as template using the RT2 First Strand Kit 
The cDNA was then mixed with RT2 Sybr Green and RNAse-free water according to 
manufacturer’s instructions, and 10μl of PCR component mix was added to each well 
containing primers specific for each gene of interest. Each 384-well plate contains 4 
replicates of 84 genes, enough for 2 WT repeats and 2 iCCR-/- repeats. The array was 
therefore repeated twice, thus bringing the number of repeats for both WT and iCCR-/- cells 
to 4.  The cycling conditions were chosen specifically for the BIORAD machine and the 
results analysed via the Web-based PCR Array Data Analysis Software after applying a 
stringent cycle threshold of 30.  
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3 Results- iCCR Knock-Out Strain 
 
3.1 Introduction 
 
The main inflammatory chemokine receptors CCR1, CCR2, CCR3, and CCR5 are expressed 
constitutively on a variety of leukocytes, and their expression can be upregulated or change 
altogether after differentiation or during inflammation.  ‘Classical’ inflammatory 
monocytes in the bone marrow initially express high levels of CCR2, but its expression 
rapidly decreases as maturation progresses. Conversely, CCR1 and CCR5 expression 
increases continuously with ongoing differentiation, reaching its highest values in 
terminally differentiated macrophages[188]. CCR5 expression in T-cells also fluctuates, 
increasing during differentiation of naive CD8 T cells to memory CD8 T cells and then 
decreasing during differentiation into effector CD8 T cells[250]. Even neutrophils, whose 
migration is largely dependent on CXC chemokine receptors CXCR1 and CXCR2[251], have 
been shown to increase expression of CCR1 and CCR2 during inflammation[252]–[254]. 
 
While studies on single knock-outs have highlighted the importance of each receptor, what 
has emerged is that no single iCCR is completely responsible for the migration of a 
particular subset.  Deletion of CCR3, the main chemokine receptor expressed on 
eosinophils[118][255], reduces the accumulation of these cells in the lung during 
inflammation by around 80%, but the residual perivascular and peribronchial eosinophils 
still contribute to disease[256]. Similarly, although CCR2 is expressed by virtually all 
‘classical’ Ly6C+ inflammatory monocytes, CCR2 deficient mice do not show a complete 
ablation of monocyte migration, but only an 80% reduction.  Some groups suggest that this 
finding is an indication that CCR2 does not mediate migration per se, but rather promotes 
monocyte attachment to endothelium, thus allowing other receptors on the surface of the 
monocyte to interact and begin migration in a CCR2 independent manner[257]. It could 
also be argued that the absence of CCR2 increases the levels of CCR2 ligands in the 
circulation (such as CCL2, CCL7, CCL8 and CCL12) making them available for interaction with 
lower affinity receptors such as CCR5, preserving some level of cellular migration. 
Furthermore, CCR2 and CCR5 have significant overlap in signalling machinery[258][38], and 
engagement of CCR5 alone could mediate some of the effects performed by CCR2, again 
promoting migration in its absence. 
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These findings imply that some compensatory mechanism may also be regulating iCCR 
expression, suggesting that any phenotype emerging from the inhibition of a single 
receptor could be ‘masked’ by the upregulation of others. It is only by generating a mouse 
in which the whole iCCR locus has been deleted that the issue of ICCR 
redundancy/compensation can be fully addressed.   
 
One of the main concerns in generating an iCCR -/- mouse was the effect that a whole cluster 
deletion would have on murine development.  Some leukocytes (such as monocytes) are 
necessary for vital processes of tissue formation and maintenance in embryogenesis, and 
while studies in single knock-outs have shown no obvious developmental abnormalities, a 
developmental phenotype might only emerge if the migration of these cells is completely 
abrogated when all the main inflammatory chemokine receptors are inhibited 
simultaneously. 
 
 
3.2 Role of Monocytes in Development 
 
Before being able to replenish tissue macrophages and DCs in the steady state, mediate 
direct antimicrobial activities and affect tissue development, monocytes and dendritic cell 
precursors (MDPs) have to egress from the bone marrow into circulation[259]. 
 
Generally, classical monocytes can remain in circulation for up to two days expressing high 
levels of CCR2 to respond to localised CCL2 induced by tissue injury or infection. If they 
have not been recruited to tissues, monocytes undergo apoptosis and are removed from 
the circulation[189]. If diapedesis does occur, then other cytokines in the 
microenvironment alter the monocyte’s fate. Generally, terminal differentiation of 
monocytes to macrophages is achieved by exposure to their primary growth and 
differentiation factor CSF-1, which is secreted by a number of cell types, including epithelial 
cells [186]. 
 
Alternatively, classical CCR2+ Ly6Chi monocytes recruited to sites of infection can also 
differentiate into dendritic cells that produce TNF𝛼 and iNOS which contribute to innate 
defence against pathogens such as L. monocytogenes, M. tuberculosis and various protozoa 
(Plasmodium, Toxoplasma and Leishmania)[260]. 
 68 
Remodelling deficiencies in the absence of macrophages have been noted in several 
tissues, including the mammary gland, kidney and pancreas, suggesting a general 
requirement for macrophages in tissue patterning and branching morphogenesis[261]. 
Skin-resident macrophages have recently been implicated in epithelial hair follicle stem cell 
activation during the murine hair cycle and their ablation resulted in hair growth inhibition 
[262]. Depletion of uterine and ovarian macrophages demonstrated their importance in 
normal progesterone synthesis in early pregnancy, which ultimately results in complete 
implantation failure[263]. In stem cell biology, similar roles for macrophages have been 
suggested in the maintenance of intestinal integrity and hepatic regeneration after damage 
[264]. 
 
Unexpected roles for macrophages in development can also be observed in erythropoiesis, 
where maturing erythroblasts surround macrophages that ingest the extruded erythrocyte 
nuclei[265]. In their absence, erythropoiesis is blocked and lethality soon ensues. In 
addition, spleen and liver macrophages are responsible for maintaining the haematopoietic 
steady state through engulfment of neutrophils and erythrocytes and depleting these 
macrophage populations results in neutropenia, splenomegaly and reduced body 
weight[266]. Macrophages also regulate angiogenesis through a number of mechanisms. 
Specifically, in the retina, macrophages secrete WNT, which in turn induces the expression 
of soluble VEGFR1. This ultimately reduces the availability of VEGF to the vascular 
endothelium, reducing branching and vascular complexity so that the vascular system is 
appropriately patterned[267]. Brain development is also controlled by macrophages, as 
microglia have been shown to promote neuron viability, modulate neuronal activity[268] 
and prune synapses during development[269], as well as expressing a range of neuronal 
growth and survival factors, including NGF[270].  
 
While the role of macrophages in development is becoming clearer, our understanding of 
the role of inflammatory chemokines in these processes is still at an early stage and limited 
to the study of single chemokine receptors knock outs. 
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3.3 Effect of iCCR Deletion on Murine Development 
 
 
Homozygous iCCR-/- mice were born at the expected Mendelian frequency from het/het 
crosses and were healthy and fertile. No differences in embryo size, foetal liver monocytes 
or cKIT+ haematopoietic progenitor cells were observed[271],  suggesting that iCCRs are 
not essential for embryonic developmental and postnatal survival, and their deletion does 
not result in gross developmental abnormalities. Once confirmed that no overt 
developmental phenotype was present, various iCCR-/- adult tissues were collected, 
processed and analysed (both at rest and under various inflammatory stimuli) to assess the 
extent of cellular migration and distribution of cellular subpopulations to specific tissues in 
the absence of CCR1 CCR2 CCR3 and CCR5. 
 
3.4 Effect of iCCR Deletion on Resting Tissues 
 
3.4.1 Bone Marrow 
 
The expression of iCCRs in the bone marrow and their role in leukocyte mobilisation from 
this niche has been addressed by several studies in the past, often resulting in conflicting 
information and incompatible mechanisms of action. For example, while the role of CXCR4 
in hematopoietic stem cell migration has been known for some time[272][273], more 
recently some groups have uncovered a potential role for CCR3[274], CCR1[275] and 
CCR2[276]. Similarly, a study by Flaishon et al. suggested that expression of CCR2 in 
immature B-cells is required to retain these cells in the bone marrow, as CCR2-/- B-cells 
exhibit up-regulation of chemokine-induced actin polymerisation, migration and increased 
homing of immature B-cells to the lymph node[83]. While in this study CCR2 expression 
was assessed by PCR, other groups failed to find functional CCR2 protein on those same 
cells[277], suggesting that even if CCR2 is detectable at the transcript level, there would 
not be enough protein to mediate any effects. 
 
In contrast to B-cell precursors, the roles that specific iCCRs have in regulating migration 
and function of other leukocyte subsets is a lot more obvious and unambiguous.  For 
example, the role of CCR2 in monocyte mobilisation from the bone marrow is well 
described[257] both in resting conditions[73] and inflammation[74]. Deletion of CCR2 
ligands, CCL2 or CCL7, was shown to diminish the recruitment of monocytes during 
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infection by approximately 50% [278]. Lack of CCR2 engagement does not allow for actin 
remodelling required for bone marrow extravasation, resulting in an accumulation of 
Ly6Chigh leukocytes in the bone marrow, severe impairment of the peripheral 
reconstitution of inflammatory monocytes and increased mortality in infectious models of 
inflammation[279][74].  
 
To assess the effects of deletion of the 4 main iCCRs on the cellular composition of the bone 
marrow, iCCR-/- bone marrow was extracted and compared to WT, CCR1, CCR2, CCR3 and 
CCR5 single knock-out mice.  
In all strains, neutrophils were the most prominent bone marrow leukocyte subset, 
representing approximately 35% of all live cells recovered. Immature B-cell numbers were 
the second most prominent subset, representing approximately 10% of all live cells in all 
strains examined. None of these lineages were affected in the iCCR-/-. Similarly, T-cell 
precursor numbers (~3%) and dendritic cells were also not affected by the iCCR deletion 
(Figure 3-1A). 
 
Figure 3-1 Leukocyte Subpopulations in Resting Bone Marrow. A – Bone marrow leukocyte 
subpopulations in resting bone marrow from WT, CCR2-/- and iCCR-/- mice. B- Normalised Inflammatory 
Monocyte numbers in WT, Het, CCR2-/- and iCCR-/- bone marrow. C- Representative FACS plots showing 
inflammatory monocytes (CD45+ CD11b+Ly6C++Ly6G-) in CCR2 and iCCR-/- bone marrow compared to 
WT. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was performed to determine 
statistical significance, with a p value of 0.05 determined as significant, n>3. 
 
Curiously, even inflammatory monocytes were not affected, with no significant 
accumulation observed in the iCCR-/-  (WT: 6.79%, iCCR-/- : 7.15%) and in the CCR2-/- bone 
marrow (7.86%) (Figure 3-1A,C). As this was unexpected, further experiments using 
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counting beads to determine actual numbers of inflammatory monocytes confirmed that 
there was no difference in the number of inflammatory monocytes at rest in WT, CCR2 and 
iCCR-/- bone marrow (Figure 3-1B), in contrast with previous studies on CCR2-/- 
mice[74][280].  
 
 
Figure 3-2 Eosinophil Subpopulations in Resting Bone Marrow- A- Representative FACS plots showing 
mature (Siglec F++) and Immature (Siglec F+) Eosinophil populations in WT, CCR1, CCR2, CCR3, CCR5 and 
iCCR-/- bone marrow. B- Graphs summarising normalised mature (Siglec F++) and immature (Siglec F+) 
eosinophil numbers in resting bone marrow in each iCCR-/- strain. Ordinary one-way ANOVA with 
Dunnett’s multiple comparisons test was performed to determine statistical significance, with a p value 
of 0.05 determined as significant, n>3.  
 
Eosinophils were the only major leukocyte subset showing profound differences when 
comparing WT, CCR2 and iCCR-/- resting bone marrow sub-populations. As seen from the 
representative FACS plots in Figure 3-2A, 2 populations of eosinophils can be found in the 
resting bone marrow of iCCR-/- mice, a Siglec F+ and Siglec F bright population. Analysis of 
bone marrow from CCR1, CCR3 and CCR5 single knock-out mice showed that the 
phenotype observed in the iCCR-/- is attributable to CCR3 deletion only (Figure 3-2B,C), as 
the CCR3-/- also shows the presence of two eosinophil populations (Figure 3-2A). These 
results suggest that CCR3 might be required for bone marrow egress of mature (Siglec F 
bright) eosinophils. Furthermore, the absence of this Siglec F bright populations from WT, 
CCR1, CCR2 and CCR5-/- bone marrow may suggest that CCR3 is upregulated only when 
eosinophils mature from Siglec F+ to Siglec F++. As soon as a mature eosinophil expresses 
CCR3, extravasation into the blood can occur, explaining why only a single Siglec F+ 
eosinophil population was detectable in the CCR1, CCR2 and CCR5-/- strains. 
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3.4.2 Blood 
 
 
Analysis of peripheral blood leukocytes showed a marked reduction in CD11b+ F480 low 
cells in iCCR-/- circulation (FACS plots Figure 3-3A). Further gating with Ly6C showed that 
this overall reduction is attributable to a decrease in two main subpopulations (Figure 3-
3B,C), the inflammatory monocytes (CD11b+ F480 low Ly6C++), and patrolling monocytes 
(CD11b+ F480 low Ly6C low) both of which reportedly express CCR2 [276][187].  
 
 
Figure 3-3 Leukocyte Subpopulations in Resting Blood- A- Representative FACS plots showing the 
reduction in CD11b+F480 low cells in CCR2-/- and iCCR-/- circulation. B- Graph summarising the 
distribution of several leukocyte subsets in WT, CCR2 -/- and iCCR-/- resting circulation. C- Summary of 
normalised inflammatory monocyte (F480 lo Ly6C++) numbers from WT, CCR1-/-, CCR2-/-, CCR3-/- and 
CCR5-/- blood. D- Summary of normalised patrolling (F480+Ly6C low) monocyte numbers from WT, CCR1-
/-, CCR2-/-, CCR3-/- and CCR5-/- blood. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test 
was performed to determine statistical significance, with a p value of 0.05 determined as significant, n>3 
CCR2-/- mice displayed a similar reduction in both circulating Ly6C++ monocytes (WT: 
0.93%, CCR2-/-: 0.31%, iCCR-/-: 0.41%)  and patrolling macrophages (WT: 0.97% , CCR2-/-: 
0.58%, iCCR-/-: 0.76%), indicating that, in terms of peripheral blood leukocyte 
subpopulations, iCCR-/- mice are essentially a phenocopy of CCR2-/- mice.  
There was also a modest but significant reduction in circulating Ly6C++ monocytes in the 
blood of CCR1-/- mice (WT: 1.23%, CCR1-/- 0.81%). While this defect has been mentioned in 
the literature before [281], the relevance is unclear as the overall defect observed in iCCR-
/- mice can be wholly attributed to CCR2, with no evidence of an additive reduction brought 
by the absence of CCR1 in iCCR-/- circulation. Eosinophils were also reduced in iCCR-/- 
circulation (Figure 3-3B). 
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While the data presented so far compared blood and bone marrow across all knock out 
strains, the remaining analysis on resting tissues will focus on WT, CCR2-/- and iCCR-/- KO 
samples. A more complete analysis including  CCR1, CCR3 and CCR5-/- skin, lung and spleen 
samples was performed by Dr. Dyer and Dr. Medina-Ruiz[271]. 
 
 
 
3.4.3 Skin 
 
Various organs, such as skin, lung and spleen were also analysed to determine if the 
observed defects found in iCCR-/- blood and bone marrow would amplify as the leukocytes 
continue to migrate towards their target organ. Indeed, just by looking at the number of 
CD45+ cells in resting skin samples it was apparent that iCCR-/- skin contained fewer 
leukocytes when compared to the WT (WT: 10.5% of live cells, iCCR-/-: 3.5%, Figure 3-4A). 
While CCR2-/- skin also had a reduction in skin CD45+ cell content (6.5%, Figure 3-4A,C), the 
defect was more pronounced in iCCR-/- skin, suggesting an additional role for CCR1, CCR3 
and CCR5. 
 
 
Figure 3-4 - Leukocyte Subpopulations in Resting Skin. A- Number of CD45+ cells (expressed as % of live) 
in excised resting skin from WT, CCR2 and iCCR-/-. B-- Representative FACS plots (after CD45 and CD11b 
gating) showing 3 main subpopulations in WT and iCCR-/- skin: CD11c+MHCII+, CD11c+ MHCII int and 
CD11c-MHCII- representing dendritic cells, macrophages, and monocytes/eosinophils respectively.  C- 
Graph summarising the distribution of different leukocyte subpopulations in WT, CCR2 and iCCR-/- resting 
skin. Data representative of one experiment with n>4. Ordinary one-way ANOVA with Dunnett’s multiple 
comparisons test was performed to determine statistical significance, with a p value of 0.05 determined 
as significant. 
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Further flow cytometric analysis on CD45+ CD11b+ cells revealed a substantial reduction in 
3 distinct populations in iCCR-/- skin: CD11c-MHCII-, CD11cloMHCII int and CD11c+MHCII++, 
corresponding to monocytes/eosinophils, tissue macrophages and dendritic cells 
respectively (Figure 3-4B). Whilst both iCCR-/- and CCR2-/- skin displayed a similar ~50% 
decrease in DC numbers, the reduction observed in macrophage numbers was significantly 
greater in iCCR-/- mice (~65% reduction against 80% reduction in the full knock-outs) (Figure  
3-4C) 
 
Furthermore, while the defects in eosinophils were also seen in CCR3-/- skin[271], tissue 
macrophage and DC numbers were unaltered in CCR1, CCR3 and CCR5-/- [271], indicating 
that no single receptor can account for the substantial reduction in the aforementioned 
leukocyte subsets. Together, these data suggest that multiple iCCRs can contribute to the 
effective establishment of myeloid leukocyte subpopulations in the skin, hinting at some 
degree of redundancy of receptor involvement which was not observed in either blood or 
bone marrow. No difference was detected in any lymphoid cell subtype in resting skin of 
any of the single receptor null mice[271]. 
 
 
 
 
3.4.4 Spleen and Lung 
 
 
Leukocyte distribution in resting spleen generally recapitulated the same defects observed 
in resting circulation, with lymphoid cell populations unaffected and a decrease in Ly6C++ 
inflammatory monocytes, observed in both iCCR and CCR2-/- mice (Figure 3-5 A,B). Unlike 
tissue macrophages in the skin however, red pulp macrophage numbers (a tissue specific 
set of tissue macrophages) were unaffected by iCCR deletion. This was expected, as it has 
been shown that red pulp macrophages differ from other resident macrophage populations 
not just in function but also origin[282]. 
 
 75 
 
Figure 3-5- Leukocyte Subpopulations in Resting Spleen. A- Graph summarising leukocyte distribution 
in the spleen of resting WT, CCR2 and iCCR -/- mice. B- Representative FACS plots showing spleen 
Inflammatory monocytes (Ly6C++ F480 low) and eosinophils (Ly6Cint F480+). Data representative of one 
experiment with n>4. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was 
performed to determine statistical significance, with a p value of 0.05 determined as significant 
During foetal development, macrophages derived from embryonic yolk sac and foetal liver 
precursors are seeded throughout various tissues in a CCR2 independent manner 
[283][284][285] and persist in the adult as resident, self-maintaining populations. These 
include microglia in the brain, red pulp macrophages in the spleen and alveolar 
macrophages in the lung, all of which turn over locally under steady state conditions and 
perform a variety of clearance and organ-specific trophic functions, such as pruning of the 
neuronal synapses[269] or clearance of damaged or senescent erythrocytes in the 
spleen[282]. 
 
After birth, CCR2+ bone marrow-derived blood monocytes replenish resident macrophage 
populations with high turnover[286] in organs with direct contact with the external 
environment, such as the skin, lung or gut. These inflammatory monocytes are recruited in 
larger numbers following infection or injury, giving rise to infiltrating activated tissue 
macrophages. It is therefore unsurprising that red pulp macrophage numbers in the spleen 
(Figure 3-5A) and alveolar macrophage numbers in the lung (Figure 3-6A) were unaffected 
by iCCR deletion, while both organs also showed a lack of Ly6C+ inflammatory monocytes 
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(Figure 3-6C, Representative FACS plots Figure 3-6B). Similarly to the resting spleen, resting 
lung lymphoid cell numbers were also unaltered (Figure 3-6A). 
 
 
Figure 3-6- Leukocyte Subpopulations in Resting Lung. A- Graph summarising leukocyte distribution in 
the lung of resting WT and iCCR -/- mice. B- Representative FACS plots showing lung Inflammatory 
monocytes (CD11b+ Ly6C++) in WT, CCR2 and iCCR KO mice. C- Summary and comparison of spleen and 
lung inflammatory monocytes (CD11b+ F480 low Ly6C++) from WT, CCR2, iCCR -/- and iCCR -/+ 
heterozygous mice. Data representative of one experiment with n>4. Ordinary one-way ANOVA with 
Dunnett’s multiple comparisons test was performed to determine statistical significance, with a p value 
of 0.05 determined as significant. 
Dendritic cell numbers were also found reduced in iCCR-/- lung tissues (Figure 3-6A), and 
this minor defect was also observed in CCR2-/- lungs[271]. While a defect in chemotaxis of 
DC precursors might explain this phenotype, other groups have also reported altered DC 
activation and function in CCR2-/- lungs characterised by abrogated MHCII and CD40 
expression in these cells[102], hinting at an additional role for CCR2 in supporting function, 
maturation and proliferation of dendritic cells in situ. 
 
3.4.4.1 Lung Alveolar Macrophages 
 
Broncho-alveolar lavages of iCCR-/- and WT lungs confirm that local tissue resident 
populations are unaffected by iCCR deletion (Figure 3-7 Ai, Representative FACS plots 3-
7Aii). While the number of cells recovered from lung lavages after exposure to LPS was 
lower in iCCR-/- lungs compared to WT (Figure 3-7A), flow cytometric analysis of the cellular 
content revealed this decrease was attributable to impaired inflammatory monocyte and 
dendritic cell recruitment (Figure 3-7B), while the numbers of neutrophils and alveolar 
macrophages were unaffected by iCCR deletion (Figure 3-7B and Representative FACS plots 
3-7C). 
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While there have been reports in the literature of recruited inflammatory monocytes 
replacing alveolar macrophages during inflammation[287], the fact that the number of 
alveolar macrophages recovered from WT and iCCR-/- lung lavages is identical (Figure 3-7B) 
suggests that alveolar macrophages are maintained via self-renewal, with minimal input 
from recruited blood inflammatory monocyte in cases of acute inflammation[288][289]. 
 
 
Figure 3-7- Alveolar Macrophage Populations in iCCR-/- Lungs.  A- Pooled cells recovered after 3 1ml 
broncho-alveolar lavages (BALs) with PBS+EDTA of WT and iCCR -/- lungs. Aii- Representative FACS plots 
of resting BAL in WT and iCCR -/- lungs showing alveolar macrophages (CD11b+ Ly6C- Ly6G- F480+ 
SiglecF+ CD11c+) are the only cell type present in the alveolar space under resting conditions. B- Graph 
showing the different cell types recovered from BALs in WT and iCCR -/- lungs 48 hours after the lungs 
were exposed to a single dose of LPS. C- Representative FACS plots showing an absence of dendritic cells 
and inflammatory monocytes in BALs of inflamed iCCR -/- lungs compared to WT. Ordinary one-way 
ANOVA with Dunnett’s multiple comparisons test was performed to determine statistical significance, 
with a p value of 0.05 determined as significant. Data representative of one experiment with n=4. 
Overall, the data so far show that resting iCCR-/- tissues are characterised by comprehensive 
depletion of a range of myelomonocytic cell subtypes which varies according to tissue type. 
Inflammatory monocyte and eosinophil numbers are profoundly affected, although the 
absence of CCR2 and CCR3 are generally enough to explain all the phenotypes observed in 
the full iCCR-/-. The only evidence so far of a possible contribution of other iCCRs in directing 
leukocytes to different organs was found in the skin, where a decrease in skin macrophages 
in iCCR-/- mice could not be completely explained by the absence of CCR2. Tissue resident 
populations with distinct phylogenetic origin, such as alveolar macrophages in the lung or 
red-pulp macrophages in the spleen, were not affected by iCCR deletion. 
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At this stage however, it was still unclear if impaired chemotaxis was wholly responsible 
for the observed phenotype (i.e. decreased chemotaxis when CCR1, CCR2 and CCR5 are all 
absent), or if the absence of certain iCCRs is preventing maturation and proliferation of 
certain leukocyte subsets, further exacerbating the defect. In other words, while the 
absence of CCR2 would explain 65% of the reduction in skin tissue resident macrophages, 
it is unclear if the 80% reduction seen in the full knock-out is caused by impaired 
chemotaxis caused by the absence of CCR1 and CCR5, or if the lack of CCR1 and CCR5 
decreases the ability of skin tissue macrophages to mature and proliferate, reducing their 
overall numbers. 
 
3.5 Effect of iCCR deletion on Inflammation 
 
 
3.5.1 Skin Inflammation- Overview 
 
After establishing the ‘resting’ phenotype of iCCR-/- leukocyte subpopulations in most 
organs, the mice were then exposed to a variety of inflammatory agents to uncover the 
effect of iCCR deletion on the development of the inflammatory response. 
 
Aldara cream was initially chosen as a model for skin inflammation, mainly due to ease of 
application and the brief time between the first application and analysis[245]. Briefly, the 
back of the mice was shaved and ¼ of a sachet of Aldara cream was applied to the shaved 
area daily for 4 consecutive days. Mice were then culled, and various tissues (including the 
skin at the site of direct application) were collected, digested, and analysed via flow 
cytometry. 
 
Aldara is routinely used as a topical treatment for a variety of skin conditions, including 
genital warts and small superficial skin cancers[245]. The active ingredient, Imiquimod, is a 
TLR7 agonist. Toll-like-receptor 7 is usually expressed in the endosomes of macrophages 
and dendritic cells, and detects single stranded RNA, a common feature of viral genomes 
that have either been endocytosed directly by the cell or are already present inside the 
cytoplasm after infection. Activation of TLR7 induces a potent anti-viral response, 
characterised by the production of IL-1𝛽, IFN𝑦, TNF𝛼 and other pro-inflammatory 
cytokines that activate local cells and induce the recruitment of blood leukocytes to the 
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site of inflammation[290]. This strong and localised inflammatory response can override 
immune evasion mechanisms used by viruses or small cancers to persist in the skin, 
ultimately causing warts and basal cell carcinomas to regress and fade away[291]. 
 
3.5.2 Imiquimod Induced Skin Inflammation  
 
After 4 days of repeated Aldara cream application and before analysing tissues, skin 
thickness from iCCR-/-, CCR2-/- and WT mice was measured using a caliper. As shown in 
Figure 3-8A, iCCR-/- skin showed reduced thickness when compared to inflamed WT and 
CCR2-/- skin, suggesting reduced localised inflammation. Histological analysis of involved 
skin performed by Dr. Dyer also showed a reduction in the number of inflammatory cells in 
the dermis [271], suggesting either reduced recruitment, lack of proliferation at the site of 
Aldara cream application or a combination of both. iCCR-/- mice also show reduced 
Spleen/Body mass ratio compared to WT, indicating reduced systemic inflammation after 
4 days of Aldara cream application to the skin (Figure 3-8B). 
 
Figure 3-8- Effects of Imiquimod Treatment to Murine Skin. A- Caliper measurements of skin thickness 
after Aldara treatment to the skin in WT, CCR2 and iCCR -/- mice. B- Graph summarising spleen to body 
mass ratio from WT and iCCR Imiquimod treated mice.  
The site of skin application was also assessed for redness (erythema), scaling and thickness, 
the three main indices used to measure the severity of psoriasis. The scores for each were 
then combined to determine a single PASI score (Psoriasis Area and Severity Index) that 
would represent the severity of the lesion of the affected area on a scale from 0 (no 
disease) to 72 (maximal disease). As seen in Figure 3-9, iCCR-/- skin showed reduced 
erythema, scaling and thickness, with a combined average PASI score at day 5 of 21, while 
WT skin scored an average of 27. While iCCR-/- skin generally scored lower than WT skin, 
the results were highly variable and overall difference was not statistically significant. 
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Figure 3-9 Severity of Erythema, Scaling and Thickness of Imiquimod Inflamed Skin in WT and iCCR -/- 
mice- A- Daily summary of the progression of severity of skin inflammation in WT and iCCR-/- mice, 
measured as a combined PASI score combining Erythema, Scaling and Skin thickness scores. B- Summary 
of the development of Erythema, Scaling and Skin thickness from day 1 of Imiquimod application to day 
5 (culling day) in WT (black) and ICCR -/- (red) skin. 1= no symptom, 3= maximum severity. 
 
 
3.5.3 Bone Marrow and Blood Subpopulations- Imiquimod 
 
Bone marrow, blood and affected skin were also collected and analysed via flow cytometry 
to assess the cellular composition of these organs during inflammation. After exposure to 
Imiquimod, Ly6C++ inflammatory monocytes were found elevated in both CCR2-/- and iCCR-
/- bone marrow (WT: 15.3%, CCR2-/-: 19.3%, iCCR-/-: 19.3%, Figure 3-10A, 3-10B), in line with 
previous studies showing an accumulation of inflammatory monocytes in the bone marrow 
after CCR2 deletion during inflammation[292][74]. Similarly to resting blood, circulating 
inflammatory monocytes are reduced in Imiquimod treated iCCR-/- (Figure 3-11A), but 
during inflammation this defect becomes more severe. This time, while inflammatory 
monocytes constitute on average 10% of CD45+ cells in WT circulation, iCCR-/- Ly6C++ 
monocytes are found at significantly lower levels (4%) than in CCR2-/- circulation (6%) 
(Figure 3-11 B), suggesting an additional role of CCR1 and CCR5 in recruitment of 
inflammatory monocytes during Imiquimod-induced inflammation.  
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Figure 3-10- Bone Marrow leukocyte subpopulation in Imiquimod Treated Mice. A – Bone marrow 
leukocyte subpopulations in Inflamed bone marrow from WT, CCR2 and iCCR -/- mice. B- Representative 
FACS plots from WT, CCR2 and iCCR -/- bone marrow showing the distribution of inflammatory monocytes 
(Ly6C++ Ly6G-) and neutrophils (Ly6C int Ly6G++). Ordinary one-way ANOVA with Dunnett’s multiple 
comparisons test was performed to determine statistical significance, with a p value of 0.05 determined 
as significant. Data representative of one experiment with n=5. 
 
Furthermore, alterations in circulating lymphoid subpopulations were observed for the first 
time in iCCR-/-. As seen in Figure 3-11 C, both NK and CD8+ CD44+ T-cells appear elevated 
in iCCR-/- blood, and this difference does not seem to be attributable to CCR2, as CCR2-/- 
blood shows normal T-cell numbers (NK- WT: 8.8%, CCR2-/-: 9.2%, iCCR-/-: 17.8%. CD8mem- 
WT: 2.0%, CCR2-/-: 3.2%, iCCR-/-: 4.5%). 
 
Activated T-cells upregulate CD44[293], and are known to express CCR3, CCR5[294] and NK 
cells CXCR4, but also CCR1, CCR2 and CCR5[295][296]. Lack of some iCCRs might therefore 
prevent these specific leukocyte subsets from reaching their final destination in the dermis, 
leading to an accumulation in the circulation. 
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Figure 3-11- Blood leukocyte subpopulation in Imiquimod Treated Mice. A- Representative FACS plots 
showing inflammatory monocytes (CD11b+ Ly6C++) in WT, CCR2 and iCCR -/- circulation.  Ordinary one-
way ANOVA with Dunnett’s multiple comparisons test was performed to determine statistical 
significance, with a p value of 0.05 determined as significant. B- Blood Leukocyte subpopulations in 
inflamed blood from WT, CCR2 and iCCR -/- mice. C- Blood T-cell subpopulations in inflamed blood from 
WT, CCR2 and iCCR -/- circulation. Blood data representative of two experiments with n=3. T-cell data of 
one experiment with n=5.  
 
 
3.5.4 Skin Subpopulations and Resolution- Imiquimod 
 
The site of cream application was also excised, digested and analysed via flow cytometry. 
The number of CD45+ cells in skin was significantly lower in iCCR-/- mice (Figure 3-12A), and 
further analysis showed that tissue macrophages, inflammatory monocytes and monocyte 
derived dendritic cells were all reduced (Figure 3-12B). Again, this was expected, as 
monocytes from the bloodstream can differentiate in situ into either tissue macrophages 
or monocyte derived dendritic cells under inflammatory conditions[297][259]. Further 
analysis in CCR1, CCR2, CCR3 and CCR5-/- skin performed by Dr. Dyer and Dr. Medina-Ruiz 
showed that the decrease observed in multiple iCCR-/- myeloid leukocyte subsets could be 
attributed to lack of progenitor monocytes in circulation caused by the deletion of CCR2 
exclusively[271]. 
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Figure 3-12- Skin Leukocyte Distribution after Imiquimod Induced Inflammation. A- CD45+ cell counts 
in excised Imiquimod treated skin from WT and iCCR -/- mice. B- Graph summarising the number of tissue 
macrophages, monocyte derived DCs and inflammatory monocytes detected in excised inflamed skin 
samples. C- Representative FACS plots showing the decrease in CD11b+CD11c- (tissue macrophages and 
inflammatory monocytes) and CD11b+ CD11c+ (monocyte derived DCs) subpopulations in excised 
inflamed skin samples. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was 
performed to determine statistical significance, with a p value of 0.05 determined as significant. Data 
representative of one experiment with n=5. 
 
While a reduction in inflammation was indeed observed, it was still unclear if iCCR-/- mice 
were genuinely incapable of mounting an efficient inflammatory response, or if 
inflammation was just delayed and leukocytes would eventually be able to reach the target 
organ using iCCR independent pathways. The ability of iCCR-/- mice to resolve inflammation 
was therefore also assessed. 
 
Following imiquimod application, the mice were allowed to recover for 1 week, and their 
tissues were again analysed via flow cytometry to uncover any differences in resolution of 
inflammation. One week after inflammation, both WT and iCCR-/- tissues showed the same 
differences previously seen in resting tissues (Figure 3-13 A,B), suggesting that iCCR-/- mice 
can resolve effectively with no evidence of delayed onset inflammation. 
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Figure 3-13- Resolution of Inflammation after Imiquimod- A- Leukocyte Distribution in murine 
circulation six days after the final application of Imiquimod to the skin. B- Summary of the fluctuation of 
circulating inflammatory monocytes before, during and after inflammation (Ly6C++ F480 low) in WT 
(black), CCR2 -/- (dark blue), iCCR -/- (light blue). Ordinary one-way ANOVA with Dunnett’s multiple 
comparisons test was performed to determine statistical significance, with a p value of 0.05 determined 
as significant. Data representative of one experiment with n=5. 
 
 
3.5.5 Discussion- Imiquimod Model 
 
Collectively, the data generated so far showed that iCCR cluster deletion results in a 
dramatic reduction in the recruitment of myeloid cells both to resting tissues and to the 
site of inflammation, and a disruption activated T-cell and NK cell chemotaxis leading to an 
accumulation of these lymphoid subsets in the circulation. It was also obvious, however, 
that iCCR-/- mice are indeed capable of mounting an inflammatory response when treated 
with Imiquimod, as swelling and redness at the site of cream application was readily 
observed. 
 
 It was also surprising that most of the phenotypes observed were generally attributable to 
the deletion of a single receptor, CCR2, with little evidence of a combinatorial effect 
brought by the simultaneous deletion of CCR1 CCR3 and CCR5. Differentiated tissue 
macrophages have been shown to upregulate CCR1 and CCR5, and it has been suggested 
these two receptors contribute to the recruitment of monocytes into or within inflamed 
tissues[298][188]. Using this specific model of inflammation however, it appears that the 
contribution of CCR1 and CCR5 to the maintenance of tissue macrophages and monocyte 
derived dendritic cell populations in the skin is negligible.  
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The use of Imiquimod as an inflammation model however might offer an explanation for 
this discrepancy. Aldara cream has been shown to activate the immune response in TLR7 
independent pathways: isosteric acid alone, one of the components of Aldara cream, has 
been shown to activate the inflammasome directly ultimately causing the release of the 
pro-inflammatory cytokine IL-1[299]. Other studies have also shown how the 
administration route of Aldara can have a dramatic impact on the development of skin 
inflammation. While the effects of Imiquimod ingestion on the development of dermatitis 
has never been tested before, Grine et al. tried to address the issue by placing small plastic 
“Elizabethan collars” on the mice to prevent them from licking their back skin. The group 
found that unintentional ingestion of Aldara can result in an inflammatory loop in which 
the intestine system enhances the inflammation of the skin via the release of high levels of 
type 1 interferons. Thus, while the topical treatment with Aldara does indeed induce 
dermatitis-like skin inflammation, the mode of action partially depends upon ingestion of 
the chemical, as preventing oral uptake blocked not only the systemic effects but also 
decreased the severity of local cutaneous inflammation[300].  
 
Tissue macrophages have been shown to proliferate after stimulation with IFNy [301]–
[303], suggesting that production of gut type 1 interferons caused by ingestion of Aldara 
cream might be activating and promoting the proliferation of skin tissue macrophages, 
masking the effects of CCR1 and CCR5 deletion in iCCR-/- skin. Thus, while the Aldara model 
is easy to perform, local proliferation of tissue-resident leukocytes may be confounding the 
contribution that recruited leukocytes bring to the development of inflammation. 
Furthermore, unintentional ingestion of Aldara cream by some mice might explain the high 
variability observed when assessing erythema, scaling and skin thickness. A new model of 
localised inflammation was therefore required, one in which the amount of inflammatory 
irritant can be controlled more effectively and where local tissue-resident leukocytes 
would only contribute minimally to the development of the immune response. 
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3.6 Effect of iCCR deletion on Synovial Inflammation – 
Air Pouch Model 		
3.6.1 Air Pouch Model- Overview 
 
In the air pouch model, an air pouch is produced by the subcutaneous injection of sterile 
air under the dorsal skin of the mouse. The resulting cavity, providing a new localized 
environment in which to study cell trafficking and inflammatory responses. After repeated 
air injections, the pouch stabilises forming a thin protective membrane, which is essentially 
a new organ lacking any resident leukocyte populations. The stabilised cavity can be then 
be filled with inflammatory irritants that have known effects, such as the sea-weed extract 
carrageenan, and the membrane around the airpouch and the fluid inside can be analysed 
via flow cytometry to determine leukocyte recruitment. In addition, as the air pouch does 
not contain any resident leukocytes, this offers the opportunity to observe recruitment de 
novo without the confounding presence and contribution of resident cells. 
 
Carrageenan extract has been routinely used for decades [246][304] to induce 
inflammation and to test the efficacy of novel anti-inflammatory agents [305][306]. 
Tumour Necrosis Factor a (TNF𝛼) and vasodilator prostaglandin E2 can be detected as soon 
as 3 hours after Carrageenan administration in the air-pouch[307],  rapidly followed by high 
levels of pro-inflammatory cytokines such as IL-1𝛽 and IL-6, iNOS (inducible nitric oxide 
synthase)[308] and  vascular endothelial growth factor (VEGF) [309].  
 
All these inflammatory mediators work together to rapidly recruit leukocytes from the 
circulation: vasodilation induced by prostaglandin E2 increases blood flow to the air pouch, 
VEGF secretion increases the expression of adhesion protein ICAM-1 on endothelial cells 
[310], aiding chemotaxis and trans-endothelial migration of leukocytes that have been 
activated by exposure to circulating TNF𝛼, IL-1𝛽 and IL-6. 
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3.6.2 Bone Marrow and Blood Subpopulations – Air Pouch 
 
Bone marrow leukocytes in the bone marrow 48 hour after carrageenan injection into the 
air-pouch showed a similar distribution observed in Imiquimod treated mice, with an 
accumulation of classical Ly6C++ inflammatory monocytes observed in both CCR2-/- and 
iCCR-/- mice (Figure 3-14 A, Representative FACS plots 3-14B). This accumulation however 
is surprisingly more severe in CCR2-/- (WT: 8.9%, CCR2-/-: 15.9%, iCCR-/-: 12.2%, Figure 3-
14C). 
 
Three different mechanisms might be at play here: lack of all iCCRs simultaneously might 
either be promoting iCCR independent migration by inflammatory monocytes causing 
some to escape the bone marrow regardless of CCR2 expression, or iCCR absence in bone 
marrow might be affecting proliferation rates and activation of inflammatory monocytes.  
In other words, while the absence of CCR2 does indeed trap Ly6C++ monocytes in the bone 
marrow, engagement of CCR1 and CCR5 might be providing survival and proliferation 
signals to the developing monocytes. In their absence, the inflammatory monocytes would 
be both trapped and proliferating more slowly, resulting in an accumulation of monocytes 
similar to CCR2-/-, but in lower numbers.  
 
Alternatively, this apparent accumulation in CCR2-/- bone marrow may be the results of a 
shift in percentage in the iCCR-/- due to the accumulation of other cells which are not 
accounted for. For example, mast cells are also reportedly present in the bone 
marrow[311] and express CCR3[118]. In iCCR-/- bone marrow, the presence of additional 
trapped leukocytes might skew the percentages, making inflammatory monocytes appear 
less frequent in terms of percentage when compared to CCR2-/- bone marrow. 
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Figure 3-14- Air Pouch Bone Marrow Leukocyte Subpopulations- A-Summary of the main leukocyte 
subpopulations present in iCCR -/-, CCR2 -/- and WT BM after Imiquimod induced Inflammation. B- 
Representative FACS plots showing neutrophils (Ly6Cint Ly6G++) and inflammatory monocytes (Ly6Gint 
Ly6C++) in WT, CCR2 -/- and iCCR -/- BM. C- Graph comparing normalised Inflammatory monocyte 
(CD11b+ Ly6Gint Ly6C++) numbers in CCR1 -/-, CCR2 -/-, CCR3 -/-, CCR5 -/- and iCCR -/- and their respective 
WT. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was performed to determine 
statistical significance, with a p value of 0.05 determined as significant (n>3). 
The distribution of leukocytes in the circulation 48 hours after carrageenan administration 
into the air pouch showed a similar pattern to what has been observed in Imiquimod 
treated mice (Figure 3-15 A, Representative FACS plots 3-15B) but the defect was more 
severe.  
 
iCCR deletion resulted in an approximate 90% reduction of the number of circulating 
inflammatory monocyte(WT: 2.1% iCCR: 0.28%), while the reduction observed in the 
circulation of Imiquimod treated mice was closer to 30% (WT: 5.5%, iCCR: 3.8%). A minor 
but significant difference in patrolling monocytes was also seen in CCR1-/- circulation 
(Figure 3-15C), but just like in Imiquimod treated mice, its biological relevance is unclear as 
the defect observed in iCCR-/- circulation can be wholly attributed to CCR2, with no 
evidence of an additive reduction brought by the absence of CCR1.  
 
Similarly to inflamed skin in the Imiquimod model, the membrane around the pouch was 
removed, digested and its cellular content analysed, together with the cells in the air pouch 
fluid itself. 
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Figure 3-15 Air Pouch Blood Leukocyte Subpopulations- A-Summary of the main leukocyte 
subpopulations present in iCCR -/-, CCR2 -/- and WT BM after Imiquimod induced Inflammation. B- 
Representative FACS plots showing neutrophils (Ly6Cint Ly6G++) and inflammatory monocytes (Ly6Gint 
Ly6C++) in WT, CCR2 -/- and iCCR -/- BM. C- Graph comparing normalised Inflammatory monocyte 
(CD11b+ Ly6Gint Ly6C++) numbers in CCR1 -/-, CCR2 -/-, CCR3 -/-, CCR5 -/- and iCCR -/- and their respective 
WT. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was performed to determine 
statistical significance, with a p value of 0.05 determined as significant. (n>3) 
 
3.6.3 Membrane Subpopulations – Air Pouch Model 
 
The cellular content of the air pouch membrane in iCCR-/- mice contained virtually no 
dendritic cells, macrophages or eosinophils. While the absence of dendritic cells was 
attributed to the lack of CCR2 exclusively (Figure 3-16 A,C) and the absence of eosinophil 
to CCR3 (Figure 3-16 C), macrophages in the air pouch (CD64+ F480+) were significantly 
more reduced in iCCR-/- membranes (99% reduction) compared to CCR2-/- (95% reduction 
compared to WT). This is evident in the representative FACS plots in Figure 3-16 B, showing 
a residual CD64+CD11b+ population in CCR2-/- samples, but a complete absence in iCCR-/- 
membranes. While the more profound defect in the iCCR-/- mice could be explained by a 
contribution of CCR1 and CCR5 to chemotaxis, the single knock-outs did not show any 
reduction in membrane macrophage numbers (Figure 3-16C), suggesting some level of 
redundancy by which CCR1 and CCR5 need to be deleted simultaneously to achieve a 
complete block of recruitment from circulation. 
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Figure 3-16 Air Pouch Membrane Leukocyte Subpopulations-  A- Summary of the main leukocyte 
populations in the membrane surrounding the air pouch in WT, CCR2 -/- and iCCR -/- mice. B- 
Representative FACs plots showing an absence of CD11b+ CD64+ cells in iCCR -/- membranes compared 
to CCR2 -/- and WT air pouch membranes. C- Graph comparing normalised Dendritic Cell (CD11b+ CD64+ 
CD11c+ MHCII ++), Macrophage (CD11b+ CD64+ CD11c- MHCII int F480 low Ly6C+) and eosinophil (CD64-
CD11b+ Ly6G- Siglec F+) numbers  in CCR1 -/-, CCR2 -/-, CCR3 -/-, CCR5 -/- and iCCR -/- and their respective 
WT. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was performed to determine 
statistical significance, with a p value of 0.05 determined as significant (n>3). 
 
What is also unclear is the nature of the residual population seen in CCR2-/- membranes but 
completely absent in the full knock-outs (Figure 3-16B). This monocyte/macrophage 
population either represents a phenotypically discrete CCR2 independent population 
dependent on CCR1 and CCR5, or could be the result of ‘leaky’ monocytes that have 
escaped the bone marrow and have managed to home to the membrane using CCR1 and 
CCR5 exclusively.   
 
To address the issue, these cells were isolated from the air pouch of WT and CCR2-/- mice 
and their transcriptomic profile was compared[271]. The two populations differed 
significantly in gene expression, with 222 upregulated and 218 downregulated transcripts. 
This residual population in the CCR2-/- air pouch was characterised by high expression of 
CD209a and a range of transcripts involved in antigen presentation, suggesting that this 
population did not arise from ‘leaky’ monocytes but rather a specific monocyte subset 
which does not require CCR2 for bone marrow egress.  
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The transcriptomic data, particularly with respect to genes involved in antigen 
presentation, bear striking similarity to a novel DC-like CD209a+ monocyte subpopulation 
described by Menezes et al.[312]. According to their studies however, this monocytic 
population is reported to be substantially dependent on CCR2 for mobilisation from the 
bone marrow to peripheral blood. The data obtained so far might indicate that this CD209a 
population is in fact heterogenous, with one subset being dependent on CCR2 for 
recruitment to acutely inflamed sites, while the other one being CCR2 independent and at 
least capable of also using other iCCRs[271]. 
 
No difference in neutrophil recruitment was detected in CCR1-/-, CCR3-/- and CCR5-/- mice, 
while in the iCCR-/- mice neutrophils made up more than 90% of the membrane cellular 
content. This apparent accumulation of neutrophil is not seen when the data are expressed 
as an absolute number, thus, the discrepancy is likely to be a consequence of a relative 
reduction in size of other cellular populations in iCCR and CCR2-/- air pouch membranes. 
 
 
3.6.4 Fluid Subpopulations – Air Pouch 
 
The air pouch fluid was finally analysed to determine which cells had successfully managed 
to cross the air pouch membrane and reach the carrageenan-filled cavity. The fluid 
represents the origin of the inflammatory stimulus, and inflammatory cells were expected 
to be fully differentiated by the time they reached this artificial niche. At this stage, 
monocytes recruited from the bone marrow should have fully differentiated into 
macrophages, and the impact of CCR1 and CCR5 deletion should be most evident. Analysis 
of the cellular components of the air pouch fluid revealed that the vast majority of cells in 
the cavity are neutrophils (~90%), with minimal contributions from DCs (~0.5%), 
macrophages (~5%) and eosinophils (~1%) (Figure 3-17 A). While expecting a more severe 
abrogation of myelomonocytic cell recruitment to the iCCR-/- air pouch compared to CCR2-
/-, it was surprising to discover that iCCR-/-  recruitment of DCs (WT: 0.15%, CCR2-/-: 0.01%, 
iCCR-/-: 0.003%) and macrophages (WT: 1.52%, CCR2-/-: 0.016%, iCCR-/-: 0.016%) was 
identical to CCR2-/-, with no evidence of any contribution of CCR1 and CCR5 (Figure 3- 17B, 
17C).  
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Figure 3-17 Air Pouch Fluid Subpopulations-  A- Summary of the main leukocyte populations in the fluid 
inside the air pouch of WT, CCR2 -/- and iCCR -/- mice. B- Representative FACs plots showing an absence 
of CD11b+ CD64+ cells in iCCR -/- and CCR2 -/- membranes compared to WT air pouch membranes. C- 
Graphs comparing normalised Dendritic Cell (CD11b+ CD64+ CD11c+ MHCII ++), Macrophage (CD11b+ 
CD64+ CD11c- MHCII int F480 low Ly6C+) and eosinophil (CD64-CD11b+ Ly6G- Siglec F+) numbers in CCR1 
-/-, CCR2 -/-, CCR3 -/-, CCR5 -/- and iCCR -/- and their respective WT. Ordinary one-way ANOVA with 
Dunnett’s multiple comparisons test was performed to determine statistical significance, with a p value 
of 0.05 determined as significant (n>3) 
 
3.6.5 Discussion – Air Pouch Model 
 
While the composition of bone marrow leukocyte subpopulations 48 hours after 
carrageenan injection into the air-pouch generally showed a similar distribution to that 
observed in Imiquimod treated mice (with an accumulation of ‘classical’ inflammatory 
monocytes in both iCCR-/- and CCR2-/- mice), the accumulation was surprisingly more severe 
in CCR2-/- (WT: 8.9%, CCR2-/-: 15.9%, iCCR-/-: 12.2%). Three different mechanisms were 
proposed to explain the phenotype: lack of all iCCRs simultaneously might either be 
promoting iCCR independent migration by inflammatory monocytes causing some to 
escape the bone marrow regardless of CCR2 expression, the iCCR absence in bone marrow 
might be affecting proliferation rates and activation of inflammatory monocytes, or simply 
a shift in percentage due to the accumulation of cells which were not accounted for. 
 
While all mechanisms of action are plausible, CCR2 independent migration of inflammatory 
monocytes has only been observed in a handful of cases, all of which were seen in models 
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of severe systemic inflammation (such as La Crosse Encephalitis Virus infection [313] or 
200𝜇g dose of CpG1826 [314] ) where other inflammatory stimuli, such as TLR9 
engagement, were enough to override CCR2 mediated retention of monocytes ultimately 
mobilising them from the bone marrow.  
 
It is thus unclear why and how deleting the iCCRs CCR1 and CCR5, whose expression is 
already minimal in bone marrow inflammatory monocytes, would cause the inflammatory 
monocytes to respond more potently to other inflammatory signals. On the other hand, 
studies have shown that  soluble CCL5 (which binds to both CCR1 and CCR5) promotes 
macrophage survival through activation of the AKT and ERK signalling pathways, and its 
neutralisation in vivo reduced TNF𝛼 and IL-10 secretion after LPS administration[315]. 
Inflammatory monocytes in the bone marrow might be expressing both CCR1 and CCR5 
transiently or at low levels during development, and their absence could potentially be 
affecting their proliferative rates resulting in lower numbers in iCCR-/- bone marrow 
compared to CCR2-/-.  Analysing bone marrow inflammatory monocytes from iCCR reporter 
mice would make it possible to confirm if CCR1 and CCR5 are indeed expressed at low levels 
in developing monocytes.  
 
Finally, if the experiment were to be repeated, the addition of counting beads to the 
samples and an expanded flow cytometry panel would confirm If the accumulation of 
monocytes observed in CCR2-/- is genuine or an artefact due to the presence of 
unaccounted leukocyte subsets in iCCR-/- bone marrow. 
 
Another surprising finding was the virtual absence of inflammatory monocytes and 
dendritic cells in the air-pouch fluid of both CCR2-/- and iCCR-/- mice. These data might 
suggest that the role of CCR2 goes beyond monocyte bone marrow egress and is actually 
vital in every step towards the inflammatory stimulus. For example, it could be argued that 
CCR2 engagement is providing the developing macrophage with a critical signalling event 
that enables migration through the air-pouch membrane, and without it, even if CCR1 and 
CCR5 are present, the cell is not capable of reaching the air pouch fluid. This would explain 
why the cellular component of the air pouch fluid in iCCR-/- mice is a phenocopy of CCR2-/- 
mice (Figure 3-17A, 17B). There is no evidence in the literature however of CCR2 mediating 
this ‘critical signalling event’, and it is also unclear how such a specific and important signal 
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would be provided by CCR2 exclusively, as CCR2 and CCR5 share several ligands and have 
overlapping signalling machinery[38].  
 
More plausibly, 48 hours might have not been enough time for inflammatory monocytes 
from the bone marrow to egress, reach circulation, reach the membrane, differentiate and 
enter the fluid. This would also explain why no difference was observed in the air pouch 
fluid between CCR2-/- and iCCR-/-, as impaired monocyte egress from the bone marrow in 
both strains would ultimately delay macrophage transmigration into the fluid until after 48 
hours. Sampling the air pouch fluid at 72 or even 96 hours after carrageenan administration 
could address this hypothesis as it would allow more time for any defect brought on by the 
deletion of CCR1 and CCR5 to become more visible. 
 
 
3.7 Overall Discussion 
 
The main inflammatory chemokine receptors CCR1, CCR2 CCR3 and CCR5 have emerged as 
prominent players in the development of a wide range of inflammatory conditions. 
However, despite extensive research and attempts at pharmacological intervention, the 
combinatorial (and in some cases the individual), roles for these receptors in leukocyte 
recruitment remain unclear. The issue of iCCR redundancy versus specificity also remains 
unresolved.  
 
While studies on single knock-outs have highlighted the importance of each receptor, what 
has emerged is that no single iCCR is completely responsible for the migration of a 
particular subset, suggesting that some compensatory mechanisms might be also 
regulating iCCR expression. Starting ‘from scratch’ by completely removing the iCCR locus 
provides a starting point to gradually develop a clearer picture of the roles of CCR1, CCR2 
CCR3 and CCR5 in the development of the inflammatory response. 
 
Homozygous mice with the iCCR deletion were born at expected Mendelian frequency from 
het/het crosses, were healthy and fertile. No differences in embryo size, foetal liver 
monocytes or cKIT+ haematopoietic progenitor cell numbers were observed, suggesting 
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that iCCRs are not essential for embryonic developmental and postnatal survival, and their 
deletion does not result in gross developmental abnormalities. 
 
Immature B-cell numbers, T-cell precursor numbers, neutrophils and dendritic cells were 
not affected by the iCCR deletion. In contrast to other studies [73], no accumulation of 
inflammatory monocytes was observed in iCCR-/- or CCR2-/- bone marrow, suggesting that 
iCCRs are not involved in the maintenance of bone marrow leukocyte subpopulations 
under resting conditions.  The only leukocytes affected in resting iCCR-/- bone marrow were 
eosinophils, which were elevated in the bone marrow and divided in two subpopulations 
(Siglec F+ and Siglec F++). As the Siglec F++ population is not present in other single knock 
outs, this would suggest that mature Siglec F++ eosinophils upregulate CCR3 expression 
and leave the bone marrow. This is in line with published literature[316][317]. 
 
iCCR-/- mouse circulation was characterised by reduced ‘classical’ Ly6C++ monocyte, ‘non-
classical’ patrolling monocyte and eosinophil numbers, all of which were attributable to 
either CCR2 or CCR3, with no evidence of contribution from CCR1 or CCR5. Expectedly, 
deletion of iCCRs had no effect on resident populations which are generally thought of as 
iCCR independent, such as alveolar macrophages in the lung or red pulp macrophages in 
the spleen which distribute throughout these organs at birth and generally self-renew in 
resting conditions without contribution from the inflammatory monocytes recruited from 
the circulation. 
 
At rest, the only evidence so far of a possible contribution of other iCCRs in directing 
leukocytes to different organs was found in the skin, where a decrease in skin tissue 
macrophages in iCCR-/- mice could not be completely explained by the absence of CCR2. It 
was still unclear, however, how much of this difference could be attributed to a 
combinatorial effect of the simultaneous deletion of CCR1, CCR2 and CCR5 on monocyte 
recruitment, or if the absence of CCR1 and CCR5 was affecting the proliferation of the 
newly recruited monocytes, further decreasing their overall numbers resulting in a 
phenotype that is more profound than in the CCR2-/- mice. The in vitro work on 
macrophages and monocyte derived DCs in the following chapter will address this issue. 
 
Under inflammatory conditions, these initial defects in recruitment become more severe 
and affect more leukocyte subsets. While both the Imiquimod and the air pouch models 
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showed defects in recruitment of inflammatory monocytes, dendritic cells, eosinophils and 
macrophages, there was again little evidence of redundancy in receptor involvement, as 
most of the phenotypes were explained by an absence of either CCR2 or CCR3. 
Macrophages were the only leukocyte subset hinting at a possible combinatorial role for 
iCCRs, as the numbers in iCCR-/- air pouch membrane were lower than in the CCR2-/- mice. 
 
Differences in lymphoid cells were not observed in the air pouch model. Conversely, after 
Imiquimod application to the skin, activated T-cells were found elevated in blood, 
potentially suggesting they were trapped in circulation. This could suggest that certain 
ligands can induce the upregulation of specific sets of iCCRs on a leukocyte, and changing 
the inflammatory conditions by using, for example, a model for bacterial or fungal 
infections, might reveal more profound phenotypes in more leukocyte subsets than was 
observed in iCCR-/- mice exposed to Imiquimod or carrageenan. 
 
Overall, the data so far show that CCR2 is the dominant receptor for myelomonocytic cell 
recruitment to acutely inflamed sites and that, in its absence, migration is profoundly 
impaired with minimal evidence of other receptors ‘taking over’ and allowing efficient 
migration. What remains unclear at this stage is the contribution that CCR1 and CCR5 have 
on the development of the immune response. The roles these two receptors might have in 
myelomonocytic cell recruitment to acutely inflamed sites will be explored in more detail 
in the following chapters by analysing iCCR expression in recruited leukocytes from a novel 
iCCR reporter mouse model.  
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4 Results- In vitro Validation of iCCR 
Reporter Protein 
 
4.1 Overview 
 
 
While the data from iCCR-/- mice highlighted the importance of CCR2 and CCR3 in the 
recruitment of monocytes and eosinophils respectively, the specific role of inflammatory 
chemokine receptors CCR1 and CCR5 remained unclear. Indeed, every defect encountered 
in the resting iCCR-/- was attributed to the absence of either CCR2 or CCR3, with only a 
minor contribution by CCR1 and CCR5. 
 
While CCR2 and CCR3 are expressed in resting inflammatory monocytes and eosinophils, 
CCR1 and CCR5 are generally thought to be upregulated only during differentiation and 
after activation with inflammatory mediators. Thus, for example, while CCR1 has been 
shown to aid trans-endothelial migration of inflammatory monocytes[298][318], those 
same cells are probably able to migrate just as efficiently using other receptors, and the 
absence of CCR1 would not stop chemotaxis but delay it slightly.  
 
Similarly, while studies have described a wide range of phenotypes in CCR5-/- mice both at 
rest and under inflammatory conditions[79][319][320], humans with Δ32 mutation with a 
non-functional CCR5 are healthy, with minor phenotypes emerging only during severe 
infections or auto-immune disorders. Therefore, while CCR5’s role in macrophage function 
has been well documented[321][322][323], the receptor itself might be dispensable or at 
least perform a function that overlaps with other receptors, allowing the leukocyte to 
function in its absence[324]. 
 
In other words, while the experiments on the iCCR-/- mouse model identified the pivotal 
roles of CCR2 and CCR3, it might not be the best model to uncover the role of CCR1 and 
CCR5 as these receptors are only upregulated during a specific temporal window in the life 
of a leukocyte and their effect might have gone undetected. Another model was therefore 
required to assess the temporal fluctuations of chemokine receptors on developing 
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leukocytes and uncover the potential additive roles of CCR1, CCR2 and CCR5 on leukocyte 
migration and function. 
 
4.2 A novel iCCR Reporter Murine Strain 
 
 
A reporter knock-in mouse defines an animal model in which fluorescent, bioluminescent 
proteins or biochemical tags are inserted into the genome. In this case, a murine stem cell 
was transfected with a BAC, a bacterial artificial chromosome, encoding the iCCR locus, but 
the genes for the iCCRs themselves have been replaced with genes encoding for fluorescent 
proteins (Figure 4-1).  
 
Thus, mice generated from this transfected stem cell should express both the inflammatory 
chemokine receptors and specific fluorescent proteins under the same conditions, and 
allow for direct tracking of leukocyte migration and a direct visualisation of chemokine 
receptor expression in these cells without having to isolate them, stain them with 
antibodies or lyse them to infer iCCR expression via mRNA expression. This model also 
allows assessment in greater detail as to whether leukocytes express all iCCRs at the same 
time, if some chemokine receptors are preferentially expressed at different stages or if 
their expression is stochastic and follows random probability distribution. 
 
 
 
Figure 4-1- Generating a novel iCCR Reporter Strain (iREP)- Schematic provided by Dr. Medina-Ruiz 
showing the structure of the BAC (Bacterial Artificial Chromosome) encoding for a modified iCCR locus 
expressing different fluorescent proteins instead of CCR1, CCR2, CCR3 or CCR5. Each florescent protein 
has a distinct emission spectrum which should be detectable by microscopy and flow cytometry. CCR1-
Clover, CCR2-mRuby2, CCR3-mTagBFP2, CCR5-iRFP682 
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4.3 BAC validation in iCCR expressing leukocytes in 
vitro 
 
 
The early stage of this project was focused on determining if the BAC reporter proteins 
were detectable via flow cytometry and microscopy and to gain preliminary data to confirm 
whether the expression of fluorescent proteins correlates with iCCR expression. 
Macrophages were chosen as an ideal leukocyte model to track iCCR expression, as they 
express 3 of the 4 main iCCRs (CCR2, CCR1 and CCR5) in vitro. 
 
For research purposes, macrophages can be obtained in three different ways. One method 
includes the isolation of primary macrophages or their precursors from bone marrow, but 
at this stage, live mice were not available as the strain was still being generated at Taconic. 
Another method includes culturing and analysing a macrophage lineage cell line. However, 
while this method gives yield to good cell numbers, the cells are removed from their normal 
state, are immortalised and are transcriptionally very different from their primary 
counterparts, thus not giving an accurate representation of what would happen in vivo. 
The third method involves culturing embryonic stem cells (ES cells) derived from the inner 
cell mass of blastocyst-stage mouse embryos and then differentiating the ES cells into 
macrophages[325]. 
 
This method generates a high number of differentiated macrophages with a similar lifespan 
to bone marrow macrophages. As a result, the macrophages obtained with this 
technique are transcriptionally closer to their in vivo counterpart than macrophages 
obtained using other methods[326].  Moreover, while primary cells are inherently difficult 
to genetically manipulate, ES cells are highly amenable to genetic manipulation, and can 
therefore be transfected with the same BAC found in the reporter (iREP) mice, ultimately 
resulting in the production of fully differentiated macrophages expressing the same 
fluorescent proteins under the endogenous iCCR promoters. 
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4.4 Generating ES-cell derived Macrophages  
 
 
 
Generating ES-cell-derived macrophages requires up to three weeks of culture and involves 
growing ES cells under different growth factors and conditions [326]. Briefly, ES- cells were 
initially grown in media containing LIF (Leukaemia Inhibitory Factor) to maintain their 
undifferentiated state. Upon removal of LIF and addition of IL-3 and CSF-1, the ES-cells start 
differentiating into embryoid bodies which increase in size over the next 10 days. Over the 
next few weeks, these embryoid bodies release macrophage precursors into the media, 
which can then be collected and grown in CSF-1 containing media for a few days to obtain 
fully differentiated macrophages. 
 
Initially, embryoid bodies were allowed to grow on petri dishes as described by Zhuang et 
al[326]. However, it was soon noticed that during the initial stages of differentiation, 
developing embryoid bodies are extremely ‘sticky’, causing many to fuse together and form 
large aggregates which ultimately resulted in low macrophage precursor yields. To avoid 
this issue, and to generate uniform embryoid bodies, the protocol was altered to include 
the ‘hanging drop method’ in the first days of ES-cell differentiation[327].  
 
Briefly, ES-cells were collected and resuspended in IL-3+CSF-1 containing media, but 
instead of allowing differentiation and growth in petri dishes, the ES-cell suspension was 
carefully pipetted onto the lid of a petri dish in 27ul drops (approximately 1000 ES-
cells/drop, 120-150 drops/petri dish). The drops ‘hanging’ from the inverted lid were then 
incubated for 4 days before collection and re-plating for an additional week in the same 
media. Differentiating ES-cells in individual drops allows each embryoid body to grow in 
isolation, enabling the formation of consistently uniform embryoid bodies that release high 
numbers of macrophage precursors after approximately 2 weeks of culture. 
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4.4.1 ES-cell-derived Macrophages are similar to their BM 
counterpart 
 
At day 12 of the differentiation process, the media containing macrophage precursors was 
collected, spun down, and the pellet resuspended in CSF-1 containing media for 4-6 days 
to generate fully differentiated macrophages. These embryoid-body macrophages (Eb-
macrophages) were then stimulated with inflammatory mediators, analysed and compared 
to bone-marrow-derived macrophages to assess whether ES-cell-derived macrophages can 
be used as an appropriate macrophage model for our studies. 
 
 
Figure 4-2 ES-derived macrophages are similar to BM derived macrophages- A- x400 magnification 
representative bright field image showing the physical characteristics of macrophages grown from either 
embryonic stem cell (ES) or bone marrow precursors. B- Representative FACS plots showing CD11b+ 
F480+ cells in ES or BM derived macrophage cultures. C- Histograms showing expression of CCL2 in ES 
(red histogram) and BM derived macrophages (blue), unstained control in orange. D- qPCR data showing 
ES derived macrophages express macrophage-specific iCCRs CCR1, CCR2 and CCR5  
 
As seen in Figure 4-2 A, after 6 days of culture, differentiated embryoid body macrophages 
look morphologically similar to bone-marrow-derived macrophages. Flow cytometric 
analysis of those cells also show that >95% of cells in Embryoid body and bone marrow 
cultures express the macrophage markers CD11b and F480 (Figure 4-2B), and staining with 
fluorescent CCL2 (Figure 4-2C) showed that embryoid body and bone marrow macrophages 
express similar levels of CCR2. qPCR analysis on embryoid body macrophages showed that 
these cells also express CCR1 and CCR5, but not CCR3 (Figure 4-2D).  
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After overnight stimulation with 100ng/ml of LPS, embryoid body macrophages were 
shown to upregulate classical macrophage costimulatory molecules CD40 and CD86 (Fig. 4-
3A), and secrete pro-inflammatory (Il-1𝛽, IL-6 and TNF𝛼) and anti-inflammatory cytokines 
(IL-10) at concentrations which were very similar to bone-marrow-derived macrophages 
cultured and stimulated in identical conditions (Figure 4- 3B). Overall, these results indicate 
that the differentiation of ES-cells results in the generation of bona fide macrophages which 
are phenotypically and morphologically very similar to bone-marrow-derived 
macrophages. 
 
 
Figure 4-3- Costimulatory molecule expression and cytokine release by ES-derived macrophages- A- 
Representative histograms showing ES-derived macrophages are capable of upregulating costimulatory 
molecules CD40 and CD86 after overnight exposure to 100ng/ml of LPS. B- Graphs summarising secretion 
of pro-inflammatory cytokines (IL-1𝜷, IL-6 and TNF𝜶) and anti-inflammatory IL-10 measured via ELISA 
in BM and ES-derived macrophages before and after exposure of LPS (100ng/ml) overnight. n=3 
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4.5 Generating Macrophages from BAC-ES cells 
 
After showing that the differentiation protocol successfully generates functional 
macrophages, the next stage focused on determining if the fluorescent reporter proteins 
that will be expressed in the iREP mouse strain are detectable via flow cytometry and if 
their pattern of expression in ES-derived macrophage recapitulates the fluctuating 
expression of CCR1, CCR2 and CCR5 of macrophages in vivo. 
 
 
Figure 4-4 Emission of Fluorescent Reporter Proteins- A- Histogram adapted from Dr. Medina-Ruiz 
showing the different emission spectra of each fluorescent reporter protein. Clover corresponds to CCR1 
expression (green), mRuby2 to CCR2 (red), mTagBFP2 to CCR3 (blue), IRFP682 to CCR5 (purple). B- These 
representative images at x40 magnification show BAC insertion (reporter) has no effect on the 
development of embryoid bodies in culture. 
 
ES-cells transfected with the BAC encoding for iCCR-loci incorporating fluorescent reporter 
genes (Figure 4-4A) were differentiated into macrophages following the same hanging-
drop method described previously. BAC insertion appeared to have no effect on the 
progress of differentiation, with transfected ES-cells growing into normal embryoid bodies 
undistinguishable from WT embryoid bodies (Figure 4-4B). Macrophage precursors from 
transfected and non-transfected embryoid bodies were then collected and differentiated 
into macrophages, stained for macrophage markers CD11b and F480 and analysed via flow 
cytometry at specific timepoints during differentiation or after exposure to inflammatory 
stimuli. As seen from the representative FACS plots in Figure 4-5, un-transfected embryoid-
body derived macrophages did not express any of the fluorescent proteins and were not 
auto-fluorescent in any of the detection channels. 
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Figure 4-5- Reporter Expression in BAC-ES derived macrophages- BAC-transfected macrophages 
express CCR1 (Clover), CCR2 (mRuby2) and CCR5 (IRFP682) but no CCR3 (mTagBFP2). WT ES-derived 
macrophages express none of the fluorescent proteins. 
 
 
 
4.6 iCCR Expression in ES-derived Reporter 
Macrophages 
 
 
In contrast to WT differentiating macrophages, fluorescent reporter proteins could be 
detected from the first day of differentiation (Day 0) in reporter macrophages. As seen in 
Figure 4-6A, the macrophage precursors collected from developing embryoid bodies are 
mainly comprised of two populations based on expression of CD11b and F480. CD11b- 
F480- cells are considered ‘uncommitted precursors’, as these cells will eventually gain 
expression of CD11b+ F480+ after the first few days of culture. Almost 99% of cells in the 
uncommitted precursor stage express no florescent reporter proteins whatsoever, with a 
minor ~1% expressing CCR2 (measured as mRuby2 fluorescence, Figure 4-6 Bi).  
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Figure 4-6 iCCR fluctuation in developing ES-derived macrophages- A- Representative FACS plot 
showing CD11b+ and F480+ expression in ES-macrophage precursors collected ad day 10 of the ES 
differentiation process (day 0 in macrophage differentiation). The precursors can be split in two main 
populations: committed precursors are CD11b+F480+, uncommitted precursors are negative for both 
markers. B- iCCR expression on uncommitted (Bi) and committed precursors (Bii) (green= CCR1, red= 
CCR2, purple= CCR5, gradient colours indicate iCCR co-expression. n=4 
 
Fluorescent reporter protein expression was instead readily detected in precursor 
macrophages that already express CD11b and F480 (Fig. 4-5Bii). While the majority (~60%) 
of these ‘committed precursors’ expressed no fluorescent reporter protein, almost 30% 
expressed CCR1 (measured as Clover fluorescence), 20% expressed CCR2 and only a minor 
portion (~4%) expressed CCR5 (IRFP682 fluorescence). In these committed precursors, the 
dominant chemokine receptor pair was CCR1 and CCR2, with more than 8% of committed 
precursors co-expressing clover and mRuby2 fluorescent proteins. 
 
As the precursors mature, expression of CD11b and F480 increases, the ‘uncommitted 
precursor’ population begins to differentiate and more that 95% of cells in culture are 
CD11b+ F480+ (Figure 4-7 A). After two days of culture (Day 2 Macrophages), 
differentiating macrophages markedly increased iCCR expression, with the majority now 
expressing at least one iCCR. More than 60% of cells at day 2 expressed CCR1, and the 
percentage of cells expressing CCR2 fell slightly, from 20% at the precursor stage to less 
than 10% after two days of culture (Figure 4-7 Bi). On the other hand, CCR5 expression 
doubled, from 4% to 9% at day 2 of differentiation. The dominant receptor pair was still 
CCR1 and CCR2, with 6% of cells co-expressing both mRuby2 and Clover fluorescent 
proteins. 
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Figure 4-7 iCCR expression in differentiating macrophages (Day 2-4)- A- representative FACS plot 
showing CD11b and F480 expression in Day 2 and Day 4 ES-derived macrophages. Bi- Pie chart showing 
iCCR expression in Day 2 macrophages (CD11b+ F480+). Bii- Pie chart summarising iCCR expression in 
Day 4 ES-derived macrophages. (green= CCR1, red= CCR2, purple= CCR5, gradient colours indicate iCCR 
co-expression. n=4 
 
As differentiation reached day 4, iCCR expression continued to change. The dominant 
receptor pair at this stage was CCR1 and CCR5, with ~11% of macrophages co-expressing 
both Clover and IRFP682. CCR2 expression dropped steadily as differentiation progressed, 
going from 20% at the precursor stage to 6% by day 4, while CCR5 increased from 4% to 
15% by day 4 (Figure 4-7 Bii).  
 
As macrophage reached the end of their life-span in vitro at day 7, iCCR expression 
generally decreased (Figure 4-8 A). By this stage, CCR2 expression was practically absent 
and the dominant receptor pair was CCR1 and CCR5. ICCR expression in these late-stage 
macrophages could be rescued by stimulating the cells with IFNy for 48 hours (Figure 4-8 
Bi). Exposure to IFNy increased expression of all iCCRs, rescuing CCR2 and boosting CCR5 
expression and tripling the number of macrophages co-expressing CCR1 and CCR5 from 4% 
to 12%. On the other hand, exposure to 100ng/ml of LPS decreased expression of all iCCRs, 
with more than 60% of macrophages negative for all reporter proteins after 48 hours 
(Figure 4-8 Bii). 
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Figure 4-8- iCCR expression in Stimulated ES-derived macrophages. A- Pie chart summarising iCCR 
expression in late stage macrophages (Day 7 of differentiation). Bi- Pie chart summarising iCCR 
expression in Day 7 macrophages stimulated at Day 5 with 100ng/ml of IFNy for 48 hours. Bii- Pie chart 
summarising iCCR expression in Day 7 macrophages stimulated on Day 5 with 100ng/ml of LPS for 48 
hours. 
 
The macrophages were also stimulated with other inflammatory factors, such as TNF𝛼, and 
iCCR expression was tracked from Day 0 to Day 7 at two-day intervals. As shown in Figure 
4-9A, exposure to IFNy increased expression of all iCCRs (apart from CCR3, which was not 
expressed at any point). Conversely, TNF𝛼 and LPS decreased expression of CCR1, CCR2 
and CCR5.  
 
Inflammatory mediators were not the only factors affecting iCCR expression, as the time in 
culture also appeared to have an effect on the repertoire of iCCR expressed by 
macrophages. 
 
As seen in Figure 4-9, expression of CCR2 peaked early in the differentiation pathway, with 
the highest levels detected in the ‘committed precursor’ stage and marked downregulation 
as maturation progressed. On the other hand, CCR1 expression was highest after 3-4 days 
of culture, and decreased as maturation progressed into the late stage or after addition of 
LPS or TNF𝛼. Lastly, CCR5 expression peaked at the end of the macrophage’s 
differentiation, reaching maximal levels at days 5-6. Thus, iCCR expression in BAC-
transfected macrophages appears to fluctuate in ‘waves’, with CCR2 appearing early, 
followed by CCR1 and finally CCR5 (Figure 4-9B). 
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Figure 4-9 CCR2, CCR1 and CCR5 expression in Stimulated ES-derived Macrophages from day 0 to day 
7. A- CCR2, CCR1 and CCR5 expression as macrophages differentiate (Day 0-5) and after 48 hour 
stimulation (Day 5-7) with various inflammatory mediators (black: non-stimulated, blue: IFNy 100ng/ml, 
pink: TNF𝜶 50ng/ml, red: LPS 100ng/ml) B- Summary of CCR2, CCR1 and CCR5 expression throughout 
macrophage differentiation, showing early CCR2 expression (red) and late CCR5 expression (purple). 
Data representative of one experiment with 3 different sets of pooled GGiREP bone marrow (n=3). 
 
4.7 Discussion 
 
The results obtained show that the fluorescent proteins incorporated into the BAC are 
easily detectable by flow cytometry. In addition, the data suggest that the BAC is 
functioning correctly, as the main macrophage iCCRs were all detected in culture with the 
exception of CCR3 which was not expressed at any point. 
 
When the data for the expression of each iCCR were overlaid (Figure 4-9B), it seemed 
evident that specific iCCRs are regulated at specific temporal stages, with CCR2 maximally 
expressed at the precursor stage and CCR5 peaking in expression at the latest stages of 
culture. This change in iCCR expression tied to macrophage maturation has already been 
reported both in vitro and in vivo [188][328][79]. 
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4.7.1 Role of Inflammatory Mediators in Macrophage iCCR 
Expression 
 
As shown in the previous chapter, CCR2 is pivotal for bone marrow egress of macrophage 
precursors into the circulation. Once the monocyte reaches the site of inflammation and 
differentiates into a macrophage, CCR2 expression is downregulated, presumably to 
restrict the ‘reverse migration’ back into the bloodstream and to promote retention of 
differentiated monocytes within the site of inflammation[328][329]. While the 
mechanisms of CCR2 downregulation can be varied, many studies have highlighted the 
importance of tissue specific factors in monocyte CCR2 regulation. In the aorta for example, 
oxidised LDL (low density lipoprotein) regulates PPARy signalling and markedly lowers CCR2 
gene expression and mRNA stability, facilitating the accumulation of macrophages in 
atherosclerotic plaques [330]. Similarly, cytokines and reactive oxygen intermediates (ROI) 
frequently produced at the sites of acute inflammation can alter CCR2 expression, halving 
its mRNA half-life from 1.5 hours to 45 minutes [331]. Conversely, ROIs such as hydrogen 
peroxide have been shown to upregulate CCR5 expression in monocytes and increase their 
responsiveness to the CCR5 ligand CCL4 [332]. 
 
Microbial signals have also been shown to modulate iCCR expression. CCR2 in primary 
monocytes can be inhibited by bacterial LPS and other microbial agents [333], and although 
the exact mechanisms are still unclear, studies have suggested that this effect is mediated 
both directly and  indirectly by LPS-induced production of inflammatory cytokines such as 
IL-1𝛽 and TNFα. Indeed, a simple injection of Escherichia coli LPS into human volunteers 
decreased the monocyte density (MFI) of CC chemokine receptor 2 (CCR2) [334], while 
exposing isolated monocytes to low doses of LPS (1ng/ml) can dramatically reduce 
transcript levels of CCR1 , CCR2 and CCR5 in as little as four hours [333].  
 
Similarly to LPS, TNFα can also modulate iCCR expression in monocytes. This effect was first 
described in 1999, when it was observed that TNFα could reduce HIV-1 replication in 
human peripheral blood monocytes (PBMCs) and alveolar macrophages [335]. Further 
analysis via flow cytometry revealed that TNFα-treated PBMCs show decreased CCR5 
expression on their surface, making them refractory to HIV-1 infection as CCR5 is required 
for viral entry [335]. While the mechanism of action of TNFα on CCR5 expression is still 
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unclear, a 2 hour pre-treatment of in vitro macrophages with TNFα is enough to decrease 
HIV-1 viral entry via CCR5 by 75% [336].  The in vitro data generated from BAC-transfected 
macrophages have shown a similar trend, with both LPS and TNFα downregulating 
expression of CCR1, CCR2 and CCR5. 
 
4.7.2 Role of Differentiation in Macrophage iCCR Expression 
 
iCCR expression also fluctuates according to age and state of cell differentiation. Several 
studies using human monocytes cultured in vitro have shown a dramatic decrease in CCR2 
expression both on the surface and at the mRNA level as cells differentiate into 
macrophages [188] [337]. Specifically, CCR2 was shown to be expressed on the cell surface 
in day 0 monocytes, with a marked decrease after 24 hours and undetectable expression 
after 7 days of culture. At the same time, the decrease in CCR2 was accompanied by an up-
regulation of CCR1 and CCR5 expression, which coincided with an increased responsiveness 
of monocyte-derived macrophages to CCL3 (chemokine binding to CCR1 and CCR5) [337].  
 
Elegant studies in vitro have tried to uncover the specific roles of CCR1 and CCR5 in 
monocyte chemotaxis. Administration of CCR1 and CCR5 antagonists to monocytes in 
laminar flow assays that simulate the shear flow experienced by circulating leukocytes have 
shown blocking CCR1 but not CCR5 resulted in a significant inhibition of CCL5-induced 
arrest of these cells in flow [298]. 
  
Monocytes express more CCR1 than CCR5[298][188], while fully differentiated 
macrophages generally express more CCR5 than CCR1[111]. This suggests a role for CCR5 
in events following arrest, such as affecting activity[321] or survival of emigrated cells[338] 
or to promote the morphological changes required by the cell to initiate trans-endothelial 
migration[298]. Therefore, this iCCR fluctuation on the surface of monocytes might reflect 
the cell’s function over a specific temporal window, with CCR2 required for bone marrow 
egress into the circulation, CCR1 for arrest under shear flow conditions and CCR5 for trans-
endothelial migration and ‘spreading’ at the site of inflammation. 
  
While the process of monocyte migration described is probably an oversimplification, the 
findings on the BAC-transfected macrophages seem to support this current model. CCR2 
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was expressed at the very beginning of differentiation, and gradually decreased until 
undetectable by day 7, hinting at its role in early monocyte precursor migration from the 
bone marrow. CCR1 expression peaked at around days 3-4, possibly reflecting its role in 
vascular adhesion, while CCR5 was expressed towards the late stages of differentiation, 
supporting the notion that CCR5 has a role in modulating the activity and survival of late 
stage macrophages. 
 
CCR5 expression was still relatively low however, with only 15% of differentiated 
macrophages expressing this receptor, compared with ~50% expressing CCR1. This 
apparent mis-match in receptor expression might be an effect of the nature of the BAC 
transfection process. Due to the BAC’s relatively large size, integration in ES cells did not 
happen in a single event, as suggested by qPCR analysis on these cells by Dr. Medina-Ruiz 
(Figure 4-10 A,B).  
 
 
Figure 4-10- BAC copy number in transfected ES cells- A- Diagram showing primer localisation to detect 
various BAC fragments. Some primers are specific for the genes encoding for the fluorescent reporter 
proteins (like QPCR1, QPCR5 and QPCR6). Other primers were designed to recognise regions in between 
the reporter proteins (such as QPCR2, QPCR3 and QPCR4). This specific primer design allows to determine 
how many BAC fragments are present in the genome. B- Bar graph showing the average BAC copy 
number for each fragment detected by BAC-specific primers. Bar graphs with multiple colours represent 
regions of the BAC in between two fluorescent proteins (for example, primer qPCR2 binds a region 
between qPCR1 (clover, green) and qPCR3 (mTagBFP2, blue), so the bar is both green and blue. 
 
Her findings show that the BAC has integrated itself in multiple fragments in different parts 
of the genome. Specifically, qPCR data using primers designed to detect particular sections 
of the BAC showed that these BAC-transfected ES cells possess 10 copies of CCR1-Clover, 5 
copies of CCR2-mRuby2 and 3 copies of CCR5-IRFP682 (Figure 4-10 B).  
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Therefore, the overexpression of fluorescent reporter protein Clover (CCR1) in 
differentiated macrophages might be the result of a high number of integrations of Clover 
expressing BAC fragments. Similarly, fewer integrations of IRFP682 BAC fragments 
(corresponding to CCR5) compared to Clover might result in apparently low expression of 
CCR5. The location of the genome where the integrations took place probably also has an 
impact, with BAC copies integrated in highly transcribed areas producing larger amounts of 
fluorescent reporter proteins.  
 
Regardless of the levels of expression, CCR1, CCR2 and CCR5 levels in ES-derived 
macrophages fluctuate with age and when exposed to inflammatory mediators in a way 
that is similar to what has been described in other studies, suggesting that the BAC itself is 
working properly and murine cells are capable of expressing detectable levels of 
fluorescent reporter proteins. 
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5 Results- iCCR Reporter Strain (iREP) 
in vivo 
 
5.1 Overview 
 
 
Once the BAC encoding for 4 iCCR reporter proteins had been validated in vitro, 
experiments were performed to determine if BAC expression could also be detected in the 
novel murine iCCR reporter strain and if it carried any negative burden on mouse fitness. 
 
One of the concerns was a potential effect on leukocyte chemotaxis by a process known as 
‘squelching’[339]. As the fluorescent proteins (and each iCCR) share the same promoters, 
the presence of several BAC copies in the genome might make the transcription factors 
binding to these promoters less available for iCCR expression, ultimately making 
chemotaxis less effective.  
 
Before analysing fluorescent reporter expression, iREP mice were analysed to determine if 
BAC expression had any effect on leukocyte subpopulations in various tissues at rest and if 
it also had any impact on the recruitment of leukocytes to the site of inflammation. 
 
5.2 BAC Integration 
 
The iCCR Reporter strain (iREP) was generated by Taconic via micro-injection of the BAC 
(designed and made by Dr. Medina-Ruiz) into developing murine embryos. In this way, two 
different founder lines containing several copies of the BAC were obtained. Extensive qPCR 
analysis showed the BAC integrated itself in multiple copies in a single area of the murine 
genome. The first founder line was found to possess 3-5 BAC copies located in the same 
area of chromosome 3. Analysis on the second founder line revealed that it contained 5-7 
BAC copies, all integrated in the same area on chromosome 16. Further sequencing 
revealed that the BAC integrations in both founder lines happened in a section of the 
genome containing non-coding DNA, indicating that no genes were disrupted during 
insertion. 
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Both founder lines were caged separately, kept under specific pathogen free conditions 
and breeding was initially done using HETxHET crosses. Preliminary data had shown 
detectable fluorescence in BAC hemizygote mice, suggesting that BAC expression in a single 
chromosome is enough to produce detectable levels of fluorescent reporter proteins. 
Hemizygotes for the BAC were used for all the experiments in this chapter, as they 
possessed enough reporter proteins for detection while still expressing an unaffected 
endogenous locus, minimising any potential negative effects caused by BAC integration. 
Homozygote littermates were used for breeding purposes, while WT littermates were used 
as negative controls. 
 
 
5.3 Effect of BAC Integration on Leukocyte Subsets 
 
 
Adult 8-10 week BAC-hemizygote mice were culled, and their tissues were analysed to 
detect any effect of BAC expression on leukocyte subpopulations in various tissues under 
resting conditions. 
 
As seen from Figure 5-1, BAC integration and fluorescent reporter expression had no 
significant impact on the composition of leukocyte subpopulations in the bone marrow 
(Figure 5-1A) and blood (Figure 5-1B) of resting reporter mice when compared to their WT 
littermates. In the bone marrow of all strains analysed, neutrophils were the most 
prominent leukocyte subset (WT: 37.1% , 3-5 BAC: 33.1%, 5-7 BAC: 36.5%), followed by B-
cells (WT: 11.9% , 3-5 BAC: 12.1%, 5-7 BAC: 13.0%), inflammatory monocytes (WT: 7.8% , 
3-5 BAC: 7.1%, 5-7 BAC: 6.9%) and eosinophils (WT: 4.2% , 3-5 BAC: 4.5%, 5-7 BAC: 4.5%). 
In circulation, the most prominent leukocyte subset was B-cells (WT: 52.2%, 3-5 BAC: 
45.5%, 5-7 BAC: 52.9%), followed by neutrophils (WT: 8.8%, 3-5 BAC: 8.5%, 5-7 BAC: 12.1%), 
inflammatory monocytes (WT: 1.9%, 3-5 BAC: 1.9%, 5-7 BAC: 2.0%) and eosinophils (WT: 
0.9%, 3-5 BAC: 1.0%, 5-7 BAC: 0.8%). 
 115 
 
Figure 5-1 Leukocyte Composition of Resting iREP bone marrow and blood- A- Graph summarising the 
prevalence of 4 main leukocyte populations in WT, iREPs 3-5 BAC copies and iREPs  5-7 copies bone 
marrow. B- Graph summarising the prevalence of 4 main leukocyte populations in WT, iREPs 3-5 BAC 
copies and iREPs  5-7 copies circulation. Both graphs summarise values expressed as % of CD45+ cells. 3-
5 BAC data is an average of 2 experiments with n=3, 5-7 BAC data from 3 experiments with n>3. 
Similarly, no defect in leukocyte recruitment was detected under inflammatory conditions, 
with B-cell, Inflammatory monocyte, neutrophil and eosinophils numbers identical 
between reporter positive and reporter negative mice in inflamed bone marrow, blood, or 
air pouch membrane (Figure 5-2A,B,C). The number of BAC copies also did not appear to 
have an effect, with no differences observed in neutrophil, B-cells, inflammatory 
monocytes, eosinophils or macrophage numbers in inflamed tissues of 3-5 and 5-7 BAC 
mice (Figure 5-2). 
 
Figure 5-2- Leukocyte Composition of Inflamed iREP tissues- A- Graph summarising the prevalence of 
B-cells, Inflammatory monocytes, neutrophils and eosinophils in inflamed bone marrow from WT, iREP 
3-5 and iREP 5-7 BAC mice. B- Graph summarising the prevalence of B-cells, Inflammatory monocytes, 
neutrophils and eosinophils in inflamed circulation from WT, iREP 3-5 and iREP 5-7 BAC mice. C- Graph 
summarising the prevalence of B-cells, Inflammatory monocytes, neutrophils, dendritic cells and 
eosinophils on the air pouch membrane from WT, iREP 3-5 and iREP 5-7 BAC mice. Data is representative 
of 3 experiments, with n=3. 
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Next, each individual leukocyte subpopulation was analysed to detect possible fluorescent 
protein expression.  
 
 
5.4 Resting iREP Tissues 
 
 
5.4.1 iREP Bone Marrow 
 
As seen in Figure 5-3, fluorescent proteins were detected in several leukocyte subsets in 
iREP resting bone marrow. B-cells (CD45+ CD19++) were found to express fluorescent 
protein Clover (corresponding to CCR1), inflammatory monocytes were brightly positive for 
mRuby2 (corresponding to CCR2) and most eosinophils were positive for mTagBFP 
(corresponding to CCR3). Fluorescent protein IRFP682, corresponding to CCR5, was not 
detected in any bone marrow leukocyte subset. Furthermore, there was little evidence of 
iCCR co-expression, as each cell-type seemed to be expressing a single fluorescent protein 
at any given time. B-cells and eosinophils exclusively expressed CCR1 and CCR3 
respectively, and <98% of inflammatory monocytes express mRuby2 (CCR2), with only ~3% 
also expressing Clover (CCR1). 
 
As expected, neutrophils did not express any of the reporter proteins, although some 
neutrophils (~0.5%) appeared positive for CCR2 and CCR3. These CCR2+ and CCR3+ 
neutrophils are, in all probability, contaminating inflammatory monocytes and eosinophils, 
as no neutrophil specific antibody was added due to the limited number of colours available 
for detection on the flow cytometers. As a result, neutrophils were isolated via their 
physical characteristics (side scatter) and negative staining for other markers, and this 
gating probably includes a small fraction of other cell types. 
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Figure 5-3  iCCR Expression on Bone Marrow Leukocytes. The panel shows fluorescent reporter protein 
expression in B-cells, inflammatory monocytes, neutrophils and eosinophils. The markers and gating 
strategy used to identify these leukocytes are shown in the first FACS plot beside the name of each subset. 
The representative FACS plots that follow show leukocyte fluorescent reporter protein expression in each 
of the 4 main detection channels (CCR1= Clover= Green, CCR2=mRuby2=red, CCR3=mTagBFP=blue, 
CCR5=IRFP682=purple). Positive reporter expression was determined using non-fluorescent WT 
leukocytes 
 
While high CCR2 expression in inflammatory monocytes and CCR3 expression in eosinophils 
was expected and well documented[98][340], CCR1 expression in ~20% of bone marrow B-
cells was somewhat surprising. While CCR1 expression has been described in B-cells only 
recently [341] [107], its function has not been fully investigated, as B-cells generally use 
other chemokine receptors for chemotaxis[342] and are thought to express CCR1 only 
under specific conditions of inflammation [343]. Thus, expression of CCR1 in unchallenged 
immature bone marrow B-cells is a novel finding. 
 
While no difference in recruitment to inflamed sites was recorded between WT, 3-5 and 5-
7 BAC mice, expression of fluorescent proteins was generally higher in leukocytes extracted 
from 5-7 BAC animals. As seen from Figure 5-4A, the number of CCR1+ B-cells in the bone 
marrow increased from 14% to 26% if 5-7 BAC copies are present. While the number of 
bone marrow inflammatory monocytes positive for CCR2 does not change between 3-5 or 
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5-7 BAC mice (97% vs 98%), a higher BAC copy number correlates with increased CCR2 MFI 
(9400 vs 1100) (Figure 5-4B). As a high BAC number had no effect on recruitment but 
facilitated iCCR detection, the remaining experiments focused on 5-7 BAC mice.  
 
Figure 5-4 iCCR Expression in Bone Marrow Leukocytes with different BAC number. A- Representative 
FACS plots showing increased fluorescent reporter protein expression in leukocytes expressing more BAC 
copies. The gating identifying positive reporter protein expression was drawn using non-fluorescent WT 
leukocytes. B- Bar graph summarising the change in iCCR expression in B-cells, inflammatory monocytes 
and eosinophils from the resting bone marrow of iREPs with 3-5 BAC and 5-7 BAC copies. 
 
 
5.4.2 iREP Blood 
 
Next, circulating leukocytes from iREP mice were also analysed for fluorescent reporter 
protein expression. As seen in figure 5-5, CCR1 expression was detected in B-cells, CCR2 
expression and marginal CCR1 expression in inflammatory monocytes and CCR3 in 
eosinophils. Almost 70% of patrolling vascular macrophages (Ly6Clow F480+), which derive 
from Ly6C+ inflammatory monocytes [344], also expressed CCR2. CCR5 was not detected 
in any leukocyte subset, and neutrophils were negative for all fluorescent reporter 
proteins. 
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Figure 5-5 iCCR Expression on Circulating Leukocytes. The panel shows fluorescent reporter protein 
expression in B-cells, inflammatory monocytes, vasculature patrolling macrophages, neutrophils and 
eosinophils. The markers and gating strategy used to identify these leukocytes are shown in the first 
FACS plot beside the name of each subset. The representative FACS plots that follow show leukocyte 
fluorescent reporter protein expression in each of the 4 main detection channels (CCR1= Clover= Green, 
CCR2=mRuby2=red, CCR3=mTagBFP=blue, CCR5=IRFP682=purple). Positive reporter expression was 
determined using non-fluorescent WT leukocytes 
 
 
5.4.3 Monitoring iCCR fluctuation  
 
iCCR expression fluctuates according to the level of differentiation and activation of a 
leukocyte.  This is the case with inflammatory monocytes, which express high levels of CCR2 
in the bone marrow, higher levels of CCR2 while in the blood, and then decrease its 
expression during terminal differentiation into macrophages.  
 
More than 90% of inflammatory monocytes in reporter mice were CCR2+, while 70% of 
patrolling monocytes in the circulation expressed this receptor. This finding raised the 
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possibility that fluorescent reporter expression could be used to track monocytes at 
different stages of differentiation. Bone marrow, blood, and lung samples were collected 
from 5-7 BAC reporter mice and CCR2 expression was analysed in all the monocyte and 
macrophage populations in these organs. Figure 5-6 summarises the average mean 
fluorescent intensity of mRuby2 (CCR2) on each of these cell subtypes. ‘Classical’ bone 
marrow inflammatory monocytes express high levels of CCR2, which peaks as the 
monocytes reach the circulation. As the monocytes differentiate into ‘non-classical’ 
patrolling monocytes or move into distal tissues, CCR2 expression decreases. Interstitial 
macrophages in the lung, which derive from inflammatory monocytes, showed only 
marginal CCR2 expression. Alveolar macrophages, which have a distinct origin and develop 
from CCR2 independent foetal monocytes [345] expressed no detectable levels of CCR2, 
and no CCR1, CCR3 or CCR5. 
 
 
Figure 5-6 CCR2 expression on different monocyte/macrophage subsets from iREP bone marrow, blood 
and lung. The different tissues were analysed on the same day on the same flow cytometer with identical 
settings. The MFIs for each subset represent an average from 3 3-5 BAC copy iREP mice. Solid arrows 
show the direction of migration. Circular arrows indicate the leukocyte in question has the ability to self-
renew. The dotted arrow shows potential contribution of inflammatory monocytes to maintain the 
alveolar macrophage population in cases of severe inflammation. 
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5.4.4 Preliminary Conclusions on Resting iREP mice 
 
Collectively, the data gathered from resting iREP tissues show that fluorescent reporter 
proteins can be reliably detected in leukocytes and that their pattern of expression 
correlates with the correct iCCR, as almost the totality of inflammatory monocytes express 
CCR2 and marginal levels of CCR1, and eosinophils CCR3, consistent with the literature. 
CCR1 expression in resting bone marrow and circulating B-cells is a novel finding, and it 
would be interesting to explore the role this inflammatory chemokine receptor has in a 
leukocyte that generally relies on other receptors for chemotaxis. 
 
The data on CCR2 expression in ‘classical’ inflammatory monocytes compared to lung 
resident macrophages show that this murine model also allows for direct visualisation of 
the activation and maturation state of a leukocyte by assessing the intensity of the 
fluorescence of the reporter protein. 
 
Under resting conditions, those leukocyte subsets expressing iCCRs expressed only a single 
iCCR, with the exception of inflammatory monocytes which marginally (~3%) co-expressed 
CCR1 with CCR2. Not only does this indicate that iCCR expression under resting conditions 
is tightly regulated, but it also means that it is possible to identify leukocytes in the absence 
of lineage specific markers. In other words, an mTagBFP positive leukocyte in the 
circulation could only be an eosinophil, making the iREP strain ideal for microscopy or other 
imaging techniques where staining tissues to identify cells is impractical. 
 
The number of BAC copies had no effect on leukocyte recruitment or leukocyte 
subpopulation distribution, but the mean fluorescent intensity for reporter proteins was 
higher in leukocytes with 5-7 BAC copies, compared to leukocytes with 3-5 BAC copies. 
Having several BAC copies also increased the number of leukocytes positive for a specific 
iCCR, with 17% of B-cells in 3-5 BAC mice expressing CCR1 compared to 30% in 5-7 BAC 
mice. As such, further experiments on iCCR upregulation during inflammation focused on 
5-7 BAC mice, as it was hypothesised that 5-7 BAC copies would make small fluctuations in 
iCCR expression easier to detect. 
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5.4.5 Resting iREP Data Discussion 
 
 
Fluorescent reporter protein expression in adult tissues revealed that iCCR-expressing 
resting leukocytes generally express only a single iCCR, with the exception of ‘classical’ 
inflammatory monocytes in which ~3% co-express CCR1 with CCR2.  
 
This was somewhat surprising, as several studies have reported simultaneous expression 
of multiple iCCRs in certain leukocytes. A group looking at patterns of CCR2 and CCR5 
expression in mouse peripheral blood leukocytes found that 2-15% of circulating T-cells 
express CCR2, and 10% of CD4 T-cells, 40% of CD8 T-cells and most NK cells expressed CCR5 
[79].  
 
To detect these receptors, the authors generated in house monoclonal antibodies by 
immunising rats with CHO cells stably transfected with murine CCR2 or CCR5. The 
specificity of the antibodies was determined on CHO cells overexpressing these two 
receptors, and while the data shows that the antibodies do not cross react with each other, 
the authors did not test these antibodies with CHO cells expressing other chemokine 
receptors. As mentioned in previous chapters, high structural homology between related 
chemokine receptors makes detection through antibodies prone to high levels of cross 
reactivity and false positives.  It is therefore possible that some of the CCR2 and CCR5 
expression detected in T-cells could be the result of cross-reactivity of the antibody with 
other T-cell chemokine receptors. 
 
Another group looking at iCCR expression on leukocytes also found evidence of co-
expression of CCR3 and CCR1 in RNA transcripts from resting eosinophils [340]. 
Transcription however does not necessarily result in expression of functioning protein on 
the surface, as chemokine receptors such as CCR5 can be stored in endosomes for later 
use[346] or can be recycled like CCR2 and CCR3[44] so expression can be immediate 
without de novo protein synthesis. Other receptors, such as CCR1, are not recycled and are 
continuously reformed [347], so CCR1 might appear more highly expressed than other 
receptors at the transcript level without necessarily being more evident on the surface. 
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Evidence from the literature of iCCR co-expression in resting leukocytes is vague, and 
reporter leukocytes from iREP mice showed no expression of iCCR in T-cells, no co-
expression of iCCRs in eosinophils, and only minor co-expression of CCR1 and CCR2 in 
inflammatory monocytes. 
 
Regardless of the method of detection however, strong iCCR upregulation has been well 
documented in leukocytes exposed to a variety of inflammatory stimuli, from macrophages 
in CNS lesions[348], inflammatory monocytes in atherosclerotic plaques[205], to T-cells 
and NK-cells during pulmonary inflammation [349] or viral infections[350].  
 
During infection or acute inflammation, epithelial cells upregulate the secretion of a wide 
variety of inflammatory chemokines and cytokines. To respond to this wide variety of 
stimuli, recruited leukocytes have been shown to diversify their chemokine receptor 
expression to better respond to the local inflammatory conditions.  Once engaged several 
times, a receptor becomes desensitised, gradually losing its ability to promote cell 
migration towards a specific target[71]. Expression of a second or a third receptor once the 
leukocyte has reached the inflamed site allows the cell to keep moving and follow other 
chemotactic cues. As mentioned previously, simultaneous expression of several receptors 
at the site of infection can also be considered a form of defence against pathogen-induced 
perturbation of chemotaxis[166], allowing the immune system to function even if the 
pathogen has managed to disable key signals. To assess the effect of inflammation on 
leukocyte iCCR expression (and potential co-expression), the air-pouch model was 
performed on iREP mice. 
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5.5 Inflamed iREP Tissues 
 
 
5.5.1 Model of Inflammation 
 
An air pouch was produced by the subcutaneous injection of sterile air into the back of the 
mouse, as described previously (see Methods). The resulting pouch mimics a body cavity, 
providing a new localized environment in which to study cell trafficking and inflammatory 
response. The benefits of the air pouch model have been described in detail earlier, but 
the main advantage in this particular case is that the air pouch is free of tissue resident 
leukocytes. As the main focus of this experiment was to assess any potential iCCR co-
expression in recruited leukocytes, the absence of resident cells ensures that the data 
collected relates to recruited leukocytes only. 
 
48 hours after the addition of carrageenan into the air pouch, iREP mice were culled. Bone 
marrow, blood, air pouch membrane and fluid were all collected, and fluorescent reporter 
protein expression on leukocytes was analysed via flow cytometry. The air pouch model 
was also simultaneously performed on non-fluorescent WT littermates, and their WT 
leukocytes were used as baseline to determine positive fluorescence in the iREPs. 
 
This was important as inflammation causes some leukocytes to become auto-fluorescent 
at certain wavelengths. Once activated by an inflammatory stimulus, leukocytes will 
increase protein synthesis and vacuolisation, reflecting and diffracting light differently. This 
increase in cellular granularity is detected as genuine fluorescence by microscopes and flow 
cytometers, generating false positives[351]. WT leukocytes were therefore exposed to the 
same inflammatory conditions as the iREPs to determine a true negative baseline for 
reporter protein detection. 
 
Bone marrow was extracted from iREP mice 48 hours after the administration of 
carrageenan, stained for the same markers and analysed with the same gating strategy 
used when fluorescent reporter expression under resting conditions was assessed. 
Specifically, fluorescent reporter protein expression was analysed in ‘classical’ 
inflammatory monocytes (CD11b+Ly6C++), eosinophils (CD11b+ SiglecF+) and B-cells 
(CD19++). 
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5.5.2 Inflammatory Monocytes 
 
5.5.2.1 Bone Marrow 
 
Similar to resting conditions, more than 95% of inflammatory monocytes expressed CCR2. 
CCR1 expression however increased more than 6-fold, from 3% at rest to 16% during 
inflammation (Figure 5-7 A,B). Analysis of iREPs with 3-5 copies also showed a similar 
increase in inflammatory monocytes co-expressing CCR1 and CCR2, but the increase was 
more modest (4-fold compare to resting), again showing that a higher BAC number 
correlates with higher levels of fluorescent protein detection. 
 
 
Figure 5-7 iCCR Expression on bone marrow inflammatory monocytes- A- Pie charts and representative 
FACS plots showing the % of 5-7 BAC copy bone marrow inflammatory monocytes expressing CCR2 and 
CCR1 at rest and during inflammation. Expression of CCR2 alone is shown in red, co-expression of CCR2 
and CCR1 in red/green shading, no fluorescent reporter protein expression is shown in grey. Positive 
reporter expression was determined using non-fluorescent WT inflammatory monocytes. B- CCR1 
expression in bone marrow inflammatory monocytes with 3-5 or 5-7 BAC copies, both at rest and during 
inflammation. Resting data representative of 3 experiments with n>3, Inflammation data representative 
of 3 experiments with n=4. 
 
5.5.2.2 Blood 
 
Inflammatory monocytes in the circulation showed a similar pattern to that seen in the 
bone marrow during inflammation. As seen in Figure 5-8 (A,B), circulating Ly6C++ 
leukocytes exposed to inflammation increased CCR1 expression 4-fold, from 2.5% at rest 
to 10.6%. The number of CCR1+ve monocytes however was higher in the bone marrow 
(16%) than in the circulation (10.6%). This finding was somewhat counter-intuitive, as CCR1 
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had previously been shown to facilitate firm adhesion of leukocytes to the blood vessels 
under shear flow[352], so CCR1 expression was expected to be highest while inflammatory 
monocytes are circulating in the blood.  
 
 
Figure 5-8 iCCR Expression on circulating inflammatory monocytes- A- Pie charts and representative 
FACS plots showing the % of 5-7 BAC copy blood inflammatory monocytes expressing CCR2 and CCR1 at 
rest and during inflammation. Expression of CCR2 alone is shown in red, co-expression of CCR2 and CCR1 
in red/green shading, no fluorescent reporter protein expression is shown in grey. Positive reporter 
expression was determined using non-fluorescent WT inflammatory monocytes. B- CCR1 expression in 
circulating inflammatory monocytes with 5-7 BAC copies, both at rest and during inflammation. Resting 
data representative of 3 experiments with n>3, Inflammation data representative of 3 experiments with 
n=4. 
As CCR1 expression was lower in circulating monocytes, this raises two possibilities. Either 
CCR1 is upregulated briefly during inflammatory monocyte bone marrow egress and 
downregulated rapidly while in circulation, or more simply, CCR1+ monocytes are ‘stuck’ 
along the inflamed vessel walls, leaving mainly CCR2+ monocytes in extracted blood. Data 
gathered previously from CCR1-/- and iCCR-/- mice showed no accumulation of inflammatory 
monocytes in the bone marrow, suggesting that CCR1 is dispensable for bone marrow 
egress.  
 
If CCR1 is indeed required for inflammatory monocyte arrest under shear flow, then the air 
pouch membrane should be ‘enriched’ with CCR2+CCR1+ co-expressing monocytes, as the 
ones expressing CCR1 should have been able to cross the endothelial cells lining the blood 
vessels more easily.  
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5.5.2.3 Air Pouch Membrane 
 
As inflammatory Ly6C+ monocytes from the circulation migrate towards the site of 
inflammation, increased exposure to inflammatory stimuli should promote their 
differentiation into F480+Ly6C low macrophages. 
 
Analysis of the cellular content of the membrane surrounding the air pouch showed two 
populations of macrophages (CD11b+CD64+CD11c-), an F480++Ly6C low population and 
another Ly6C++ F480 low. These two populations are thought to represent the two 
opposites of monocyte/macrophage differentiation, with Ly6C++ F480- cell retaining their 
undifferentiated inflammatory monocyte phenotype, while Ly6C-F480++ cells represent 
fully differentiated macrophages. As seen in the FACS plots in figure 5-9A, the two Ly6C++ 
and F480++ populations are not clearly distinct but present themselves as two extremes of 
a ‘smear’, which contains monocytes/macrophages at different stages of differentiation.  
 
CCR2 Expression 
 
Unlike inflammatory monocytes in the circulation, CCR2 expression on 
monocyte/macrophages in the air pouch is not uniform but can be divided in two CCR2 
expressing groups: CCR2 bright and CCR2 mid (FACS plots Figure 5-9 B,C). While the 
presence of CCR2 bright and CCR2 mid monocytes might suggest that these cells have 
different origins, the fact that the air pouch membrane is devoid of resident leukocytes and 
only one population of CCR2 bright monocytes was detected in the circulation suggests 
that the CCR2 mid population derives from the CCR2 bright, and not the result of another 
monocytic subset migrating from the periphery. 
 
Supporting this hypothesis, CCR2 bright cells look phenotypically closer to circulating 
inflammatory monocytes, and represent almost 40% of Ly6C++ cells in the air pouch 
membrane (Fig. 5-9 B). In contrast, the vast majority (~85%) of F480++ cells express mid 
levels of CCR2 (Fig. 5-9 C). These finding suggest that inflammatory monocytes are CCR2 
bright, and these cells differentiate into CCR2 mid F480++ macrophages. 
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Figure 5-9- CCR2 Expression in Differentiating Monocytes- A- Gating strategy showing 
CD64+CD11b+(CD11c-MHCII-) macrophages and their F480+ and Ly6C+ expression. F480++ were 
classified as macrophages, Ly6C++ as less differentiated monocytes. B- Pie chart showing the proportions 
of CCR2 bright and CCR2 mid Ly6C++F480low monocytes. The representative FACS plots shows CCR1 
expression on CCR2 bright and CCR2 mid monocytes. C- Pie chart showing the proportions of CCR2 bright 
and CCR2 mid F480++Ly6C low macrophages. The representative FACS plots shows CCR1 expression on 
CCR2 bright and CCR2 mid macrophages. D- Graph comparing CCR1 expression on CCR2 bright and CCR2 
mid monocytes. Graph representative of several experiments. n=4 
 
What is also of interest is how CCR2 expression is regulated as monocytes differentiate. As 
seen from the FACS plot in Figure 5-9A, staining for F480 and Ly6C expression presents 
itself as a smear, showing monocytes and macrophages at varying degrees of maturation. 
The FACS plots in Figure 5-9 B and C instead show that CCR2 bright and CCR2 mid 
populations present themselves as two distinct populations.  
 
Downregulation of CCR2 expression during monocyte differentiation is well documented 
in the literature[188], and is believed to occur to avoid reverse migration back into 
circulation[328]. The data from iREP inflammatory monocytes suggest downregulation of 
CCR2 is more tightly controlled than previously thought, with two distinct expression 
‘modes’: CCR2 bright for circulating monocytes and CCR2 mid for monocytes committing 
to differentiation 
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CCR1 expression 
 
CCR1 expression was higher in CCR2 bright cells, compared to the CCR2 mid-monocytes 
(Figure 5-10 A). This difference in CCR1 co-expression on different monocyte/macrophage 
subsets can be explained by taking into consideration the differentiation state of these cells 
and the previous findings on iCCR expression on circulating inflammatory monocytes. 
 
While only 10-15% of circulating inflammatory monocytes expressed CCR1, 24% of 
membrane inflammatory monocytes co-express CCR1 and CCR2 (Figure 5-10 B), indicating 
that the air pouch membrane is indeed ‘enriched’ for CCR1+CCR2+ monocytes and 
explaining the unexpected prevalence of CCR2+CCR1- monocytes extracted from blood. 
 
Figure 5-10- CCR1 expression on Monocytes and Macrophages in the Air Pouch Membrane. A- CCR1 
expression on CCR2 bright and CCR2 mid inflammatory monocytes in the Air Pouch Membrane. B- Pie 
charts (and representative FACS plots) summarising expression and co-expression of CCR1 (green) CCR2 
(red) and CCR5 (purple) in Ly6C++F480low monocytes and F480++Ly6Clow macrophages. Data 
representative of 3 experiments with n=4. 
CCR1 expression, measured as mean fluorescent intensity, was highest in the CCR2 bright 
monocytes (~2200 MFI compared to 750 in CCR2 mid). On the other hand, while lower in 
MFI, more macrophages expressed CCR1 than inflammatory monocytes (35% against 24%) 
(Figure 5-10 B). This increase in CCR1 expressing macrophages in the air pouch membrane 
could either be the result of in situ CCR1 upregulation as the monocyte differentiates, or, 
more simply, evidence that CCR1+ inflammatory monocytes differentiate into CCR1+ 
macrophages.  
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In other words, while both CCR2+ and CCR2+CCR1+ inflammatory monocytes are capable 
of migrating towards inflammation, the presence of CCR1 might strengthen the monocyte’s 
adhesion to the vessel walls and promote migration through the air pouch membrane. 
Thus, while both CCR2+CCR1- and CCR2+CCR1+ inflammatory monocytes can be found on 
the air pouch membrane, co-expression of both receptors speeds up the migration and 
differentiation process, resulting in a higher proportion of macrophages expressing CCR1. 
 
CCR5 expression and Air Pouch Fluid 
 
CCR5 expression (IRFP682 fluorescence) was detected for the first time in both Ly6C++ 
monocytes and F480++ macrophages in the air pouch membrane. 1.6% of inflammatory 
monocytes were triple positive for CCR1 CCR2 and CCR5, increasing slightly to 2% in 
macrophages (Figure 5-10 B). While the levels of CCR5 detected were still rather low, 
analysis of the cellular content of the air pouch fluid revealed further upregulation of this 
receptor. While Ly6C++ monocytes made up the majority (~60%) of the 
CD11b+CD64+CD11c- leukocytes in the air pouch membrane, the air pouch fluid contained 
a majority of F480++ macrophages, showing that effective migration into the site of 
inflammation correlates with differentiation state (Figure 5-11A). Analysis of iCCR 
expression of fluid F480+ macrophages revealed that 54.5% co-expressed CCR1 and CCR2 
(increased from 34.7% in the membrane), and a six-fold increase in macrophages co-
expressing CCR1 CCR2 and CCR5 (from 2% to 13%) (Figure 5-11 B), although this was still 
considered unexpectedly low.  
 
Figure 5-11 CCR5 Expression on Fluid Macrophages. A- Scatter plot graph showing distribution of 
macrophages and monocytes in the membrane and the fluid of the air pouch. B- Pie charts summarising 
iCCR expression on F480++Ly6Clow macrophages in the air pouch fluid compared to bone marrow 
derived F480++ macrophages. Air pouch Data representative of 3 experiments with n=4. In vitro data 
representative of one experiment with 3 different sets of pooled iREP bone marrow (n=3).  
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The short duration of the model (48 hours after carrageenan injection) might explain this, 
as there might not have been enough time for a monocyte recruited from the bone marrow 
to migrate successfully and differentiate sufficiently for CCR5 expression to be prevalent. 
To test if iREP macrophages were capable of expressing CCR5, bone marrow derived 
macrophages were grown as described previously, stained for CD11b and F480, and 
analysed for iCCR expression via flow cytometry. The in vitro pie chart in Figure 5-11 B 
shows that after 5 days of culture more than 85% of macrophages express CCR5, indicating 
that iREP macrophages are indeed capable of expressing CCR5 and that low expression in 
vivo is probably due to the temporal limitations of the air pouch model. 
 
 
5.5.3  Eosinophils 
 
5.5.3.1 Bone Marrow 
 
Compared to inflammatory monocytes, inflammation appears to have the opposite effect 
on iCCR expression in eosinophils. Not only do CD11b+SiglecF++ cells not upregulate other 
iCCRs, but the number of bone marrow eosinophils positive for CCR3 (mTagBFP2) drops 
from 61.4% under resting conditions to 49.9% in the air pouch model (Figure 5-12 A,B).  
 
The representative FACS plots offer a possible clue to explain this reduction. These images 
show a very small CCR3 bright population under resting conditions, which disappears 
completely under inflammatory conditions (Figure 5-12 A). This small population of CCR3 
bright eosinophils looks similar to the population of mature eosinophils (Siglec F++) trapped 
in bone marrow of iCCR-/- and CCR3-/- mice (Figure 5-12 C) described in the previous 
chapter.  A possible conclusion could be the following: under inflammatory conditions, 
rapidly maturing eosinophils increase CCR3 expression and leave the bone marrow, leaving 
behind a disproportionately high number of immature eosinophils (reporter negative) 
which are not yet equipped with the cellular machinery required for bone marrow egress. 
If high CCR3 expression is indeed a requirement for bone marrow egress, then almost the 
totality of eosinophils in the circulation should be CCR3+ve. 
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Figure 5-12 CCR3 Expression on Bone Marrow Eosinophils. A- Pie charts summarising CCR3 (blue) 
expression in CD11b+Ly6G-SIglec F++ eosinophils at rest and during inflammation. Circled in red on the 
representative FACS plots the faint CCR3 bright eosinophil population at rest and during inflammation. 
Resting data representative of 1 experiment with n=3, Inflammation data representative of 3 
experiments with n=4. B- Graph showing the decrease in CCR3 expression (MFI) in CCR3 positive 
eosinophils after inflammation. C- Representative FACS plots showing eosinophils in WT, CCR3 KO and 
iCCR KO bone marrow. 2 populations (Siglec F++ and Siglec F+) can be seen in the CCR3 and iCCR KO. 
 
5.5.3.2 Blood 
 
 
As seen in Figure 5-13A. more than 90% of eosinophils express CCR3 in the circulation, 
suggesting that CCR3 is a necessary requirement for eosinophil bone marrow egress.  
 
While the vast majority of eosinophils in the circulation express CCR3 (>90%), a small 
percentage (~5% at rest) expresses very high levels of the receptor, and was classified as 
CCR3 bright. While the number of CCR3+ eosinophils does not change before or after 
inflammation (91.3% and 92.7% respectively), inflammation reduces the numbers of CCR3 
bright eosinophils in circulation, from 5% to 1.5% (Fig. 5-13B). 
 
The mechanism of action could be similar to the one proposed for inflammatory 
monocytes, as CCR3 has been shown to promote eosinophil arrest on inflammatory 
endothelium in shear flow[353]. 
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Figure 5-13 CCR3 Expression on Circulating Eosinophils. A- Pie charts showing the proportions of CCR3 
bright and CCR3 positive eosinophils in circulation at rest and during inflammation. Representative FACS 
plots shown below. B- Graphs summarising the change in distribution of CCR3 positive and CCR3 bright 
eosinophils before and after inflammation. Resting data representative of one experiment with n=3, 
Inflammation data representative of 3 experiments with n=4.  
 
CCR3 bright eosinophils are more mature, better capable of binding to the activated 
endothelium, and probably better equipped for trans-endothelial migration than CCR3 
positive eosinophils. Similar to CCR1 expressing monocytes, CCR3 bright eosinophils might 
be ‘stuck’ along the inflamed vessel walls, leaving only CCR3-mid eosinophils in extracted 
blood. As a result, CCR3 bright eosinophils should be enriched in the air pouch membrane 
and fluid, as these cells should have been able to transmigrate from vasculature more 
efficiently. 
 
 
 
5.5.3.3 Air Pouch Membrane and Fluid 
 
 
Analysis of iCCR expression of air pouch membrane eosinophils revealed that 24% could be 
classified as CCR3 bright (Figure 5-14A), the highest concentration of CCR3 bright cells in 
any of the tissues analysed. Only 1.2% of eosinophils in circulation were CCR3 bright, 
suggesting that either CCR3 positive cells upregulate the receptor once at the site of 
inflammation, or that CCR3 bright eosinophils are better equipped for chemotaxis and 
migrate more effectively to inflamed areas than their CCR3-mid counterparts.  
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Analysis of CCR3 expression in air pouch fluid revealed a drop in CCR3 bright eosinophils, 
from 23.8% to 14.6% (Figure 5-14 B,C). If CCR3 expression was tied to proximity to the 
inflammatory stimulus, then a higher proportion of eosinophils should have been CCR3 
bright, as the fluid contains the inflammatory stimulant. It is therefore more likely that 
CCR3 bright eosinophils are better equipped for chemotaxis and downregulate CCR3 
expression once the site of inflammation is reached.  
 
 
 
Figure 5-14 Distribution of CCR3 bright and CCR3 positive Eosinophils in the air pouch membrane. A- 
Representative FACS plots showing two main CCR3 expressing populations of eosinophils on the air 
pouch membrane, CCR3 bright and CCR3 mid. B- Pie charts summarising the proportion of CCR3 bright 
and CCR3 positive eosinophils in the membrane and the fluid of the air pouch. Data representative of 3 
experiments with n=4.  
 
 
The nature of CCR3 expression in eosinophils (bright and mid distinct populations) is 
reminiscent of CCR2 expression in inflammatory monocytes, where CCR2 bright 
inflammatory monocytes differentiate into macrophages and downregulate to CCR2 mid 
expression to avoid reverse migration back into circulation. The same mechanism could be 
at play here, where CCR3 bright eosinophils that have reached the site of inflammation 
downregulating to CCR3 mid expression to avoid reverse migration. 
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5.5.4 B-cells 
 
5.5.4.1 Bone Marrow 
 
Inflammation did not appear to have a major effect on B-cell iCCR expression. B-cell 
(CD19++) CCR1 expression increased modestly (6%) after inflammation from 25.3% to 
31.8% (Figure 5-15 A,B), but no other iCCR was detected. The failure of B-cells to upregulate 
other iCCRs is not surprising, as B-cells in the bone marrow do not simply home to a site of 
inflammation, but migrate through the blood towards secondary lymphoid organs where 
they will receive a constant supply of antigen through circulating lymph and activate 
accordingly. As this process is dependent on CCR7, CXCR4, CXCR5 [354], upregulation of 
other iCCRs would be counterproductive and result in aberrant B-cell activation. 
 
 
Figure 5-15 CCR1 Expression on bone marrow B-cells. A- Pie charts (and representative FACS plots) 
showing the proportion of B-cells expressing CCR1 (green) in resting and inflamed bone marrow. B- 
Graph showing the proportion of CCR3 expressing B-cells at rest and during inflammation. Resting data 
representative of one experiment with n=3, Inflammation data representative of 3 experiments with n=4. 
 
 
5.5.4.2 Blood 
 
 
Circulating B-cells during air-pouch induced inflammation also increased CCR1 expression 
by 6% (Figure 5-16A). The proportion of CCR1+ B-cells in the bone marrow and in the blood 
is very similar (31.8% and 27.7%), and inflammation increases CCR1 expression in both 
tissues by the same amount (+6%) (Figure 5-16B). In addition, B-cells were not detected in 
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the air pouch membrane or fluid. The findings suggest that CCR1 expression in B-cells is not 
required for bone marrow egress, migration through blood or transendothelial migration. 
While the reasons as to why this receptor is expressed are still unclear, Dr. Medina-Ruiz 
detected very high levels of CCR1 in splenic B-cells, suggesting the expression of this 
receptor might have a role in B-cell positioning in the spleen or in other secondary lymphoid 
organs. 
 
 
Figure 5-16 CCR1 Expression on circulating B-cells. A- Pie charts (and representative FACS plots) showing 
the proportion of B-cells expressing CCR1 (green) in resting and inflamed blood. B- Graph showing the 
proportion of CCR3 expressing B-cells at rest and during inflammation. Resting data representative of 
one experiment with n=3, Inflammation data representative of 3 experiments with n=4. 
 
5.6 Overall Discussion 
 
Studying the fluctuations of inflammatory chemokine receptor expression on the surface 
of leukocytes has, until now, relied heavily on mRNA analysis and antibody staining. Both 
methods of detection have their drawbacks: iCCR specific antibodies are prone to cross-
reactivity and detection of false positives, and mRNA analysis relies on extensive 
procedures of leukocyte isolation before the RNA is extracted, which in itself could modify 
the activation state of the leukocyte and alter iCCR transcript detection. mRNA analysis also 
does not take into account the contribution that recycled chemokine receptors have on 
leukocyte activation. 
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This novel inflammatory chemokine receptor reporter (iREP) mouse strain has the potential 
to revolutionise our understanding of the role of inflammatory chemokine receptors CCR1, 
CCR2, CCR3 and CCR5 on the development of the immune response. The data gathered in 
this chapter show that this reporter strain allows for effective iCCR detection on a variety 
of leukocytes, and can be used to track changes in iCCR expression in vivo as leukocytes 
react to an inflammatory stimulant. 
 
Analysis of iREP mouse fitness and tissue leukocyte content showed no difference between 
WT and iREP mice, indicating that BAC integration and fluorescent protein expression have 
no impact on mouse development or on the number of leukocytes in various tissues. 
 
Fluorescent reporter proteins were detected in several leukocyte subsets, including 
‘classical’ inflammatory monocytes (CCR2), eosinophils (CCR3), B-cells (CCR1), and ‘non-
classical’ patrolling monocytes (CCR2). Under resting conditions, detection of fluorescent 
reporter proteins via flow cytometry revealed high CCR2 expression (>95%) in 
inflammatory monocytes and high CCR3 expression in eosinophils (>90% in circulation), in 
line with expectations.   In the circulation, patrolling monocytes (which have been shown 
to derive from CCR2+ Ly6C+ inflammatory monocytes[344]) also expressed CCR2 (>65%). 
 
The level of CCR2 expression on a monocyte/macrophage could also be used to determine 
the leukocyte’s differentiation state or location in the body: CCR2 expression was highest 
in circulating ‘classical’ monocytes and decreased gradually as the monocytes developed 
into ‘non-classical’ patrolling monocytes or lung tissue macrophages. CCR2 was not 
expressed in alveolar macrophages, which have a distinct  embryonic origin[345].  
 
Numerous reports in the literature describe upregulation of chemokine receptors and iCCR 
co-expression on leukocytes during inflammation, so the air pouch model was performed 
on iREP mice to assess if it was possible to detect iCCR fluctuations in inflamed leukocytes.  
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Figure 5-17- iCCR expression in Inflammatory Monocytes during migration and differentiation in vivo- 
Graph summarising the expression of CCR1 (green), CCR2 (red) and CCR5 (purple) (expressed as 
percentage positive for each population) as inflammatory monocytes migrate from the bone marrow 
into the air pouch fluid, differentiating into macrophages. Inflammation data representative of 3 
experiments with n=4. 
Not only was iCCR co-expression detected in inflamed inflammatory monocytes, but their 
distribution throughout various tissues on their way to the air pouch revealed that 
CCR1/CCR2 co-expressing monocytes are probably better able to chemotax than their 
CCR2+CCR1-negative counterpart, resulting in an accumulation of CCR1+ macrophages 
(>65% in the air pouch fluid). CCR5 was also detected in air pouch fluid macrophages, 
suggesting that this receptor is only expressed at the latest stages of differentiation (Figure 
5-17). 
 
A portion of circulating B-cells also expressed CCR1, but no B-cells were found in the air 
pouch membrane or fluid, suggesting that expression of CCR1 is not enough for migration 
to inflamed sites. 
 
Unlike inflammatory monocytes, eosinophils in inflammation did not upregulate other 
iCCRs, but some appeared to upregulate their levels of CCR3, resulting in two populations 
of CCR3 bright and CCR3 mid eosinophils in the air pouch membrane. As CCR3 bright 
eosinophils only accounted for 1.2% of eosinophils in the circulation but made up 24% of 
eosinophils in the membrane, it was concluded that CCR3 bright eosinophils are 
preferentially recruited to the site of inflammation over CCR3 mid eosinophils. 
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Detection of the mean fluorescence intensity of reporter proteins in iREP leukocytes also 
revealed differential mechanism of CCR2 and CCR3 regulation compared to CCR1 and CCR5. 
As seen in Figure 5-18A, both eosinophils and inflammatory monocytes present themselves 
as two clearly separated populations, a bright and a mid. On the other hand, expression of 
CCR1 on B-cells and CCR1 and CCR5 on inflammatory monocytes appears as a ‘smear’, 
representing more of a spectrum of expression.  
 
This difference may be attributable to the nature of CCR2 and CCR3 expression, as these 
were the only receptors found to be expressed constitutively at high levels under resting 
conditions. As these two receptors control basal migration of inflammatory monocytes and 
eosinophils respectively, their expression has to be tightly regulated. On the other hand, 
upregulation of CCR1 and CCR5 might be tied more closely to the individual activation 
status of the cell or the local inflammatory conditions, and thus appear as a spectrum of 
expression.  
 
 
Figure 5-18 Patterns of iCCR expression in iREP leukocytes- A- Representative FACS plots showing the 
pattern of expression of CCR2, CCR1 and CCR5 in inflammatory monocytes and CCR3 in eosinophils. B- 
Graph showing iCCR expression in iREP bone marrow derived macrophages stimulated overnight with IL-
6 (50ng/ml), IFNy (100ng/ml) and Poly I:C (10𝝁g/ml). Values expressed as fold change in percentage 
positive using   non-stimulated iREP macrophages as baseline. Data representative of one experiment 
with 3 different sets of pooled iREP bone marrow (n=3).   
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The findings on in vitro bone marrow macrophages summarised in Figure 5-18B support 
this hypothesis: CCR2 expression on macrophages stimulated with a variety of 
inflammatory stimulants does not change, probably because most macrophages in culture 
have a stable CCR2 mid expression. CCR1 and CCR5 expression on the other hand fluctuates 
depending on the inflammatory stimulant (3-fold increase in CCR1 expression after 
addition of IFNy in culture, 2-fold increase in CCR5 after IL-6). 
 
Ultimately, all the data collected so far validates the iREP as a novel reporter mouse model 
for studying the main inflammatory CC-chemokine receptors, and lays the foundation for 
further future experiments that will dissect the roles of CCR1, CCR2, CCR3 and CCR5 with a 
wider range of inflammatory models. 
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6 Results- Role of iCCRs in 
Macrophage and DC function in vitro 
 
 
6.1 Overview 
 
In vivo analysis of iCCR-/- mice revealed a profound defect in recruitment of inflammatory 
monocytes from the bone marrow and a severe decline in numbers of macrophages and 
dendritic cells in most tissues analysed. While the role of ‘classical’ inflammatory 
monocytes in replenishing macrophages and dendritic cells both at rest[187][355][356] and 
during inflammation is well established[357][297][358][98], it is unclear if the defects seen 
in iCCR-/- tissues are exclusively caused by decreased migration of inflammatory monocytes 
to the site of inflammation, or if the reduction in macrophage and dendritic cell numbers 
is also exacerbated by the failure of the inflammatory monocytes to respond to local 
environmental stimulation and differentiate into effector cells.  
In vivo work on iCCR Reporter (iREP) mice has shown that macrophages can express various 
combination of chemokine receptors, with CCR2+, CCR1+CCR2+ and CCR1 CCR2 and CCR5 
triple positive populations all present simultaneously in the air pouch membrane. It was 
unclear however if these different subsets were phenotypically identical, or if the 
expression of particular chemokine receptors was able to alter differentiation and effector 
function of these cells. 
Indeed, some groups have shown that engagement of inflammatory chemokine receptors 
is necessary for correct maturation and function of macrophages and dendritic cells. 
Chemokines have been shown to prolong macrophage survival[338] , while interaction 
between CCL2 and CCR2 has been shown to provide critical signals for correct dendritic cell 
maturation in the lung[102]. Furthermore, experiments performed by Dr. Hughes using 
Influenza virus as a model of inflammation on iCCR-/- mice, have shown an altered immune 
memory response, suggesting a potential role of CCR1, CCR2 CCR3 and CCR5 in correct 
maturation and development of the adaptive immune response. 
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To explore the potential effect of iCCR engagement and signalling on inflammatory 
monocyte differentiation, bone marrow inflammatory monocytes were collected and 
differentiated in vitro into either macrophages or dendritic cells. The differentiated 
leukocytes were then collected and analysed by flow cytometry, ELISA and PCR arrays at 
different stages of development to track changes in phenotype and effector function. 
 
6.2 iCCR-/- Bone Marrow Derived Macrophages and 
DCs 
Isolation and characterisation of resident macrophages from mouse tissues usually 
requires multiple steps of enzymatic digestion and purification, generally resulting in low 
yields of highly heterogenous cells[359]. An alternative method for generating high 
numbers of homogenous macrophages for functional assays involves the culture of bone 
marrow cells in vitro with appropriate growth factors.  
 
Several early studies on macrophage differentiation have identified two main cytokines 
responsible for macrophage proliferation and survival: GM-CSF and CSF-1[360].  Mice 
deficient in CSF-1R expression exhibit a more significant phenotype than mice deficient in 
GM-CSF [361]. Indeed, studies using the Csf1op/op murine strain which possesses an 
inactivating mutation in the CSF-1 gene, have established the central role of CSF-1 in a wide 
range of developmental abnormalities, including skeletal, neurological, growth and fertility 
defects, primarily arising from the severe deficiency in tissue macrophages 
[186][362][363]. Furthermore, CSF-1 has non-redundant functions in development, as 
administration of GM-CSF is not able to correct the growth and skeletal deficiencies in CSF-
1-deficient mice [364]. 
 
While these developmental defects are severe, CSF-1-deficient mice exhibit surprisingly 
few immunological defects. This is in contrast to granulocyte-macrophage colony-
stimulating factor (GM-CSF), where GM-CSF deficient mice are superficially healthy and 
fertile, have normal levels of the major types of mature hematopoietic cells and their 
precursors in blood, marrow, and spleen[365], but profound defects in pulmonary 
physiology and inability to clear to local infections[366].  
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CSF-1 is constitutively expressed by many tissues and exhibits a mostly homeostatic 
expression pattern, suggesting that it controls macrophage phenotype and function under 
basal conditions[361]. Accordingly, CSF-1 regulates the numbers of various tissue 
macrophage and monocyte populations without altering their activation status or cytokine 
secretion profile. Conversely, expression of GM-CSF is rapidly upregulated during 
inflammation, and can stimulate monocytes directly, causing a polarisation towards a pro-
inflammatory phenotype characterised by high secretion of IL-1, IL-12, IFNy, a high 
expression of antigen presentation molecules [367], and increased phagocytic rates [368], 
ultimately resulting in the differentiation of macrophages with dendritic cell (antigen-
presenting) properties [369]. Thus, while colony-stimulating factor 1 (CSF-1) regulates the 
survival, proliferation, and differentiation of macrophages at rest, GM-CSF is responsible 
for shaping the monocyte/macrophage function during an inflammatory response [370].  
 
As inflammatory chemokine receptors might be involved in both CSF-1 and GM-CSF 
maturation pathways, iCCR-/- bone marrow cells were grown in media supplemented with 
either GM-CSF or CSF-1, and the development of macrophages and dendritic cells was 
tracked for several days until terminal differentiation in an attempt to uncover any 
phenotypic difference between WT and iCCR-/- monocyte differentiation. 
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6.3 Effect of iCCR deletion on CSF-1 dependent 
monocyte- derived Macrophages 
 
 
 
Figure 6-1 CSF-1 BM derived macrophages- A- Representative FACS plots showing CD11b+F480+ cells in 
WT and iCCR cultures after 7 days of growth under CSF-1. B- Representative histograms showing 
expression of macrophage costimulatory molecules CD40 and CD86 (WT: blue, iCCR: red).  Ci- Phagocytic 
Rates of WT/iCCR-/- macrophages, measured as incorporation of fluorescent ovalbumin. n=4, Student T-
test was performed to determine statistical significance, with a p value of 0.05 determined as significant. 
Cii- Representative histograms showing a slight decrease in fluorescent OVA incorporation by iCCR-/- 
macrophages (blue) against WT macrophages (orange). 4’C control shown in red.  
 
After 1 week of culture with media containing CSF-1, both WT and iCCR-/- bone marrow 
cultures produced a uniform population (~99%) of CD11b+ F480+ cells (Figure 6-1A). 
Macrophages from both cultures express identical levels of the macrophage costimulatory 
molecules CD40 and CD86 under resting conditions (Figure 6-1B). The only difference 
observed was a minor decrease in phagocytosis in iCCR-/- macrophages after incubation 
with fluorescent ovalbumin (Figure 6-1Ci, 6-1Cii). 
 
As no major differences were observed under resting conditions, macrophages in culture 
were stimulated overnight with LPS, and their co-stimulatory molecules, phagocytic rates 
and cytokine secretion profiles were analysed. 
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Figure 6-2- CSF-1 BM derived macrophages (LPS treated)- A- Graph summarising costimulatory 
molecule expression (MHCII, CD40, CD80, CD86) in WT (black) and iCCR -/- (white) macrophages after 
stimulation with LPS overnight  (n=3). B- Cytokine secretion (TNF𝜶, IL-6 and IL-10) measured via ELISA by 
WT and iCCR-/- macrophages in 96 well plates (100.000 cells/well) after overnight LPS stimulation (n=4). 
C- Phagocytic Rates of WT/iCCR-/- macrophages, measured as incorporation of fluorescent ovalbumin 
with accompanying representative histograms (n=4). 
 
As seen in Figure 6-2, the absence of iCCRs had no effect on macrophage function after 
overnight LPS treatment: costimulatory molecule expression (Figure 6-2A) and pro and 
anti-inflammatory cytokine secretion (TNF𝛼, IL-6 and IL-10) (Figure 6-2B) were identical 
between iCCR-/- and WT macrophages. Surprisingly, the small defect in phagocytosis 
observed at rest disappears after overnight LPS administration (seen as overlapping 
histograms in Figure 6-2C).   
 
The absence of a phagocytosis defect under inflammatory conditions in iCCR-/- 
macrophages could be explained by a change in culture conditions after LPS administration. 
Under resting conditions, engagement of inflammatory chemokine receptors might be 
required for optimal phagocytosis. Under inflammation, macrophages can probably 
override the lack of iCCRs by engaging other receptors, such as cytokine receptors or 
costimulatory molecules, that ultimately promote phagocytosis in the absence of iCCR 
signalling. 
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As no major differences were observed in CSF-1 macrophages, bone marrow from iCCR-/- 
and WT mice was collected and grown in media supplemented with GM-CSF to obtain GM-
CSF-derived macrophages and monocyte derived dendritic cells (mo-DCs). The phenotype 
of these cells was then assessed with various techniques to determine if iCCR deletion had 
any effect on proliferation rates or function. 
 
6.4 Effect of iCCR deletion on monocyte-derived DCs 
 
After 7 days of proliferation in GM-CSF, two main populations can be found in culture: in 
broad terms, non-adherent cells can be thought of as mature and immature monocyte 
derived DCs at different stages of maturation [371] although their nature is heavily debated 
[372][373] , while the adherent ones are generally discarded as “non-dendritic cells” or 
macrophages, even though they are very similar to DCs in surface marker expression and 
DC-related function[374] . Initially, the non-adherent fraction was collected after a week in 
GM-CSF containing media, and the proliferation, phagocytic rates and cytokine secretion 
of the mo-DCs were assessed before and after LPS administration. As shown in figure 6-3, 
iCCR-/- mo-DCs proliferated more slowly in culture (Figure 6-3A) and were less capable of 
phagocytosing antigen as measured via uptake of fluorescent OVA-488, both before (Figure 
6-3 Bi,Bii) and after administration of LPS (Figure 6-3 Ci,Cii).  
 
Figure 6-3 Proliferation Rates and Phagocytic Ability of iCCR-/- mo-DCs.  A- Cell number in GM-CSF 
cultures of WT/iCCR-/- bone marrow, monitored every 2 days after plating at 1million cells/ml in 10ml of 
IMDM media containing 20ng/ml of recombinant murine GM-CSF. Cell counts preformed automatically 
on the Luna Cell Counter. Bi- Graph showing phagocytic rates expressed as MFI for OVA-488 between 
WT/iCCR GM-CSF mo-DCs in non-stimulated cultures. Bii: Representative FACS plots showing decreased 
OVA-488 incorporation by WT/iCCR-/- DCs. Ci Cii- Phagocytic rates after overnight LPS administration. 
Student T-test was performed to determine statistical significance, with a p value of 0.05 determined as 
significant. Results elaborated from an average of at least 3 independent GM-CSF cultures for both WT 
and iCCR-/- samples. 
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Cultured iCCR-/- mo-DCs stimulated with LPS for 12 hours secreted lower levels of IL-12p70 
as measured by ELISA (a DC-specific cytokine capable of modulating T-cell development 
and function), but similar levels of anti-inflammatory IL-10 when compared to WT mo-DCs 
(Figures 6-4 A,B). Furthermore, as seen in Figure 6-4C, iCCR-/- mo-DCs show decreased 
expression of CCR7 (measured via binding of fluorescent CCL19[375]), the main chemokine 
receptor required for lymph node homing of activated DCs. The same iCCR-/- mo-DCs also 
seemed less capable of degrading antigen, as pHRODO fluorescence (pH sensitive 
fluorescent emission that increases in intensity with increasing acidity) is decreased both 
before and after LPS administration (Figure 6-4D).  
 
Figure 6-4 Cytokine Secretion and CCR7 Expression in iCCR-/- mo-DCs- A/B- Graph showing cytokine 
secretion of bioactive IL-12p70 and IL-10 respectively, in both WT and iCCR cultures before and after 
administration of 200ng/ml of LPS for 12h, as measured via ELISA. Ci- Graphs summarizing expression of 
CCR7 in WT/iCCR GM-CSF-moDCs measured via flow cytometry by detecting fluorescently labelled CCL19 
(after a 20 minute incubation at 4’C). Cii- Representative FACS plots showing decrease in CCL19 
fluorescence in iCCR-/- cultures when compared to WT mo-DCs. Di- Graph showing decreased pH Rodo 
Dextran fluorescence after 20 minute incubation at 37’C (20𝝁g/ml), indicating reduced ability to process 
antigen, in iCCR-/- mo-DCs. Dii- representative FACS histograms showing increased pH Rodo fluorescence 
in WT (red) and ICCR-/- (blue) mo-DCs. Student T-test was performed to determine statistical significance, 
with a p value of 0.05 determined as significant. Results elaborated from an average of at least 3 
independent GM-CSF cultures for both WT and iCCR-/- samples.  
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6.4.1 Effect of iCCR deletion on antigen presentation by mo-DCs 
 
Dendritic cells are vital for the correct functioning of the immune system by linking the 
innate and adaptive branches of the immune response. Indeed, DCs are responsible for 
acquiring antigen at the site of infection, processing it and presenting on specialised 
molecules known as major histocompatibility complexes (MHCI and MHCII). The antigen-
loaded dendritic cell then migrates to the closest draining lymph node using CCR7 by 
detecting gradients of CCL19 and CCL21 produced by lymphatic endothelial cells and lymph 
node stromal cells[16][376][15], and once in the lymph node, the DC is then capable of 
activating lymphocytes specific for the presented antigen, which then undergo clonal 
expansion[377][378] and antibody recombination[379][380] to produce cells and 
antibodies with high affinity against the invading pathogen.  
 
Activating an antigen specific lymphocyte is a complex process, as aberrant activation can 
result in the activation of wrong lymphocytes or the generation of ineffective 
antibodies[381]–[383]. Currently, the ‘three-signal hypothesis’ is the accepted 
immunological model of how antigen specific lymphocytes can be activated by DCs [384]–
[386]. The first signal involves the interaction between the DC’s antigen loaded MHCII or 
MHCI with the lymphocyte’s own antigen specific receptors (such as T-cell receptors, TCRs).  
 
The second signal, also known as a co-stimulatory signal, is mediated by molecules 
collectively known as co-stimulatory molecules. Not only can engaged costimulatory 
molecules signal intracellularly, directly amplifying any activating signals[387], but by 
binding to each other (for example B7 on DCs binding to CD28 on T-cells) they can physically 
stabilise the immune synapse[388][389] and keep the MHC-peptide-TCR complex between 
the APC and T-cell in place for longer, resulting in prolonged signalling and complete cell 
activation. The third signal comes in the form of soluble factors, by which inflammatory 
cytokines such as IL-12 and IL-1 secreted by the DCs directly stimulate neighbouring T-cells, 
further amplifying activator signals and promoting T-cell proliferation[386][390]. 
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The data shown so far suggest that iCCR-/- monocyte-derived DCs phagocytose antigen less 
efficiently (fluorescent ovalbumin uptake) and are unable to process it appropriately (pH 
Rodo dextran). Furthermore, LPS treated iCCR-/- mo-DCs show an altered cytokine secretion 
profile characterised by decreased production of IL-12p70. It was therefore hypothesised 
that iCCR-/- DCs would not be able to activate cognate T-cells effectively, as both signal one 
and signal three of the ‘three-signal hypothesis’ seem to be altered. To test the ability of 
iCCR-/- DCs to stimulate cognate lymphocyte, an antigen presentation assay was performed 
using ovalbumin as a model antigen.  
 
After incubating the DCs with latex beads coated in ovalbumin (to mimic particulate 
antigen), the cells were then activated with LPS (which increases expression of MHC and 
costimulatory molecules on the DCs), fixed, and co-incubated with ovalbumin specific T-
cells for 12 hours (OT-1 or OT-2). If all three signals are delivered correctly to the antigen 
specific T-cells, the T-cells should respond by rapidly increasing in number. To support this 
clonal expansion, correctly activated T-cells also secrete large amounts of IL-2, which can 
be detected by ELISA. Detecting IL-2 levels in media is thus an effective and established 
method to determine the extent of DC-dependent T-cell activation[247][391]. 
 
 
Figure 6-5- Analysis of antigen presentation by WT/iCCR mo-DCs. A- IL-2 secretion by cognate cytotoxic 
T-cells after co-incubation with OVA-loaded DCs, indicating reduced antigen cross-presentation by iCCR-
/- mo-DCs. B- IL-2 secretion by cognate T-helper cells after incubation with OVA-loaded DCs, indicating 
reduced antigen presentation by iCCR-/- mo-DCs. Student T-test was performed to determine statistical 
significance, with a p value of 0.05 determined as significant. Results elaborated from an average of at 
least 3 independent GM-CSF cultures for both WT and iCCR-/- samples. 
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As seen in Figure 6-5, iCCR-/- DC-T-cell cultures produced half the amount of IL-2 compared 
to WT DC-T-cell cultures after 12 hours, suggesting that both antigen presentation and 
antigen cross-presentation are negatively affected in iCCR-/- DCs and that T-cells activated 
by iCCR-/- mo-DCs are less proliferative and probably less capable of performing their 
effector functions (direct cytotoxic killing by OT-1 CD8 T-cells or supporting antibody 
production by OT-2 CD4 helper T-cells). 
 
Collectively, these results show that iCCR-/- mo-DCs proliferate more slowly, are less 
capable of phagocytosing and degrading antigen, are potentially less capable of migrating 
to the lymph node after antigenic challenge, show altered cytokine secretion profile 
characterised by decreased production of bioactive IL-12 and are less able to activate 
cognate T-cells. However, it is still unclear how the lack of iCCRs would mediate all these 
effects, so further analysis by flow cytometry of these ‘mo-DCs’ was performed to 
understand the nature of WT and iCCR mo-DCs. 
 
 
6.4.2 Further characterisation of iCCR BM mo-DCs  
 
Flow cytometric analysis of the suspension fraction in WT GM-CSF cultures revealed that 
this population is in fact composed of 4 subpopulations, each characterised by different 
expression of CD11c and MHC II (Figure 6-6A). As shown in figure 6-6C, iCCR mo-DC cultures 
appear to have an accumulation of CD11c-MHCII- cells, compared to WT cultures. At this 
stage however, it was still unclear what these 4 populations represent, and how the 
accumulation of CD11c- MHCII- in iCCR-/- cultures is causing the phenotypes observed so 
far.  To determine the nature of each sub-population in the non-adherent fraction of GM-
CSF cultures, WT ‘mo-DCs’ were cultured and analysed via flow cytometry to detect 
differences in co-stimulatory molecules and maturation markers. As shown in Figure 6-6A, 
WT mo-DC cultures can be divided into CD11c+ MHCII++, CD11c+ MHCII +, CD11c+ MHCII 
int and CD11c- MHCII- populations. Each population had a distinct phagocytic ability, as 
shown by the heatmap representing levels of incorporated OVA-488 in each cell (Figure 6-
6B). CD11c+ MHCIIint and CD11c+ MHCII+ populations had the highest phagocytic rates, 
closely followed by CD11c+ MHCII++ cells. CD11c- MHCII- cells are instead non-phagocytic 
(Figure 6-6 D, E). 
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Figure 6-6 Subpopulations in WT and iCCR-/- mo-DC cultures. A- Representative FACS contour plot 
showing the division of 4 subpopulations identified in WT GM-CSF cultures according to CD11c and MHCII 
levels (left). B- FACS heatmap showing OVA-488 fluorescence in different subpopulations, indicating 
varying levels of phagocytic ability. Orange: high fluorescence indicating high phagocytic ability 
Green/Blue: non-phagocytic. C- Representative FACS plots showing the distribution of cells in WT and 
iCCR-/- GM-CSF cultures along a CD11c and MHCII axis. D, E- Histograms and overlaid histograms showing 
the MFIs for OVA-488 for each CD11c and MHCII populations.  
 
6.4.3  The 4 sub-populations in mo-DC cultures have unique marker 
expression 
 
These 4 sub-populations also expressed different levels of the lymph-node homing 
chemokine receptor CCR7. CD11c+ MHCII++ cells were CCR7+ve (>97%) and had the 
highest MFI as seen from heatmap representing levels of bound fluorescent CCL19 (Figure 
6-7A, 6-7B). More than half of CD11c+ MHCII+ cells also expressed CCR7, while the MHCII 
int and MHCII- populations showed minimal CCR7 expression, both as percentage positive 
(Figure 6-7A) and as mean fluorescent intensity (Figure 6-7C).  
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Figure 6-7 Phenotype of Subpopulations in WT and iCCR-/- mo-DC cultures. A-Representative WT FACS 
plot of the four CD11c MHCII populations (shown previously) with associated pie charts showing % 
positive cells for bound fluorescent CCL19, indicating CCR7 expression in each population. B- FACS 
Heatmap showing Fluorescent intensity for CCL19 in each sub-population. C- FACS Histograms showing 
the MFIs for CCL19 for each CD11c and MHCII population. Di: Representative FACS plot showing the 
effect of overnight LPS stimulation on the composition of the 4 main subpopulations in WT GM-CSF 
cultures. Dii: Pie charts showing CCR7 expression of each of the 3 main sub-populations (CD11c+MHCII++, 
CD11c+MHCIIint, CD11c-MHCII-) in WT GM-CSF cultures after overnight LPS stimulation (100ng/ml). E: 
Levels of expression of main DC costimulatory molecules and maturation markers in each of the four 
CD11c and MHCII sub-populations identified in WT unstimulated cultures, measured as MFI via flow 
cytometry. 
 
Co-stimulatory molecule expression also varied greatly between sub-populations: CD11c+ 
MHCII++ cells were the highest expressers of costimulatory molecules CD40 and CD86, and 
the lowest expressers of the macrophage marker F480. On the other hand, F480 was the 
most highly expressed marker in CD11c+ MHCII int population, while on CD11c- MHCII- 
cells, costimulatory molecules and maturation markers were barely expressed (Figure 6-
7E). 
 
In WT cultures and after LPS administration, the CD11c+ MHCII+ population ‘disappeared’ 
as MHCII expression was upregulated, resulting in a larger proportion of CD11c+ MHCII++ 
cells in culture (Figure 6-7Di). In addition, all the LPS treated CD11c+ MHCII++ cells 
expressed CCR7 (>94%), while CCR7 expression never increased in CD11c+MHCII int and 
CD11c- MHCII- populations, even after LPS administration (Figure 6-7Dii). 
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With this information, it was now possible to classify these subpopulations: 
 
CD11c+ MHCII++: mature DCs. Almost all are CCR7+, possess intermediate phagocytic 
ability and are the highest expressers of costimulatory molecules. 
 
CD11c+ MHCII+: immature DCs. The majority are CCR7+, have very high phagocytic ability, 
lower expression of costimulatory molecules than DCs, but higher than  
CD11c+MHCII int. Upon LPS stimulation, this population disappears and shifts toward a 
‘mature’ CD11c+ MHCII++ phenotype. 
 
CD11c+ MHCII int: macrophages. CCR7-, very high phagocytic ability, low expression of 
costimulatory molecules and high expression of F480. 
 
CD11c-MHCII-: monocytes. No CCR7 expression, very low phagocytic ability, costimulatory 
molecule and F480 expression.  
 
 
6.4.4 Most cells in iCCR-/- cultures are undifferentiated monocytes 
 
As seen in Figure 6-8 (Ai, Aii) the majority of cells (40%) after 7 days of culture of iCCR-/- 
bone marrow in GM-CSF were undifferentiated CD11c-MHCII- monocytes, double the 
number found in WT cultures (20%, Figure 6-8 (Bi,Bii). After LPS administration, the 
immature DCs (CD11c+MHCII+) in both WT and iCCR-/- cultures matured and became 
CD11c+MHCII++ (Figures 6-8 Ci,Di). In the iCCR-/- cultures however, a higher proportion of 
undifferentiated monocytes could still be observed (figure 6-Cii,Dii). 
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Figure 6-8 Subpopulations in WT and iCCR-/- mo-DC cultures before and after LPS. Ai- Representative 
FACS plot of the 4 main subpopulations identified in iCCR-/- GM-CSF cultures (Mature DCs: 
CD11c+MHCII++, Immature DCs: CD11c+MHCII+, Macrophages: CD11c+MHCIIint, Monocytes (CD11c-
MHCII-). Aii: Pie chart summarising the proportion of each sub-population in iCCR-/- cultures. Bi- 
Representative FACS plot of the 4 main subpopulations identified in WT GM-CSF cultures (Mature DCs: 
CD11c+MHCII++, Immature DCs: CD11c+MHCII+, Macrophages: CD11c+MHCIIint, Monocytes (CD11c-
MHCII-). Bii- Pie chart summarising the proportion of each sub-population in WT cultures. Ci- 
Representative FACS plot representing the main subpopulations in iCCR-/- cultures after LPS 
administration overnight (Mature DCs: CD11c+MHCII++, Macrophages: CD11c+MHCIIint, Monocytes 
(CD11c-MHCII-). Cii- Pie chart summarising the proportion of each sub-population in LPS treated iCCR-/- 
cultures. Di- Representative FACS plot representing the main subpopulations in WT cultures after LPS 
administration overnight (Mature DCs: CD11c+MHCII++, Macrophages: CD11c+MHCIIint, Monocytes 
(CD11c-MHCII-). Dii- Pie chart summarising the proportion of each sub-population in LPS treated WT 
cultures. Results elaborated from an average of at least 3 independent GM-CSF cultures for both WT and 
iCCR-/- samples.  
 
Thus, the absence of CCR1 CCR2 CCR3 and CCR5 seems to affect differentiation and 
maturation of monocytes into dendritic cells, resulting in an accumulation in culture of 
undifferentiated CD11c-MHCII- cells. Some monocytes still managed to differentiate 
appropriately, albeit in lower numbers, and the ones that did look very similar to their WT 
counterparts. As seen in Figure 6-9, there was no difference in levels of costimulatory 
molecules or maturation markers between both WT and iCCR mature (Figure 6-9A) and 
immature DCs (Figure 6-9C), suggesting that if iCCR-/- monocytes do manage to 
differentiate, their phenotype will be very close to a WT mo-DCs. However, while 
costimulatory and maturation marker expression was identical, a slight decrease in 
phagocytic activity was still observed in both immature and mature iCCR-/- DCs (Figures 6-
9B, 6-9D). 
 155 
 
Figure 6-9 Costimulatory molecule expression on subpopulations in WT and iCCR-/- mo-DC cultures. A- 
Graphs showing expression of major DC costimulatory molecules and maturation markers in WT and 
iCCR immature mo-DCs, measured as MFI via flow cytometry. B- Graph summarising the phagocytic rates 
of immature mo-DCs, measured as MFI of OVA-488 via flow cytometry. C- Graphs showing expression of 
major DC costimulatory molecules and maturation markers in WT and iCCR mature mo-DCs, measured 
as MFI via flow cytometry. D- Graph showing the phagocytic rates of mature mo-DCs, measured as MFI 
of OVA-488 via flow cytometry. Results elaborated from an average of at least 3 independent GM-CSF 
cultures for both WT and iCCR-/- samples.  
 
6.4.5 Accumulation of monocytes in culture explains the 
phenotypes observed 
 
An increase of undifferentiated monocytes in iCCR-/- cultures explains most of the 
phenotypes observed so far: 
Defect in Phagocytosis and Antigen Presentation: Undifferentiated monocytes are not 
able to phagocytose antigen and degrade it properly, resulting in overall decreased 
phagocytic rates, pH Rodo Dextran fluorescence and IL-2 secretion by T-cells after 
incubation with iCCR-/- cells. 
Defect in CCR7 expression: reduced DC number and accumulation of monocytes explains 
the observed decrease in CCR7 MFI 
Defect in IL-12p70 secretion but not IL-10: monocytes can secrete IL-10, but IL-12p70 can 
only be produced by antigen presenting cells by assembling the p35 and p40 subunits of IL-
12 to form bioactive IL-12p70. Increased monocyte numbers result in lower IL-12p70 
secretion, but unchanged IL-10. 
 156 
6.5 Role of iCCR deletion in ‘steady state’ DCs 
 
While GM-CSF is routinely used to generate in vitro mo-DCs from bone marrow monocytes 
[392], cultures can be very heterogenous and result in the formation of other cell types, 
namely macrophages and their precursors [393]. Several reports indicate that murine bone 
marrow-derived DCs (BM-DCs), human monocyte-derived DCs (MoDCs), and Langerhans 
cells (LCs) show considerable transcriptional overlap with macrophages [394]. 
Furthermore, it has also been shown that many of the proposed unique markers and 
functions of mo-DCs are, in fact, shared between different cell types [395]. 
 
Nonetheless, their similarity in phenotype, morphology, function and developmental origin 
have lead some groups  to identify GM-CSF mo-DCs as the in vitro counterpart of Tip-DCs 
[373][396], dendritic cells characterised by the secretion of high levels of TNF𝛼 and iNOS, 
which emerge from inflammatory monocytes in vivo during inflammation[397]. 
 
However, GM-CSF is not the only way to generate bone marrow derived DCs in vitro. Both 
Flt3 ligand (Flt3L) and GM-CSF can stimulate the expansion of dendritic cells 
[398][399][400].  FLT3L was observed to increase DC numbers both in vivo and in vitro 
[401], and FLT3L receptor expression can be found on early DC precursors in murine bone 
marrow [402]. Unlike GM-CSF derived DCs, FLT3L DCs, take longer to mature, migrate more 
effectively and have a cytokine secretion profile which is more similar to in vivo ‘steady-
state’ DCs [373].  
 
To determine the effect of iCCR deletion on ‘steady-state’ DCs, iCCR-/- bone marrow was 
grown in FLT3L containing media for 10 days. In WT cultures, 3 main subpopulations can 
be identified on the basis of CD11c and MHCII: CD11c+ MHCII-, CD11c+ MHCII+, and CD11c+ 
MHCII++ (Figure 6-10A). All 3 subsets express CCR7, with CD11c+ MHCII++ cells expressing 
the highest levels, both as percentage (>92%, Figure 6-10B) and MFI (Figure 6-10C). The 
CD11c+ MHCII++ subset was identified as mature FLT3 DCs, while the CD11c+ MHCII+ 
population represented immature DCs, and the CD11c+ MHCII- cells represent 
undifferentiated DC precursors[399]. 
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Figure 6-10 Subpopulations in WT FLT3 DC cultures-  A-Representative FACS plots showing 3 different 
subpopulations in WT FLT3 cultures identified by CD11c and MHCII expression. B- Pie charts showing 
expression of CCR7 on each subpopulation, measured as % positive for fluorescent CCL19. C- Overlaid 
FACS histograms showing MFI for fluorescent CCL19 in each CD11c MHCII sub-population in WT FLT3 
cultures. Results elaborated from an average of at least 3 independent GM-CSF cultures for both WT and 
iCCR-/- sample 
 
Unlike GM-CSF derived mo-DC, FLT3L DCs in WT and iCCR-/- cultures were identical in terms 
of subpopulation percentages (Figure 6-11 A,B), both before and after LPS treatment 
(Figure 6-11 Aii,Bii). 
 
 
Figure 6-11 Subpopulations in FLT3L DC cultures before and after LPS– A-Representative FACS plot and 
pie chart summarising the proportion of each CD11c MHCII sub-populations in WT and iCCR-/- FLT3L 
cultures. B- Representative FACS plot and pie chart summarising the proportion of each CD11c MHCII 
sub-populations in WT and iCCR-/- FLT3L cultures after exposure to LPS for 12h. Results elaborated from 
an average of at least 3 independent GM-CSF cultures for both WT and iCCR-/- samples.  
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WT and iCCR-/- FLT3L DCs also express the same levels of costimulatory molecules CD40 and 
CD86 before and after LPS (Figure 6-12A), have similar phagocytic rates (Figure 6-12 B), and 
have identical secretion of both IL-10 and IL-12p70 (Figure 6-12C). 
 
Thus, the previous findings of defective phagocytosis and maturation in iCCR-/- mo-DCs 
seem to be restricted to the ‘inflammatory DC’ subtype, with ‘steady-state’ DCs largely 
unaffected by iCCR deletion. However, it is still unclear how the absence of CCR1, CCR2, 
CCR3 and CCR5 cause the observed phenotype in GM-CSF-derived mo-DCs. 
 
 
Figure 6-12- Costimulatory molecule expression and cytokine secretion by FLT3 DCs. A- Graphs showing 
expression of major DC costimulatory molecules and maturation markers in WT and iCCR immature and 
mature FLT3 cultures, measured as MFI via flow cytometry. B- Overlaid histograms showing the 
phagocytic rates of mature FLT3 DCs, measured as MFI of OVA-488 via flow cytometry (Red: WT, Blue: 
iCCR-/-). C- Graphs showing cytokine secretion of IL-10 and bioactive IL-12p70 respectively, in both WT 
and iCCR cultures before and after administration of 200ng/ml of LPS for 12h, as measured via ELISA. 
Results elaborated from an average of at least 3 independent GM-CSF cultures for both WT and iCCR-/- 
samples.
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6.6 Engagement of iCCRs in GM-CSF cultures 
 
If iCCR deletion mediates the effect observed in GM-CSF mo-DCs, this means that CCR1, 
CCR2, CCR3 and CCR5 must be active in maturing WT cultures. While most cells can secrete 
chemokines under inflamed conditions, it is unclear which chemokines, if any, are present 
in resting GM-CSF cultures.  
 
Surprisingly, ELISA for CCL2 (ligand for CCR2) and CCL5 (ligand binding to CCR1, CCR3 and 
CCR5) detected high levels of these chemokines in cultures, both at rest and after LPS 
administration. While there was no difference in CCL5 levels between WT and iCCR-/- 
supernatants (Figure 6-13A), CCL2 levels where twice as high at rest and remained elevated 
after LPS administration in iCCR-/- cultures (Figure 6-13 B,C).  
 
 
Figure 6-13 Chemokine secretion in GM-CSF cultures-  A- Graphs showing cytokine secretion of CCL5 in 
both WT and iCCR cultures before and after administration of 100ng/ml of LPS for 12 hours, as measured 
via ELISA. B,C- Graph showing cytokine secretion of CCL2 in both WT and iCCR cultures before and after 
administration of 100ng/ml of LPS for 12 hours, as measured via ELISA. Results elaborated from an 
average of at least 3 independent GM-CSF cultures for both WT and iCCR-/- samples. Student T-test was 
performed to determine statistical significance, with a p value of 0.05 determined as significant. 
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Once engaged, CCR2 is rapidly internalised[403] and either recycled to the membrane or 
downregulated through lysosomal degradation[404]. The absence of CCR2 explains the 
elevated levels of CCL2 in culture, as the chemokine cannot bind to any receptor and is not 
internalised, thus accumulating in the supernatant.  
 
Binding of CCL2 to its cognate receptor should be initiating a signalling cascade, and this 
signalling is completely absent in the iCCR-/- cultures. Thus, the absence of inflammatory 
CC-chemokine signalling in iCCR-/- cultures might explain the undifferentiated phenotype 
observed in iCCR mo-DCs. 
 
 
6.6.1 Absence of iCCRs prevents formation of ‘Proliferation Clusters’ 
in GM-CSF cultures. 
 
Together with decreased proliferation, GM-CSF iCCR-/- cultures also showed a complete 
absence of what were identified as ‘proliferation clusters’ (Figure 6-14), small clumps of 
differentiating cells that grow and increase in size as maturation progresses. To assess 
whether the absence of these proliferation clusters (which appear spontaneously in 
cultures by days 3 and 4) could be attributed to the absence of a single iCCR, bone marrow 
cells of each single iCCR knock-out strain were cultured in GM-CSF-containing media and 
the development of proliferation clusters was recorded between days 3 to 7. 
 
Proliferation clusters were seen in all WT and single-/- GM-CSF cultures (figures 6-14 and 6-
16A), suggesting that complete inhibition of cluster formation requires simultaneous 
inhibition of multiple chemokine receptors. 
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Figure 6-14- Proliferation Clusters in GM-CSF cultures-  Representative bright field images at x4 and 
x10 magnifications, showing proliferation clusters in GM-CSF WT, CCR2-/- and iCCR-/- mo-DC cultures.  
 
6.6.2 Inhibiting iCCRs in WT cells replicates the ‘cluster-less’ 
phenotype 
 
To ensure that this ‘cluster-less’ phenotype was caused by the absence of iCCRs, WT 
cultures were allowed to grow in the presence of different combinations of chemokine 
receptor antagonists (CCR2 à BMS CCR2 22, CCR1/3 à UCB 35625, CCR5à Maraviroc). 
Initially, WT cells were exposed for 48 hours to 3 different antagonists, both alone and in 
different combinations. Following this, cell numbers and cell viability were assessed to 
ensure that the antagonists and their combinations were not toxic to developing dendritic 
cells. 2uM was established as a safe dosage of chemokine receptor antagonist, and no 
decrease in cell number and viability was observed even with 3 antagonists delivered 
simultaneously (Figure 6-15 A,B). 
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Figure 6-15 Determining non-toxic iCCR antagonist concentrations- A- % Live cells in WT GM-CSF DC 
cultures after 48 hour exposure to chemokine antagonists, at varying concentrations, singly or in specific 
combinations, as measured via Luna Cell Counter. B- Cell numbers in WT GM-CSF DC cultures after 48 
hour exposure to chemokine antagonists, at varying concentrations, singly or in specific combinations, 
as measured via Luna Cell Counter. 
 
Once a safe concentration was determined, WT GM-CSF cultures were exposed to an 
antagonist cocktail inhibiting CCR1, CCR2, CCR3 and CCR5 simultaneously. The media was 
changed every two days to ensure maintenance of the receptor occupancy. As seen from 
figure 6-16 B, both WT+ antagonist and iCCR-/- cultures showed no proliferation clusters by 
day 5 of culture, while the WT and single-/- culture proliferation clusters developed 
normally (Figure 6-14, 6-16A). 
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Figure 6-16 Proliferation Clusters after iCCR Antagonist Treatment- A- Representative bright field 
images of proliferation clusters in GM-CSF cultures at x40 magnification from CCR5, CCR1 and CCR2-/- 
bone marrow at day 4. B- Representative bright field images of proliferation clusters in GM-CSF cultures 
at x40 magnification from WT, iCCR-/- and WT+ iCCR Antagonist treated bone marrow cells. 
 
Next, different chemokine antagonist cocktails were administered to WT cultures to tease 
out the effect of specific iCCRs on the development of proliferation clusters. As seen from 
Figure 6-17B (Representative fields of view 6-17A), cluster number in culture falls after 
simultaneous inhibition of 2 chemokine receptors, and the effects are most pronounced 
when CCR5 inhibition is involved. 
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Figure 6-17 Proliferation Clusters with Various iCCR Antagonist Combinations- A- Representative bright 
field images of proliferation clusters in GM-CSF cultures (12 well plates) at x40 magnification from WT 
cells treated with different combinations of chemokine receptor antagonists. B- Graph showing the 
quantification of clusters in WT GM-CSF cultures in 12 well plates treated with different receptor 
antagonist combination. The same WT bone marrow was used for each culture, each condition was 
repeated in triplicate, and 5 fields of view taken from each well. Each value in the graph represents an 
average of 18 points. Cluster quantification was performed with Fiji Software’s particle analysis by 
selecting clusters larger than 1800microns2. Ordinary one-way ANOVA with Dunnett’s multiple 
comparisons test was performed to determine statistical significance, with a p value of 0.05 determined 
as significant. 
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While no effect on cytotoxicity was observed at 48 hours, it was hypothesised that 
exposure to multiple chemokine receptor antagonists for several days could still have a 
negative effect on proliferation cluster survival. To minimise the amount of iCCR antagonist 
in culture, the experiment was repeated using CCR2-/- bone marrow. As CCR2 is knocked 
out, the only antagonists required in culture to reproduce the phenotype would be CCR1/3 
(UCB35265) and CCR5 (Maraviroc). 
 
Figure 6-18 Proliferation Clusters in CCR2-/- Cultures Treated with iCCR Antagonists-  A- Representative 
bright field images of proliferation clusters in GM-CSF cultures (12 well plates) at x40 magnification from 
CCR2-/- cells treated with different combinations of chemokine receptor antagonists. B- Graph showing 
the quantification of clusters in WT GM-CSF cultures in 12 well plates treated with different receptor 
antagonist combination. The same WT bone marrow was used for each culture, each condition was 
repeated in triplicate, and 5 fields of view taken from each well. Each value in the graph represents an 
average of 18 points. Cluster quantification was performed with Fiji Software’s particle analysis by 
selecting clusters larger than 1800microns2. Ordinary one-way ANOVA with Dunnett’s multiple 
comparisons test was performed to determine statistical significance, with a p value of 0.05 determined 
as significant 
 
As seen in Figure 6-18B (Representative fields of view 6-16A), the ‘cluster-less’ phenotype 
was recapitulated in CCR2-/- cultures treated with CCR1/3 and CCR5 antagonists, showing 
that the absence of cluster formation is the result of iCCR inhibition, and not chemokine 
receptor antagonist toxicity. 
Figure 6-19A also compares the CCR2-/- findings with WT cultures treated with different 
antagonist combination. For example, the number of proliferation clusters in WT cultures 
treated with CCR1 and CCR2 antagonist is similar to the number of clusters in CCR2-/- cells 
treated with CCR1 antagonist alone. Again, this confirms that the cluster-less phenotype 
observed in WT cells treated with different antagonists was induced by iCCR inhibition and 
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not by a metabolic burden or toxicity caused by simultaneous exposure to different iCCR 
antagonists.  
 
Figure 6-19 Size and Number of Proliferation Clusters in Culture- A- Graph showing the quantification 
of clusters in WT compared to CCR2-/- GM-CSF cultures in 12 well plates treated with different antagonist 
combination. B - Graph showing the quantification of clusters in day 7 GM-CSF cultures grown in 12 well 
plates from WT, CCR2 and ICCR-/- cells. Each condition was repeated in triplicate, with 5 fields of view per 
condition. Each value in the graph represents an average of 18 points. C- Graph showing day 7 cluster 
size in WT, CCR2 and iCCR-/- cultures. Cluster quantification and size determination was performed with 
Fiji Software’s particle analysis by selecting clusters larger than 6000microns2. Ordinary one-way ANOVA 
with Dunnett’s multiple comparisons test was performed to determine statistical significance, with a p 
value of 0.05 determined as significant. 
 
After 7-8 days of culture, iCCR-/- cells eventually form proliferation clusters, but they are 
fewer in number and half the size of an average WT cluster (Figure 6-19 B,C). This suggests 
that towards later stages of culture, some other mechanism might be overriding the 
absence of iCCRs to mediate cluster formation.  
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Thus, the data so far suggest that the absence of the iCCRs CCR1, CCR2 and CCR5 prevents 
cluster formation, and that inhibiting these receptors in WT or CCR2-/- cells with chemokine 
receptor antagonists replicates the phenotype.  
 
6.7 Discussion- How can multiple iCCRs be involved? 
 
Treating WT bone marrow cells with a combination of iCCR inhibitors induces a ‘clusterless’ 
phenotype in culture. No effect on proliferation is seen when inhibiting a single chemokine 
receptor, and the phenotype only becomes apparent when two or more iCCRs are 
inhibited. These data suggest that CCR1, CCR2, CCR3, and especially CCR5, are required for 
optimal proliferation and differentiation of monocytes in GM-CSF cultures. 
 
However, flow cytometry on iREP bone marrow shows that inflammatory monocytes are 
exclusively CCR2+ (Figure 6-20A). If CCR1 and CCR5 are not expressed, how is their 
inhibition altering proliferation and differentiation? Are they upregulated in the early 
stages of culture in vitro? To test this, iREP bone marrow was cultured in GM-CSF for 7 days 
and clustered cells were analysed for expression of iCCRs via flow cytometry.  
 
6.7.1 GGiREP GM-CSF Cultures 
 
As seen from Figure 6-20A, inflammatory monocytes on Day 0 are CD11b+ CD11c- Ly6C++ 
and only express CCR2. After two days of culture in GM-CSF, those same Ly6C++ monocytes 
have upregulated CCR1 and CCR5 and 40% of Ly6C++ cells are now triple positives for iCCRs 
(Figure 6-20B). Also at day 2, some inflammatory monocytes have started downregulating 
Ly6C and upregulating CD11c, initiating the DC differentiation pathway. Up to 65% of these 
CD11c+ mo-DC precursors express CCR1 CCR2 and CCR5 simultaneously (Figure 6-20C). 
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Figure 6-20 Change in iCCR Expression in differentiating Inflammatory Monocytes- Ai: Representative 
FACS plot showing inflammatory monocyte Ly6C and CD11c expression in WT bone marrow after 
extraction and gating out of B-cells (B220+) and Neutrophils (Ly6G+). Aii: Pie chart showing expression 
of fluorescent reporter mRuby, corresponding to CCR2 expression, on Ly6C++ inflammatory monocytes 
extracted from bone marrow before culture in GM-CSF. Bi: Representative FACS plot showing Ly6C and 
CD11c expression on day 2 inflammatory monocytes. Bii: Pie chart showing expression of fluorescent 
reporter mRuby (red, CCR2), Clover (green, CCR1), IRFP682 (purple, CCR5) on inflammatory monocytes 
after 2 days of culture. Ci: Representative FACS plot showing Ly6C and CD11c expression on day 2 DC 
precursors. Cii: Pie chart showing expression of fluorescent reporter mRuby (red, CCR2), Clover (green, 
CCR1), IRFP682 (purple, CCR5) on DC precursors after 2 days of culture. Di, ii, iii-Charts showing 
fluctuating iCCR expression measured as reporter MFI via flow cytometry in each subpopulation of 
Ly6C/CD11c cell in GM-CSF cultures at day 2. 
After an additional 3 days of culture (Day 6), most inflammatory monocytes have 
downregulated Ly6C completely (Figure. 6-21A) and have fully upregulated CD11c and 
MHCII (Figure 6-21B, 6-21C), giving rise to the 4 subpopulations previously described: the 
mature mo-DCs, the immature mo-DCs, the CD11c+ macrophages and the monocytes. In 
immature mo-DCs, a third of cells co-express all 3 iCCRs, with CCR2 being the dominant 
chemokine receptor, possibly because of its early role in egress of monocytes from the 
bone marrow. At day 9, when most of the immature DCs have become mature CD11c+ 
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MHCII++ mo-DCs, CCR5 is markedly upregulated, with 90% of mature DCs positive (a 40% 
rise from immature Day 6 DCs) (Figure 6-21C). 
 
Figure 6-21 Change in iCCR Expression in Immature and Mature mo-DCs- A: Representative FACS plot 
showing expression of Ly6C and CD11c in Day6 GM-CSF cultures. B: Representative FACS plot showing 
immature mo-DCs (CD11c+ MHCII+) in Day 6 GM-CSF cultures and their iCCR expression through 
detection of fluorescent reporter mRuby (red, CCR2), Clover (green, CCR1), IRFP682 (purple, CCR5). C: 
Representative FACS plot showing mature mo-DCs (CD11c+ MHCII++) in Day 9 GM-CSF cultures and their 
iCCR expression through detection of fluorescent reporter mRuby (red, CCR2), Clover (green, CCR1), 
IRFP682 (purple, CCR5). D: Line graphs summarising iCCR expression fluctuation as differentiation in GM-
CSF cultures progresses from the early bone marrow inflammatory monocyte stage to the late day 9 
mature mo-DC stage. 
 
Therefore, iCCR expression fluctuates as mo-DCs mature in culture. Starting from an 
exclusively CCR2+ population of inflammatory monocytes, the first few days of culture are 
characterised by an upregulation of CCR1 and CCR5 in developing cells, resulting in 
approximately 65% of mo-DC precursors co-expressing all 3 receptors simultaneously 
(Figure 6-21D). 
 
Cluster development in culture also appears between days 2-4, thus suggesting that CCR1, 
CCR2 and CCR5 are all involved in cluster formation (while CCR3 was not detected at any 
point). Rapid upregulation of CCR1 and CCR5 at the beginning of differentiation explains 
why multiple chemokine receptor antagonists need to be administered simultaneously, as 
inhibiting a single iCCR would still allow signalling via the remaining iCCRs. 
 
These findings might also explain why cluster formation is delayed in iCCR-/- cultures, as 
developing mo-DCs need time to upregulate other ‘late-stage’ receptors (such as CCR7 or 
MHC II) to overcome the lack of signalling caused by the deletion of CCR1, CCR2 and CCR5.  
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However, what is the cause? Is there a cellular mechanism involving chemokine receptor 
signalling that would cause changes in adhesion/clustering, phagocytosis, proliferation and 
that is affected by multiple chemokine receptors? 
 
6.8 A Role for Integrins in Macrophage and mo-DC 
differentiation 
 
Integrins are transmembrane receptors that facilitate cell-to-cell and cell-to-extracellular 
matrix interaction[405]. Integrins are involved in a variety of processes: mediating arrest 
and stable adhesion of leukocytes to blood vessels[406], stabilisation of the immune 
synapse allowing for prolonged contact between leukocytes, and they mediate cytoskeletal 
rearrangement for migration and phagocytosis[407]. Most integrins are not constitutively 
active, and their activity is controlled bidirectionally by either ‘inside out signalling’ or 
‘outside in signalling’, which ultimately modifies the interactions between the alpha and 
beta subunits and changes their ligand binding affinity[408]. This ability to turn ‘on’ and 
‘off’ is vital for their biological function, as integrins can be activated in milliseconds to their 
active state without having to be synthesised de novo[409]. This is especially important in 
circulating leukocytes, as immediate integrin activation allows for timely adhesion to 
vasculature and egress towards the site of inflammation. This bidirectional control of 
integrin function is mediated by two different kinds of signalling: 
 
Inside-out signalling: when an extracellular signal (such as engagement of a chemokine 
receptor or a T-cell receptor) activates an intracellular signalling cascade in the cytoplasm 
which is then relayed to the integrin, inducing a change in its extracellular binding site, 
changing its affinity and avidity and mediating cell adhesion[408]. 
 
Outside-in signalling: ligand binding to integrins initiates a signal transduction cascade that 
promotes cell cycle regulation, organisation of the intracellular cytoskeleton and cellular 
differentiation[408].  
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6.8.1 Integrins on leukocytes  
 
Integrins involved in cellular adhesion are primarily expressed on leukocytes, with 𝛽2 
integrins preferentially expressed by rolling leukocytes to bind to endothelial cellular 
adhesion molecules (ICAMs) just before transendothelial migration [410]. The importance 
of the 𝛽2 subunit is highlighted in Leukocyte Adhesion Deficiency (LAD), a rare autosomal 
recessive disorder that causes a deficiency in the 𝛽2 integrin subunit and thus a defect in 
the formation of 𝛽2 integrins (LFA-1, Mac-1). Patients affected by LAD suffer from 
recurrent bacterial infections from birth and generally do not survive past infancy, 
highlighting the importance of cell to cell interactions for chemotaxis and 
phagocytosis[411].  
 
LFA-1: Lymphocyte function-associated antigen-1 (integrin LFA-1) is expressed exclusively 
by leukocytes, and plays a role in leukocyte recruitment to inflammatory sites and lymphoid 
tissues [406]. LFA-1 is involved in various cell-cell interactions, such as between T cells and 
antigen presenting cells[412], or natural killer (NK) cells and target cells[413],  and binds to 
intercellular adhesion molecules (ICAMs), including ICAM-1, ICAM-2, ICAM-3, ICAM-4, 
ICAM-5 and JAM-1[66].   LFA-1 also plays a major role in the formation of a stable 
immunological synapse between T-cells and antigen presenting cells, allowing for the 
prolonged contact required for the development of immunological memory[414].  
 
Mac-1: Macrophage antigen-1 is expressed by cells of the myeloid lineage, including 
neutrophils, monocytes, macrophages and dendritic cells. Mac-1 is also expressed, to a 
limited extent, by certain subsets of T lymphocytes[415]. While LFA-1 has been shown to 
play a dominant role over Mac-1 in mediating the firm adhesion of leukocytes to the 
endothelium, Mac-1 interacts with ICAM-1 to mediate intraluminal crawling after 
leukocyte arrest[416]. In addition, upon binding to cognate ligand, Mac-1 promotes 
differentiation of monocytes to macrophages by downregulating the transcriptional 
repressor FoxP1, allowing for phagocyte differentiation from monocytes to macrophages 
as the cell moves towards the site of inflammation[417] . 
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A lack of engaged chemokine receptors would diminish ‘inside-out’ integrin signalling, 
resulting in fewer integrins undergoing a conformational change from low affinity to high 
affinity. Low affinity integrins would not be able to bind to their cognate ligand, which in 
turn would also affect ‘outside-in’ signalling. With both ‘inside out’ and ‘outside in’ 
feedback mechanisms removed, cell growth, differentiation, adhesion, migration, 
phagocytosis and degranulation could all be negatively affected in maturing monocytes. 
 
Integrin mediated cell-cell interactions could allow for the formation of mo-DC clusters in 
GM-CSF cultures. Inside the cluster, concentrations of cytokines and growth factors are 
high, promoting correct proliferation and differentiation. A lack of integrins or integrins 
with low affinity would result in a decrease in frequency and strength of cell-cell contact, 
either resulting in incomplete cell activation or at least lack of proliferative signals. 
Integrin engagement is also required for optimal actin remodelling for phagocytosis. An 
abundance of low affinity integrins and lack of ‘outside in’ signalling might fail to reorganise 
the actin cytoskeleton thus compromising efficient internalisation. This might explain the 
defect in phagocytosis observed in immature and mature iCCR-/- DCs. 
 
 
6.8.2 Integrin Staining on ICCR-/- and WT proliferation clusters 
 
Two different antibody clones for LFA-1 exist for flow cytometry, one for the low affinity 
version (2D7), while another that binds to both the high affinity and low affinity versions 
(M174) [418] . As seen in Figure 6-22, undifferentiated cells (CD11c-, Figure 6-22A) in iCCR-
/- and WT+antagonist cultures express lower levels of integrin LFA-1 overall (Figure 6-22 
Bi,Bii) when compared to untreated WT CD11c-cells. However, those same cells have a 
higher MFI for the low affinity version of the LFA-1 (Figure 6-22Ci,Cii), indicating that not 
only do undifferentiated monocytes have decreased integrin expression when iCCRs are 
absent or inhibited, but the ones that do express LFA-1 express higher levels of the low 
affinity version.  
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Figure 6-22 Integrin Expression in GM-CSF cultures- A- Representative FACS plots showing the WT and 
iCCR-/- monocyte population analysed for integrin expression (blue box). Bi: Expression of integrin LFA-1 
on CD11c- monocytes from GM-CSF cultures of WT, CCR2-/-, ICCR-/- and WT+ Antagonist treated cells, 
measured as MFI via flow cytometry (M174 clone). Bii: : Representative overlaid histograms showing 
LFA-1 expression (M174 clone) in WT and iCCR-/- monocytes in GM-CSF cultures (red: WT, blue: iCCR-/-, 
orange: control)  Ci, Cii: Expression of low affinity LFA-1 on CD11c- monocytes from GM-CSF cultures of 
WT, CCR2-/-, ICCR-/- and WT+ Antagonist treated cells, measured as MFI via flow cytometry. E: Overlaid 
histograms showing low affinity LFA-1 (2D7 clone) expression in WT and iCCR-/- monocytes in GM-CSF 
cultures (red: iCCR-/-, blue: WT, orange: CCR2-/-). Results elaborated from an average of at least 3 
independent GM-CSF cultures for both WT and iCCR-/- samples. Student T-test was performed to 
determine statistical significance, with a p value of 0.05 determined as significant. 
 
6.8.3 Static Adhesion Assay and Intracellular Staining on Developing 
Monocytes 
 
To further determine if the decrease of LFA-1 expression and activation in iCCR-/- cultures 
correlates with a decrease in cell adhesion, a static adhesion assay was performed by 
adding mo-DCs from WT and iCCR cultures to coverslips coated with the LFA-1 ligand ICAM-
1. After a brief 30 minute incubation at 37°C, the coverslips were extensively washed in 
PBS and the number of remaining immobilised cells was counted using Fiji Image Software. 
As seen in Figure 6-23A and B, iCCR mo-DCs were found in lower numbers when compared 
to WT DCs, suggesting that their interaction with immobilised ICAM-1 is weaker and less 
stable. In addition, reduced staining against CD18, the 𝛽2 subunit of integrins CD11b, 
CD11c and LFA-1 (Figure 6-23C), further confirms that iCCR-/- monocytes fail to upregulate 
integrins while proliferating in GM-CSF cultures. 
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Figure 6-23 Static Adhesion Assay-  A- Representative bright field images at x100 magnification of WT 
and iCCR cells on an ICAM-1 coated coverslip. B- Bar graph summarising cell number counts in bright 
field images detected through ‘Particle Count’ program on Fiji Image Software (number of cells larger 
than 50𝝁m2). 5 fields of view were taken for each coverslip, resulting in an average of 15 total 
measurements for both WT and iCCR. C- Bar graph showing expression of 𝜷2 integrin CD18, measured 
as % positive on CD11c+MHCII int macrophages in WT/iCCR-/- GM-CSF cultures. Results elaborated from 
an average of at least 3 independent GM-CSF cultures for both WT and iCCR-/- samples. Student T-test 
was performed to determine statistical significance, with a p value of 0.05 determined as significant. 
 
Lack of integrin engagement should also result in decreased cell growth (measurable via 
intracellular marker Ki67) and an increased expression of transcriptional repressor FoxP1.  
FoxP1 is highly expressed in monocytes and is downregulated as integrins become 
engaged, allowing for transcription of lineage specific genes that would result in monocyte 
to macrophage differentiation. As shown in Figure 6-24A, intracellular flow cytometry on 
iCCR-/- clustered cells reveals a decrease in Ki67 expression (indicating reduced 
proliferation) and an increase in FoxP1 expression (Figure 6-24B), indicating that clustered 
monocytes in iCCR-/- cultures are less proliferative and less mature that WT or CCR2-/- 
clustered monocytes. 
 
 
 
 
 
 
 
 
 
 
 175 
 
 
Figure 6-24 Intracellular Staining on developing monocytes- A: Graph summarising Ki67 expression on 
clustered cells (CD11b+)  in WT and iCCR-/- GM-CSF cultures, before and after LPS stimulation for 12 hours, 
measured as MFI via intracellular flow cytometry. Aii: Overlaid histograms showing MFI for Ki67 
expression in WT and iCCR-/- clustered cells (iCCR:blue, WT: red, isotype control: brown), measured via 
intracellular flow cytometry. Bi: Graph summarising FoxP1 expression in clustered monocytes (CD11c-) 
from WT, iCCR-/- and CCR2-/- GM-CSF cultures, measured as MFI via intracellular flow cytometry. Bii: 
Overlaid histograms showing MFI for FoxP1 expression in  WT and iCCR-/- clustered monocytes (CD11c-) 
(iCCR:blue, WT: red, CCR2: green,  isotype control: brown), measured via intracellular flow cytometry. 
Results elaborated from an average of at least 3 independent GM-CSF cultures for both WT and iCCR-/- 
samples. Student T-test was performed to determine statistical significance, with a p value of 0.05 
determined as significant. 
 
6.8.4 PCR Array on iCCR-/- and WT Proliferation Clusters 
 
A PCR array was also performed on clustered WT and iCCR-/- cells to uncover any other 
potential difference. No major change in gene expression was observed, but several genes 
involved in inflammation, such as genes encoding for monocyte chemoattractant proteins 
and pro-inflammatory cytokines were slightly downregulated (p>0.05) (Figure 6-15A,B). 
This again suggests that monocytes in GM-CSF cultures lacking the main iCCRs are less 
activated and more immature. 
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Figure 6-25: Main Upregulated and Downregulated Genes in Clustered Cells- A: Table summarising 
most of the genes analysed via PCR-Array. Green: increased expression, Red: decreased expression) B: 
Graphs summarising the fold change of the most downregulated genes in iCCR-/- clusters compared to 
WT clustered cells. C: Scatterplot summarising the gene expression of iCCR-/- clusters compared to WT 
clustered cells. Genes above and below the dotted lines are significantly (p<0.05) either upregulated (red) 
or downregulated (blue). The Scatterplot showing the gene expression of WT and iCCR Clustered Cells 
and the statistical analyses were all performed according to the manufacturer’s instructions using the 
Qiagen Data Analysis Centre Software. Results elaborated from an average of 2 independent GM-CSF 
cultures for both WT and iCCR-/- samples. 
 
Only a few genes were found to be upregulated in iCCR-/- mo-DCs, a DC specific non-integrin 
intercellular adhesion molecule CD209a (DC-SIGN), a low affinity IgG Fc receptor FcyRt and 
the invariant chain of MHCII (CD74) also found on DCs (Figure 6-25A). While initially it was 
unclear why an intercellular adhesion molecule and a low affinity Fc receptor would be 
upregulated in iCCR-/- cultures, the findings might corroborate the discovery by Menezes et 
al. of a novel naïve monocyte subpopulation discovered in murine bone marrow [312]. Not 
only are the monocytes described CD209a+ and GM-CSF dependent, but they also require 
iCCRs to egress from the bone marrow.  This novel monocytic population was also seen and 
described previously, as CD209a+ monocytes were detected in CCR2-/- air pouch 
membranes but were missing completely from iCCR-/- air-pouch membranes. 
 
Thus, it could be argued that a lack of CCR1 and CCR5 in the iCCR-/- strain might have caused 
an accumulation of this specific monocyte subset in the bone marrow, resulting in a higher 
proportion of CD209+ FcyR+ monocytes differentiating in GM-CSF cultures into CD209+ 
FcyR+ mo-DCs. 
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6.9 Discussion & Conclusion 
 
Collectively, the data in this chapter provide a potential mechanism of action for the effects 
of CCR1, CCR2, CCR3 and CCR5 inhibition on the development and maturation of 
monocytes into mo-DCs in vitro. 
 
Developing monocytes in culture upregulate expression of CCR1 and CCR5 in as little as 48 
hours after exposure to GM-CSF. Chemokines secreted by developing cells, such as CCL2 
and CCL5, bind to their cognate chemokine receptors, initiating a signaling cascade. The 
signal from the iCCRs gets relayed to low affinity integrins (inside-out signaling), which 
change conformation to a high affinity state and promotes inter-cellular adhesion. Integrin 
upregulation stabilises the formation of proliferation clusters, allowing developing 
monocytes to stay in close contact and to deliver signals and mediators to each other more 
effectively, thus promoting differentiation and proliferation of mo-DCs and macrophages. 
 
In the absence or inhibition of iCCRs, integrins decrease in both expression and affinity, 
reducing cell-cell contact and inhibiting cluster formation, resulting in an accumulation of 
undifferentiated monocytes. The cells that do manage to differentiate have normal 
costimulatory molecule expression but decreased phagocytic ability. iCCR cluster formation 
is generally delayed from day 2-4 in WT, to day 5-7, as by this stage developing mo-DCs 
have upregulated other receptors, such as CCR7, which could override the lack of iCCR 
signaling experienced in the initial stages of culture. 
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6.9.1 Relevance in vivo  
 
While it is unclear if the conditions seen in vitro would replicate in vivo, lack of efficient 
cell-cell contact between monocytes and the stroma might explain an unexpected 
phenotype observed in iCCR-/- bone marrow.  CCR2 is required for inflammatory monocyte 
egress from the bone marrow[73][74], and accumulation of monocytes in CCR2-/- bone 
marrow has already been observed by many groups[280]. 
 
Figure 6-26 Number of inflammatory monocytes in the bone marrow during air-pouch inflammation. 
Numbers for each single-/- are normalised with their own WT to mitigate strain-specific phenotypes. 
Measured via flow cytometry. Ordinary one-way ANOVA with Dunnett’s multiple comparisons test was 
performed to determine statistical significance, with a p value of 0.05 determined as significant 
 iCCR-/- monocytes were also expected to accumulate, possibly in even higher numbers, as 
they are also lacking 3 other iCCRs. Figure 6-26 shows that while monocytes were indeed 
found in higher numbers in iCCR-/- bone marrow in inflammation compared to WT, CCR2 
single knock-out monocyte numbers were found at an even higher proportion. While other 
explanations to this phenotype were discussed previously, one of the possible mechanisms 
considered was weaker cell-cell contact in iCCR-/-, as proliferating monocytes require 
constant cross-talking with the bone marrow stroma to develop properly. While monocytes 
do accumulate in iCCR-/- bone marrow due to lack of CCR2, they might also fail to proliferate 
as fast by having weaker interactions with supporting stromal cells, reducing their 
numbers.  
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6.9.1.1 Granuloma Formation 
 
One potential mechanism involving extensive cell-cell contact between macrophages, 
monocytes and DCs in vivo is the formation of a granuloma following infection with 
M.Tuberculosis[419]. Granulomas are specialised structures that localise and 
contain M.tb while concentrating the immune response to a limited area [420] and consist 
mainly of blood-derived macrophages, differentiated macrophages and multinucleated 
giant cells, surrounded by T lymphocytes [421]. These Multinucleated Giant Cells (MGC) 
are formed by the fusion of macrophages and play important roles in a number of 
physiological and pathological processes, including the phagocytosis of large foreign 
particles that would be too big to phagocytose for a normal macrophage[422]. 𝛽1 and 𝛽2 integrins have been shown to mediate adhesion during macrophage fusion 
and multinucleated  giant cell formation [423][424], so it would be interesting to see if 
iCCR-/- leukocytes are capable of forming a granulomas and multinucleated cells to contain 
M.Tuberculosis infection. 
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7 Final Discussion and Future 
Directions 
 
 
7.1 Overview 
 
The Inflammatory CC-chemokine receptors (CCR1, CCR2, CCR3 and CCR5) are regarded as 
major contributors to in vivo inflammatory cell recruitment. However, the totality of their 
combined contribution to the overall orchestration of the inflammatory responses, and 
residual inflammatory cell recruitment in their absence, has not yet been defined. In 
addition, despite over 25 years of pharmaceutical targeted research, no antagonist of 
inflammatory chemokine receptors has been licensed for use in treating inflammatory 
diseases such as rheumatoid arthritis or other conditions in which excessive inflammation 
is the main driver of the pathology. This failure as been attributed to an incomplete 
understanding of the inflammatory chemokine receptor system and confounding effects 
attributable to the promiscuity of each receptor[4]. 
 
To investigate the contribution each iCCR has on the development of the inflammatory 
response, this project has focused on characterising two novel mouse models recently 
developed by the Chemokine Research Group, an iCCR-/- strain and an iCCR reporter strain.  
 
 
7.2 Role of iCCRs in Homeostasis 
 
Analysis of resting iCCR-/- showed little evidence of a combinatorial effect of iCCRs on 
homeostatic recruitment and leukocyte distribution in various tissues. In both bone 
marrow and blood, iCCR-/- mice were generally a pheno-copy of CCR2-/- mice, with the 
exception of impaired eosinophil recruitment in the iCCR-/- which is controlled by CCR3. In 
other words, while iCCR-/- mice showed defects in recruitment of inflammatory monocytes 
and eosinophils, all phenotypes observed were attributable to the absence of either CCR2 
or CCR3, with no evidence of contribution from CCR1 or CCR5.  
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Under resting conditions, the only evidence so far of a possible contribution of other iCCRs 
in directing leukocytes to different organs was found in the skin, where a decrease in skin 
tissue macrophages in iCCR-/- mice could not be completely explained by the absence of 
CCR2. It was still unclear however how much of this difference could be attributed to a 
combinatorial effect of the simultaneous deletion of CCR1, CCR2 and CCR5 on monocyte 
recruitment, or if the absence of CCR1 and CCR5 was affecting the proliferation of the 
newly recruited monocytes, further decreasing their overall numbers resulting in a 
phenotype that is more profound than in the CCR2-/- mice. The in vitro findings discussed 
in the previous chapter appear to support this hypothesis, as iCCR-/- monocytes or WT 
monocytes exposed to specific iCCR chemokine receptor antagonists grown into GM-CSF-
derived DCs and macrophages show decreased proliferation rates and are unable to 
differentiate effectively. 
 
Expectedly, deletion of iCCRs had no effect on tissue resident macrophage populations 
which are generally thought of as iCCR independent, such as alveolar macrophages in the 
lung or red pulp macrophages in the spleen. 
 
7.3 Role of iCCRs in Inflammation 
 
 
While both the Imiquimod and the air pouch models showed defects in recruitment of 
inflammatory monocytes, dendritic cells, eosinophils and macrophages, there was again 
little evidence of redundancy in receptor involvement, as most of the phenotypes were 
explained by an absence of either CCR2 or CCR3. Thus, the data highlight the overwhelming 
importance of CCR2 as a recruiter of monocytic cells (and CCR3 for eosinophils) to acutely 
inflamed sites. Macrophages were the only leukocyte subset hinting at a possible 
combinatorial role for iCCRs, as the numbers in iCCR-/- air pouch membrane were lower 
than in the CCR2-/- mice. 
 
Differences in lymphoid cell recruitment were not observed in the air pouch model. After 
Imiquimod application to the skin however, activated T-cells were found elevated in blood, 
potentially indicating they were trapped in the circulation. This could suggest that certain 
ligands can induce the upregulation of specific sets of iCCRs on a leukocyte, and changing 
the inflammatory conditions by using, for example, a model for bacterial or fungal 
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infections, might reveal more profound phenotypes in more leukocyte subsets than was 
observed in iCCR-/- mice exposed to Imiquimod or carrageenan. Indeed, preliminary 
experiments performed with Dr. Pingen using Semliki Forest Virus to induce encephalitis in 
iCCR-/- mice revealed defects in recruitment into the brain of multiple leukocyte subsets, 
including monocytes, B-cells, CD4 and CD8 T-cells and even neutrophils. These preliminary 
findings suggest that the choice of inflammatory stimulus might be critical for the 
upregulation of certain CC-chemokine receptors, and further studies using a systematic 
approach to identify iCCR-inducing inflammation models will probably help identify the 
additional combinatorial roles of CCR1 and CCR5. 
 
7.4 Role of CCR1 and CCR5 
 
While CCR2 and CCR3 are expressed in resting ‘classical’ inflammatory monocytes and 
eosinophils, CCR1 and CCR5 are generally thought to be upregulated only during 
differentiation and after activation with inflammatory mediators. Thus, for example, while 
CCR1 has been shown to aid trans-endothelial migration of inflammatory 
monocytes[298][318], those same cells are probably able to migrate just as efficiently using 
other receptors, and the absence of CCR1 would not stop chemotaxis but delay it slightly.  
 
Similarly, while CCR5’s role in macrophage function has been well documented[321]–[323], 
the receptor itself might be dispensable or at least perform a function that overlaps with 
other receptors, allowing the leukocyte to function in its absence[324]. 
 
In other words, while the experiments on the iCCR-/- mouse model identified the pivotal 
roles of CCR2 and CCR3, it might not be the best model to uncover the role of CCR1 and 
CCR5 as these receptors are only upregulated during a specific temporal window in the life 
of a leukocyte and their effect might have gone undetected. To address this issue, a novel 
iCCR reporter murine strain developed by Dr. Medina-Ruiz was validated and used to 
determine leukocyte iCCR expression in various organs both at rest and during 
inflammation. 
 
Fluorescent reporter proteins were detected in several leukocyte subsets, including 
inflammatory monocytes (CCR2), eosinophils (CCR3), B-cells (CCR1), and patrolling 
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macrophages (CCR2). Under resting conditions, detection of fluorescent reporter proteins 
via flow cytometry on the surface of leukocytes revealed high CCR2 expression (>95%) in 
inflammatory monocytes and high CCR3 in eosinophils (>90% in circulation), in line with 
expectations. More importantly, CCR2 and CCR1 co-expression was detected in both 
resting and inflamed iREP inflammatory monocytes, and the number of CCR1 expressing 
monocytes in various tissues offered hints on its function. During inflammation, up to 16% 
of inflammatory monocytes in the bone marrow express CCR1. The percentage drops to 
10% in circulation but increases to 40% in the air-pouch membrane, finally reaching 
maximal CCR1 expression (70%) in macrophages of the air pouch fluid. The decrease in 
CCR1 expression in circulation raises two possibilities: either CCR1 is upregulated briefly 
during inflammatory monocyte bone marrow egress and downregulated rapidly while in 
circulation, and re-upregulated as the monocytes reaches the site of inflammation, or, 
more simply, CCR1+ monocytes are ‘stuck’ along the inflamed vessel walls, leaving mainly 
CCR2+ monocytes in extracted blood. 
 
This mechanism of action is described in Figure 7-1. CCR2+ and CCR2+CCR1+ double 
positive inflammatory monocytes are both capable of bone marrow egress and enter the 
circulation. In the blood, CCR2+CCR1+ monocytes are better capable of interacting with the 
inflamed vessel lumen, binding more strongly and migrating more effectively than CCR2 
single positive monocytes. As a result, the inflamed area becomes ‘enriched’ with 
CCR2+CCR1+ co-expressing monocytes. As these monocytes continue to migrate towards 
the site of inflammation, they differentiate into macrophages and begin expressing CCR5 
(expressed on around 15% of air-pouch fluid macrophages). CCR2 single positive 
monocytes on the other hand do not migrate as effectively and probably stay in circulation, 
eventually seeding distal organs in the periphery, such as the gut, the spleen or the lungs. 
 
Thus, while the experiments performed on the full iCCR-/- have underlined the importance 
of CCR2, the findings on iREP mice suggest an important role for CCR1 in monocyte trans-
endothelial migration. 
 
 184 
 
Figure 7-1- Schematic of inflammatory monocyte chemotaxis from the bone marrow to an acutely 
inflamed area. CCR2+ and CCR1+CCR2+ inflammatory monocytes are both capable of bone marrow 
egress. Once in circulation, CCR1+CCR2+ monocytes preferentially bind to the activated endothelium and 
initiate chemotaxis. As the CCR2+CCR1+ monocytes move towards the site of inflammation, they 
differentiate into macrophages and increase expression of CCR5.  
 
7.5 Future Directions 
 
The iCCR network is still incredibly complex. and while iCCR-/- and iREP mice have answered 
some questions, many still remain: what is the role of CCR5 in macrophages? What is the 
role of CCR1 in B-cells?  
In vivo work on iREP mice has also shown that macrophages can express various 
combination of chemokine receptors, with CCR2+, CCR1+CCR2+ and CCR1, CCR2 and CCR5 
triple positive populations all present simultaneously in the air pouch membrane. Are these 
different subsets phenotypically identical, or does the expression of particular chemokine 
receptors alter the macrophage’s differentiation and effector function? Further 
experiments using another novel murine strain developed at the CRG by Dr. Schutte will 
address these issues. 
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7.5.1 A novel iCCR Conditional Knock-Out Strain 
 
RiKO (Reversible iCCR Knock-Out, generated by Dr. Schutte), is novel murine strain which 
had the endogenous iCCR locus removed and replaced with a ‘recombineered’ locus in 
which transcriptional ‘stop’ cassettes, flanked by different recombinase recognition sites 
placed next to each receptor gene (Figure 7-2). These mice are therefore conditionally-null 
at each receptor allele. By crossing with appropriate recombinase-expressing mice, it will 
also be possible to switch on these individual receptors, and thus define their individual 
contributions to leukocyte migration. It will be also possible to cross multiple recombinase 
expressing mice, allowing for the generation of mice expressing specific combinations of 
iCCRs (for example, a CCR1+CCR2+CCR3-CCR5- strain).  
 
Figure 7-2- Generating A Reversible iCCR Knock-Out Strain (RIKO)- Schematic provided by Dr. Schutte 
showing how the novel conditional iCCR murine strain was designed. The endogenous iCCR locus was 
removed and replaced with a recombineered locus which contains transcriptional stop cassettes (red) 
flanked by different recombinase recognition sites (inverted triangles in front of each gene). In the 
absence of the correct recombinase, the stop cassette does not allow for expression of a particular iCCR. 
Crossing with the appropriate recombinase-expressing mice switches on an individual chemokine 
receptor. 
 
The availability of these three novel mouse strains (iCCR-/-, iREP, RiKO) provides a unique 
opportunity to define iCCR involvement in orchestrating the inflammatory response: 
experiments on the iCCR-/- mice have provided a ‘clean slate’ to assess the development of 
the immune response in the absence of CCR1, CCR2, CCR3 and CCR5 while studies on the 
iREP strain allowed for direct visualisation in changes of iCCR expression. Future studies on 
the RiKO mice will finally be able to address the issues of iCCR co-expression and 
redundancy. 
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Taken together, experiments on these three novel iCCR strains will provide much needed 
clarity to our current understanding of the orchestration of the chemokine driven 
inflammatory responses. The results will not only increase our understanding of basic 
chemokine biology, but will also inform future pharmacological intervention on the 
chemokine system. 
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